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Abstract 
 Alzheimer’s Disease is a neurodegenerative disease affecting over five million people in 
the United States alone, with almost half a million new cases every year. As the population ages, 
these figures will only increase unless an effective treatment can be found.  Amyloid-β is the 
protein implicated in, and believed to be causal to Alzheimer’s Disease. Amyloid-β has been 
known to misfold into β-sheets and aggregate into neurotoxic oligomers or relatively inert 
amyloid fibrils. A variety of aggravating factors have been implicated including an excess of 
metal ions, various genetic anomalies, and the intracellular depositions of  neurofibrillatory 
tangles (NFT). 
 This PhD thesis advances the understanding of Alzheimer’s disease by demonstrating 
how the presence of copper ions influences the unbinding force of two amyloid-β peptides 
affecting the initial aggregation pathway by increasing the force between two amyloid-β 
peptides.  The results provide evidence to the hypothesis that the addition of metals increases the 
amyloid oligomer content in the brain beyond that which the brain can naturally clear.  
 Current Alzheimer’s pharmacological research is focused on developing amyloid 
aggregation inhibitors that would slow down the accumulation of amyloid oligomers and thereby 
slow the onset of Alzheimer’s symptoms. A high throughput method of testing potential 
aggregation inhibitors that is far more efficient than current testing methods is demonstrated. An 
aggregation inhibitor was tested that functions by inhibiting the initial self-dimerization of  
amyloid-β preventing further aggregation. The results show that this inhibitor, named SG1, 
greatly reduces the experimental yield (a parameter calculated during force spectroscopy 
experiments) of the force experiments demonstrating a drastically lower amyloid-amyloid 
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affinity. The natural conclusion to these results is that if amyloid-β cannot dimerize, it cannot 
continue to aggregate. 
 Using dynamic force spectroscopy,  the height and width of the energy barrier of 
amyloid-β dimerization is calculated using a variety of different models. These different models 
are compared and their relative advantages and disadvantages discussed.  
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Chapter 1 
Introduction 
 
This thesis contains the results of four years of investigation studying the single molecule 
interactions of amyloid-β, the protein implicated in Alzheimer’s disease. During the course of 
this research, approximately 50,000 force curves were collected and analyzed. Because of the 
dilute solutions used during these experiments, approximately 10-15% of these approaches 
provide reliable information and are subject to further analysis yielding important kinetic and 
statistical mechanical information on the single molecule interactions between two amyloid-β 
peptides.  
The first chapter of this thesis consists of  a literature review covering the most pertinent 
and current advances in the relevant fields of study. Alzheimer’s disease, the amyloid-β peptide, 
and atomic force spectroscopy are all given brief reviews to serve as a primer for the discussion 
of the results of the research. The number of journal articles being published in peer-reviewed 
periodicals, especially in the field of Alzheimer’s research, appears to be growing exponentially: 
a search of  “amyloid-beta”  on PubMed returns over 20,000 results with 90% of these reports 
having been published within the past ten years. Given the voluminous amount of research data 
available, only the results of the most highly cited and relevant publications are referenced in this 
thesis. Extensive reviews are noted in selected sections in chapter one should  the reader wish to 
explore the subject matter in further depth. 
 Chapter 2 describes the objectives of this research and hypothesis’ as identified at the 
outset of the investigations contained within the PhD thesis proposal. 
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 Chapter 3 contains the results of an atomic force spectroscopy (AFS) and atomic force 
microscopy (AFM) study of the effect of copper on single molecule interactions between 
amyloid-β.  
Chapter 4 contains the results of a study of how potential amyloid aggregation inhibitors 
affect the unbinding force between two molecules. The results demonstrate how atomic force 
spectroscopy can be used as an initial high throughput drug discovery tool to probe and ligand-
receptor interactions or competitive binding.  
Chapter 5 reports the results of the statistical mechanical and kinetic information 
involved in the dimerization of two amyloid-β peptides using competing dynamic force 
spectroscopy (DFS) models and comparing these models to one another.  
Appendix A contains all atomic force spectroscopy protocols. 
Appendix B contains list of other publications written by the author of this thesis but 
were not part of the PhD research plan. 
 Certain sections of thesis  have been adapted from the author’s PhD thesis proposal, a 
literature review conducted during course work, from the author’s master’s thesis (Hane, 2009) 
or from articles published in academic journals with the author of this thesis being the lead 
author of those articles.  
1.1. Alzheimer’s Disease 
Alzheimer’s Disease (AD) is a neurodegenerative disorder which results in progressive 
cognitive impairment, including dementia, personality changes, judgment, language skills and 
memory loss, eventually resulting in the death of the individual. AD is a member of the protein 
misfolding diseases family. The twenty-seven protein misfolding diseases identified all have an 
implicated protein which misfolds and aggregates causing a specific pathology (Sipe et al., 
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2010) (Stefani, 2012). AD is associated with the amyloid-β (Aβ) peptide. Other diseases in the 
protein misfolding disease family include Parkinson’s (α-synuclein), Huntington’s (Huntingtin), 
and Cruetzfeld-Jacobs (PrPc).  
The pathology which would later be identified as Alzheimer’s disease was first identified 
by Alois Alzheimer in 1907 (Alzheimer, 1907). A significant period of time elapsed between 
the time that Dr. Alzheimer identified the disease until any significant progress was made in the 
study of Alzheimer’s disease: it was not until the mid- to late 1980’s that the amyloid-β peptide 
was shown to be correlated with AD symptoms (Masters, Simms, Weinman, Multlraup, 
McDonaid, & Beyreuther, 1985) (Tanzi, McClatchey, Lampereti, Villa-Komaroff, Gusella, & 
Neve, 1988) and the amyloid hypothesis was proposed (Selkoe, 1991).  
Pathologically, Alzheimer’s disease is identified post-mortem by the presence of 
extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT). Research by 
Selkoe and others has shown that amyloid-β is the primary constituent in these amyloid plaques, 
and hyper-phosphorolated tau protein the primary constituent in NFT’s (Selkoe, 1991). In 
addition, advancements have been made in elucidating the factors that influence the symptoms 
of Alzheimer’s, the molecular pathways of amyloid-β aggregation, and possible therapeutic 
approaches to slow the onset of AD. 
By the turn of the last century, research results started to show that neuronal synapses 
were most affected by amyloid neurotoxicity by impairing potentiation as a result of the 
interaction between amyloid oligomers and the neuronal synapse  (Walsh, et al., 2004) (Walsh 
& Selkoe, 2004). Concurrently, various groups reported that the misfolding of amyloid proteins 
was not an abnormal occurrence: rather, it is an intrinsic property to the backbone of any 
polypeptide chain (Dobson & Karplus, 1999). In addition, research showed that cytotoxicity is a 
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generic effect of all amyloid oligomers (Bucciantini M. , et al., 2002) and is associated with the 
initial misfold of oligomers setting off the amyloid cascade (Kayed, 2003) (Stefani, 2012). 
Post mortem examinations of patients with Alzheimer’s symptoms have shown a 
reduction in the physical size of the temporal and frontal lobes, hippocampus and amygdala- the 
regions involved in memory and learning process. This cerebral atrophy is the direct result of 
neuronal apoptosis and synaptic atrophy appearing concurrently with the presence of amyloid 
plaques and tau tangles (Mattson M. , 2004). In addition, inflammatory cytokines formed by 
degenerating neurons and activated microglia around the amyloid plaques may contribute to the 
symptoms associated with Alzheimer’s disease (Mattson M. , 2004). 
Despite extensive research into Alzheimer’s and amyloid-β, no clear mechanism of 
action has been uniformly accepted, and little progress has been made in developing 
pharmaceuticals that eliminate, prevent, or even significantly slow the devastation caused by 
AD (Neugroschl & Sano, 2010). 
1.1.1. Alzheimer’s Epidemiology 
Currently, Alzheimer’s disease affects nearly 12 million individuals across the world. By 
2050, epidemiologists have estimated that this number will triple to nearly 36 million individuals 
(Citron, 2004). In the United States, 5.4 million Americans have been diagnosed with AD 
including 5.2 million citizens over the age of 65 and 200,000 with early onset AD under the age 
of 65 (Alzheimer's Association, 2011) (Hebert, Scherr, Bienas, Bennett, & Evans, 2003). Late 
onset AD is defined as AD occurring in persons over 65 years of age. Likewise, early onset AD 
is defined as AD symptoms occurring prior to the age of 65. In Canada alone, the Canadian 
Study of Health and Aging Working Group has estimated that more than 300,000 individuals 
over the age of 65 suffer from dementia and of those 64% have been diagnosed with AD. By 
4 
 
 
 
2031, 750,000 individuals will suffer from various dementias, with the majority being the result 
of Alzheimer’s disease (Canadian Study of HeaIth and And Working Group, 1994). 
AD affects women to a greater extent than men; however, given the longer mean lifespan 
of women, when age specific incidence of AD are studied, there is no significant gender 
difference  (Seshadri, Wolf, Au, & McNulty, 1997) (Hebert, Scherr, McCann, & Beckett, 2001).  
Nearly all protein misfolding diseases are age dependent. As modern medicine has found 
cures for previously lethal diseases, such as pneumonia and infectious diseases, an increasing 
number of people are living sufficiently long lives to present with Alzheimer’s symptoms 
(Krishnan, et al., 2012). Furthermore, because of the age dependent manner in which protein 
misfolding diseases manifest, the toxic amyloid misfold in implicated proteins has not been 
selected against by evolutionary pressures (Krishnan, et al., 2012).  
AD disproportionally affects North Americans of African and Hispanic descent to a 
greater extent than those of European ancestry: people of African descent are twice as likely to 
be diagnosed with AD (Potter, Plassman, Burke, Kabeto, & Langa, 2009) and Hispanics one and 
one half times more likely (Gurland, Wilder, Lantigua, Stern, & Chen, 1999) to be diagnosed 
compared to whites. 
Low levels of education, traumatic brain injury, high-fat and high-calorie diets and lack 
of physical exercise have all been correlated to higher rates of AD (Mayeux R. , 2003) (Mattson 
M. , 2003) (Cotman & Berchtold, 2002). 
The National Center for Health Statistics reported that Alzheimer’s was listed as the 
underlying cause of death for 82,476 people in the United States making it the fifth leading cause 
of death (Minino, Xu, & Kochanek, 2010). In 2008, the mortality rate for Alzheimer’s disease 
the United States was 27.1 deaths per 100,000 people (Alzheimer's Association, 2011). 
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After an AD diagnosis for a person over the age of 65 years, the average AD patient 
survives between 4 and 8 years; however, survival of up to 20 years has been reported 
(Brookmeyer, Corrada, Curriero, & Kawas, 2002) (Alzheimer's Association, 2011). 
The economic costs of AD is far greater than the direct costs associated with 
pharmaceutical treatment. For each individual suffering from AD, there is a person  responsible 
for their care.  In 80% of cases, these caregivers are unpaid family members diverting vital 
labour resources from the economy providing 17 billion hours of unpaid care (Alzheimer's 
Association, 2011). Currently, the total cost associated with AD in the US is $183 billion dollars 
annually. 
Aggregate payments for health care, long-term care and hospice care for people 
diagnosed with Alzheimer’s disease and other dementias are projected to increase from $183 
billion in 2011 to $1.1 trillion in 2050 (in 2011 dollars) (Alzheimer's Association, 2011). The 
data indicate that the incidence of AD, along with associated direct and indirect costs will 
continue to climb as the population ages. Investment in Alzheimer’s research is a wise venture 
which may mitigate the future costs of a population with a high incidence of AD. Neugroschl 
and Sano (Neugroschl & Sano, 2010) have estimated that there would be 2 million fewer cases 
of AD over a period of 50 years if the onset of AD could be delayed by two years  resulting in a 
decreased need for nursing care and lost productivity of family caregivers. 
1.1.2. Alzheimer’s Etiology 
Classically, the presence of amyloid plaques in the brain, which showed apple green 
birefringence when stained with Congo Red, was the definitive post mortem diagnosis for AD. In 
the past these plaques were believed to be causal to AD. However, research within the past ten 
years has shown that this actual case is far more nuanced. Many people display post-mortem 
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cerebral amyloid plaques without ever presenting with any Alzheimer’s symptoms. Prominent 
researchers such as Selkoe have analogized that amyloid plaque are like “jails” which neutralize 
toxic oligomers. Once the “jails” are full, there are too many oligomers for the “police” 
(neuroclearance mechanisms) to deal with and the oligomers can wreck their havoc on the brain. 
Attempting to prevent amyloid plaques would release the “bad guys” causing more damage 
(Selkoe, Amyloid hypothesis - beta oligomers and plaques). Conversely, some people diagnosed 
with Alzheimer’s disease do not have any amyloid plaques post-mortem. This inconsistent 
phenomenon can be caused by either a false diagnosis or poor specificity of the classical 
Alzheimer’s signs post-mortem. 
Amyloid fibrils were the first amyloid species identified that make up amyloid plaques. 
Amyloid fibrils are long, thin insoluble fibers made up of the amyloid-β peptide arranged in a 
cross β sheet structure. Interestingly enough, spider webs have a similar tertiary structure.  
Recent research has shown that fibrils are relatively inert compared to their oligomeric 
counterparts. Whether oligomers are precursors to fibrils or form along a separate pathway is a 
subject of current research and academic debate (Yamaguchi et al. 2010). 
The exact mechanism by which amyloid-β produces neurodegenerative symptoms 
remains unclear, although several mechanisms have been suggested to explain why amyloidosis 
results in specific pathologies. Research by Lal and colleagues indicates that oligomeric 
amyloid-β forms ion channels in lipid membranes resulting in higher levels of intracellular 
calcium (Lin, Bhatia, & Lal, 2001). Perturbations in membrane fluidity have been suggested by 
Murphy (Kremer, Pallitto, Sklansky, & Murphy, 2000) and Gattz (Muller, Eckert, Scheuer,, 
Cairns, & Gattz, 1998). Free radical production has been identified by Koppal (Butterfield, 
Varadarajan, & Koppal, 1999) and changes in lipid metabolism have been demonstrated by 
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Koudinova (Koudinov, Berezov, & Koudinova, 1998). Other mechanisms which have been 
researched are: induction of cell apoptosis (Loo, Copani, Pike, Whittemore, Walencewicz, & 
Cotman, 1993), the formation of ion channels in cell membrane altering ion homeostasis (Arispe, 
Pollard, & Rojas, 1993), and the production of toxic levels of hydrogen peroxide (Behi, Davis, 
Lesley, & Schubert, 1994). 
Clinical diagnosis for AD, based on accepted mental and cognitive testing, is considered 
to be reliable for the diagnoses of AD. 90% of patients diagnosed with AD are found to have AD 
on autopsy (Knopman, S, J, Chui, & Corey-Bloom, 2001). Recent advances have shown promise 
in making an AD diagnosis using cerebrospinal fluid or blood for patients who have not yet 
presented with AD symptoms (DeMeyer, Shapiro, Vanderstichele, Vanmechelen, & 
Engelborghs, 2010). 
1.1.3. Alzheimer’s Genetics 
A number of factors have been implicated in Alzheimer’s disease including genetic 
mutations. Amyloid-β is cleaved from the amyloid precursor protein (APP) located on 
chromosome 21. APP is cleaved by the α-, β-, and γ-secretases to from 3 amyloid products of 
which amyloid- β is one, cleaved by the γ-secretase, also referred to as BACE1. 
Autosomal dominant mutations in APP, presenilin 1 (PSEN1) or presenilin 2 (PSEN2) 
results in the individual developing familial (early onset) AD (Bertram & Tanzi, 2005) and occur 
in 10% of all AD cases. Point mutations in the APP gene result in a higher concentration of the 
more highly neurotoxic amyloid-β (1-42) compared to amyloid-β (1-40) (Suzuki, et al., 1994).  
Mutations in PSEN1 or PSEN2 occur in 50% of all early onset AD cases. Mutant PSEN1 
increases the production of Aβ42 and accelerates the deposition of AB. Knocking out PSEN1 
genes in mice neurons resulted in γ-secretase activity being abolished (Scheuner, et al., 1996). 
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All three of these genes (APP, PSEN1, PSEN2) are located on different chromosomes, 
yet all share a common biochemical pathway- all three lead to an abnormal production of 
amyloid-β. Individuals with Down’s syndrome (trisomy 21) will develop Alzheimer’s disease 
because they have two copies of chromosome 21, doubling their potential production of amyloid-
β (Masters, Simms, Weinman, Multlraup, McDonaid, & Beyreuther, 1985) (Mattson M. , 2004). 
Nearly 30 genes and a variety of environmental risk factors have been implicated in late 
onset AD, but no other gene has been shown to influence late onset AD as much as the apoE4 
allele which codes the ApoE protein (Bertram & Tanzi, 2005) which  is involved in cholesterol 
metabolism (Mahley, 1988). Inheriting one apoE4 allele increases the risk of late onset AD 
because of higher amyloid deposition in the cerebral cortex (Schmechel, 1993) as a result of a 
failure of amyloid clearance mechanisms (Mawuenyega, et al., 2010). Inheriting alleles from 
both parents compounds the probability of late onset AD (Alzheimer's Association, 2011) 
however carrying both alleles of apoE4 is no guarantee that an individual will suffer from AD. 
Apolipoprotein E2 has been shown to act as a protective factor against AD. In AD 
patients, the apoE2 allele is under represented while the apoE4 allele is overrepresented 
compared to the general population (Harper & Lansbury, 1999).  
Certain genetic mutations have also been demonstrated to increase the aggregation of 
amyloid-β. Sandberg and colleagues demonstrated that amyloid-β with the arctic E22G mutation 
forms protofibrils at a greater rate than does wildtype amyloid-β (Sandberg, et al., 2010).  
Other mutations have shown to have a neuroprotective effect. The A673T mutation in the 
APP gene, commonly found in people of Icelandic decent, has been shown to protect against 
cognitive decline in elderly people who do not suffer yet from any cognitive decline by reducing 
the aggregation of amyloid-β by approximately 40% (Jonsson, et al., 2012). 
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1.1.4. The Amyloid Cascade Hypothesis 
The notion that amyloid-β is the causative agent in the etiology of Alzheimer’s disease 
has been a controversial one (Hardy, 2006). However, few researchers have managed to present 
alternative hypothesis that explain the majority of pathological and biophysical phenomenon 
which are manifest in the progression of Alzheimer’s disease. Like all scientific hypotheses, the 
amyloid cascade hypothesis has not been without some modifications over time even though the 
basic precepts of the hypothesis remain intact. 
The identification of amyloid-β as the major constituent in amyloid plaques was first 
identified in the mid 1980’s (Allsop, Landon, & Kidd, 1983). Within a few years, Hardy and 
Higgins proposed their amyloid cascade hypothesis in their highly cited review (Hardy & 
Higgins, 1992). Hardy, Selkoe and colleagues were the first to propose that amyloid-β is the 
causative agent of Alzheimer’s disease and that all other phenomenon such as neurofibrillatory 
tangles, tau phosphorylation, vascular damage, neuronal death, dementia, and finally death, 
follow, in that order, from the over- production of amyloid-β (Hardy & Allsop, 1991) (Selkoe, 
1991). The deposition of amyloid often begins in the mediotemporal lobe, then spreads further to 
the neocortex (Bonda, Lee, Blair, Zhu, Perry, & Smith, 2011). 
A number of revisions to the amyloid cascade hypothesis have been accepted by the 
research community without compromising the underlying premise that amyloid-β is the 
causative agent of Alzheimer’s disease. Firstly, it is now widely accepted that small molecular 
weight aggregates are the most neurotoxic amyloid species rather than amyloid fibrils or amyloid 
plaques (Klug, Losic, Subasinghe, Aguilar, Martin, & Small, 2003) (Kayed R. H., 2003) leading 
some authors to refer to an “oligomer cascade hypothesis”. Secondly, in late onset AD, the 
incorrect cleaving of APP into the more pathogenic Aβ42 form as opposed to the more stable 
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Aβ40 (Bush & Tanzi, 2008) has been linked to AD symptoms rather than the overproduction of 
amyloid-β. In addition, the insufficient clearance of amyloid-β from the brain has been 
associated with late onset AD in cases where known genetic factors are absent (Mawuenyega, et 
al., 2010). The amyloid cascade hypothesis assumes a linear progression of the disease, however, 
considerable evidence is mounting that different amyloid species with varying degrees of 
toxicities may lie along different reaction pathways. Factors such as metals catalyze the 
aggregation process along differing pathways. 
One of the recurring criticisms of the amyloid cascade hypothesis is that it fails to explain 
the unequal distribution of amyloid deposition in the brain; many people have been observed to 
have neuronal amyloid plaques during post mortem autopsy without demonstrating any 
Alzheimer’s symptoms while they were alive (Bush & Tanzi, 2008). Lastly, the amyloid cascade 
hypothesis is unable to explain why Alzheimer’s is an age related disease or why there are 
considerable vascular pathologies related to AD (Roy & Rauk, 2005). 
1.2. Amyloid-β 
Amyloid-β was first identified by Glemer and Wong in 1984 as the principal component 
of amyloid deposits (Glenner & Wong, 1984). This seminal work led to the proposal of the 
amyloid cascade hypothesis which posits that the presence of these amyloid plaques, leading to a 
post-mortem diagnosis of AD, or more likely their oligomers, disrupts the neuronal cell 
membrane leading to neurodegeneration. Amyloid-β has a peptide length of 39-43, with the 
majority of amyloid found in senile plaques having a peptide length of 42 (Masters, Simms, 
Weinman, Multlraup, McDonaid, & Beyreuther, 1985).  
The amyloid-β peptide is an ill-defined peptide, the secondary structure of which is 
largely dependent on the environment. In aqueous solution, amyloid-β occurs predominantly in a 
11 
 
 
 
random coil conformation. When associated with a membrane, amyloid-β consists of a 
hydrophilic, extracellular region located at residues 1-28, and a hydrophobic, transmembrane 
alpha-helical coil at residues 29-42 (Barrow & Zagorski, 1992).  
The gene encoding the amyloid precursor protein (APP) is found on chromosome 21 and 
is expressed in a variety of glial, endothelial, epithelial and spleen cells. The function of APP is 
unclear at this point, but research has suggested that APP may have a role as an autocrine factor 
to stimulate the proliferation of fibroblasts (Saitoh, et al., 1989) and as a modulator of cell 
adhesion. In addition, APP is implicated in the regulation of intracellular calcium (Mattson, 
Cheng, Culwell, Esch, Lieberburg, & Rydel, 1993), metal ion homeostatsis (Hesse, Beher, 
Masters, & Multhaup, 1994), and cell growth (Saitoh, et al., 1989). Recently, Sanders and 
colleagues demonstrated that APP may have a cholesterol binding site with E693 and N698 
accepting and donating a hydrogen bonds to bind cholesterol providing evidence that APP may 
have a role in cholesterol regulation and metabolism (Barrett, et al., 2012). 
Once amyloid-β is cleaved from APP by the secretase enzymes, amyloid-β is a soluble 
monomeric peptide in an aqueous environment and is cleared from the brain in healthy persons. 
In pathological cases, amyloid-β misfolds, aggregates and becomes neurotoxic (Selkoe, 2000) 
with intermediate oligomers likely the most neurotoxic species (Kayed R. H., 2003). Amyloid-β 
has been shown to form a variety of quaternary structures including amyloid fibrils (Petkova, et 
al., 2002), and a broad class of possibly intermediate structures termed amyloid oligomers which 
include a variety of structures such as pre-fibrillar oligomers (PFO) (Glabe, 2008) and annular 
protofibrils (APF) (Kayed R. , et al., 2009) among others. 
1.2.1. Fibril Structure 
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The amyloid fibril appears to be a ubiquitous structure intrinsic to the protein backbone 
structure accessible to virtually any polypeptide sequence (Chiti & Dobson, 2006). Fortunately 
amyloid fibrils have only been shown to be associated with a limited number of diseases 
including Alzheimer’s, Parkinson’s, the prion disease and about twenty seven other diseases of 
various severity. Despite a similar end structure2, there seems to be no commonality among 
primary protein structure linking these proteins. The classical biophysical definition of an 
amyloid fibril is a protein structure which exhibits red-green birefringence when exposed to 
circularly polarized light. Identification of amyloid fibrils is also made by determining binding to 
Congo red or Thioflavin T. Today, various methods including x-ray diffraction, NMR, atomic 
force microscopy, and electron microscopy have shown that fibrils formed by different 
properties share similar properties, including a structure made up of unbranched protofilaments 
(Nelson 2006). Mature amyloid fibrils are observed to be approximately 100Å in diameter and 
composed of 20–35Å wide protofilaments.  
While amyloid-β has a poorly defined monomeric structure due to its insolubility and 
difficulty in crystallization, recent advances have allowed researchers to solve the structure of 
amyloid fibrils (Luhrs, et al., 2005). There is general agreement amongst researchers (Nelson & 
Eisenberg, 2006) that amyloid β peptides have a β sheet secondary structure which stack in a 
parallel or anti-parallel fashion to form β sheets running perpendicular to the fibril axis 
(Kirchner, Abraham, & Selkoe, 1986).  
Figure 1 shows a 3D cartoon of a parallel structure of a single amyloid protofilament. A 
mature amyloid fibril is formed when these single protofilaments wrap around one another to 
form a multifilament fibril as shown in figure 2. 
2 The term “native structure” and “functional structure” are purposely not used in this context. 
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Figure 1 - Model of β sheet amyloid structure. Figure reprinted with permission from (Luhrs, et 
al., 2005). Copyright 2005, National Academy of Sciences, USA. 
This model has been characterized as each monomer having an unstructured N-terminal 
(1-16) region with two hydrophobic regions (16-23 and 28-35) connected by a loop region 24-27 
(Mithu, Sarkar, Bhowmik, Chandrakesan, Maiti, & Madhu, 2011). The regions which fold back 
on themselves have been demonstrated to move by a few amino acid sequences. An interior salt 
bridge forms between Asp23 and Lys28 which is detectable by NMR and MD simulations. This 
salt bridge is imperative for the self-dimerization of amyloid-β and an important element of fibril 
structure (Buchete, Tycko, & Hummer, 2005) (Ma & Nossinov, 2002). Short amino acid 
sequences of 14-28 have been shown to form fibrils aiding in the synthesis and purification of 
fibril forming peptides (Gorevic, Castaiio, Sarnia, & Fmgione, 1987). Intermolecular interactions 
amongst the side chains are formed between the odd-numbered residues of the first strand of the 
nth molecule and the even-numbered residues of the second strand of the (n -1)th molecule 
(Luhrs, et al., 2005) (Balbach, et al., 2002). These anti parallel sheets are held together by 
hydrogen bonds. All fibrils have been shown to form a left handed helix (Bauer, et al., 1995) 
(Goldsbury, et al., 1997) (Ionescu-Zanetti, et al., 1999) (Harper, Liber, & Lansbury, 1997).  
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Figure 2 - Model of amyloid fibril. Figure reprinted with permission from (Jimenez, Nettleton, 
Bouchard, Robinson, Dobson, & Saibil, 2002). Copyright 2005, National Academy of Sciences, 
USA. 
In the past, amyloid fibrils were believed to be structures of beta sheets arranged in an 
antiparallel conformation. As a result of NMR spectra reported within the last 10 years, opinion 
has shifted and a prevailing consensus has slowly emerged that the majority of amyloid-β fibrils 
are in fact stacked in a parallel conformation in most naturally occurring fibrils (Antzutkin, 
Balbach, Leapman, Rizzo, Reed, & Tycko, 2000) (Balbach, et al., 2002),  though solid state 
NMR has shown anti-parallel β-sheet stacking under certain conditions in vitro (Buchete, Tycko, 
& Hummer, 2005).   
Fibrils formed by amyloid-β (1-40) and amyloid-β (1-42) appear to have a similar 
structure on a molecular level (Mithu, Sarkar, Bhowmik, Chandrakesan, Maiti, & Madhu, 2011).  
Differing reports have shown a few differences between amyloid-β (1-40) and amyloid-β (1-42). 
Firstly, amyloid-β (1-42) has a intramolecular β-sheet at the C-terminus whereas amyloid-β (1-
40) does not (Masuda, Uemura, & Irie, 2008). Secondly, the loop region at 24-27 is different 
from the two forms of amyloid-β although these differences are under dispute (Petkova, Yau, & 
Tycko, 2006) (Paravastu, Leapman, & Tycko, 2008) (Chimon, Shaibat, & Ishii, 2007). Despite  
these differences the two peptides contain many common structural features including the 
unstructured N-terminus, side chain interactions, and a salt-bridge formed between Asp23 and 
Lys28 (Mithu, Sarkar, Bhowmik, Chandrakesan, Maiti, & Madhu, 2011). Fibrillar structure has 
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been shown to differ when the fibrils are grown in different solutions (Petkova, Leapman, Guo, 
Yau, Mattson, & Tycko, 2005). The conformation of the less structured N-terminus of the 
monomer can alter the fibril structure even though the structural beta-sheet structures remain 
intact (Mithu, Sarkar, Bhowmik, Chandrakesan, Maiti, & Madhu, 2011). 
 X-ray diffraction studies have demonstrated beta-sheets with polypeptide chains running 
roughly perpendicular to the fibril axis and hydrogen bonds formed between chains running 
parallel to the fibril axis (Makin, Atkins, Sikorski, Johanssen, & Serpell, 2005). This is referred 
to as a cross-beta pattern (Antzutkin, Balbach, Leapman, Rizzo, Reed, & Tycko, 2000). 
Molecular dynamics simulations show that strong hydrophobic interactions between non-polar 
residues of the beta-strand result in a well packed fibril core which improves the stability of the 
amyloid fibrils (Buchete, Tycko, & Hummer, 2005). A parallel beta-sheet structure forms a 
linear chain with internuclear distance of approximately 4.8Ǻ. In an antiparallel β-sheet 
structure, a planar zigzag pattern would emerge with internuclear distances exceeding 4.8Ǻ.  
Most of the evidence for antiparallel beta sheets is from experiments conducted using 
infrared absorbance spectra which shows a strong amide I band at 1630 cm-1 and a weak band at 
1690 cm-1. This has been interpreted as being characteristic of anti-parallel sheets (Antzutkin, 
Balbach, Leapman, Rizzo, Reed, & Tycko, 2000). Stacking of amyloid-β can be anti-parallel, 
made up of parallel dimers or parallel stacks of anti-parallel dimers (Antzutkin, Balbach, 
Leapman, Rizzo, Reed, & Tycko, 2000). Tycko and colleagues compared fibrils formed from 
antiparallel beta sheets and fibrils formed from parallel beta sheets and found that antiparallel 
sheets nucleate and are metastable with respect to parallel structure conversion. Both are equally 
neurotoxic (Qiang, Yau, Luo, Mattson, & Tycko, 2012). 
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Parallel and antiparallel beta sheets have been found in a variety of different proteins 
suggesting that parallel beta sheets may be a universal feature of amyloid structures whenever 
the polypeptide contains greater than one beta strand forming segment (such as the 16-23 and 28-
35 segments of amyloid-β (Qiang, Yau, Luo, Mattson, & Tycko, 2012). The alignment of 
hydrophobic residues of amyloid-β (1-40) in parallel structures maximizes hydrophobic 
interactions within the beta sheet (Antzutkin, Balbach, Leapman, Rizzo, Reed, & Tycko, 2000). 
Usually only peptides with one hydrophobic segment form antiparallel beta sheets allowing all 
hydrophobic segments to interact within a planar antiparallel beta sheet which is favoured by 
electrostatic interactions between terminal groups (Qiang, Yau, Luo, Mattson, & Tycko, 2012).  
Tycko and colleagues modified an amyloid-β (1-40) peptide chain with a D23N amino 
acid substitution and, contrary to expectations, demonstrated the existence of anti-parallel beta 
sheets. This discovery required a revision to existing understanding of fibril structure. Previous 
assumptions (Antzutkin, Balbach, Leapman, Rizzo, Reed, & Tycko, 2000) assumed a two 
dimensional plane for fibril formation. If fibril development occurs in three dimensions, though 
beta strand segments altered by loops or bends in a multilayered structure, both parallel and 
antiparallel structures can create alignments which are favourable to hydrophobic segment 
interactions between layers (Qiang, Yau, Luo, Mattson, & Tycko, 2012). From this 
understanding, it is possible that multilayered cross beta motifs could form sequences as long as 
the sequences contain more than two hydrophobic beta strands. Substituting a charged D23 
residue for the neutral N23 residue destabilizes the electrostatic interactions. In some parallel 
amyloid-β (1-40) fibrils, D23 and K28 are paired stabilizing the structure (Qiang, Yau, Luo, 
Mattson, & Tycko, 2012). 
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 Antiparallel fibrils are thermodynamically metastable. Antiparallel structures eventually 
evolve towards parallel structures when grown together with parallel fibrils. If the rate of 
spontaneous nucleation of antiparallel structure is greater than the rate of spontaneous nucleation 
of parallel structures, antiparallel conformations will dominate leading to a greater proportion of 
relatively short antiparallel fibrils. These fibrils will eventually shrink and disappear as 
monomers become more stable parallel fibrils. Parallel structures are more stable than 
antiparallel structures because they have more ordered residues, longer beta strand segments and 
possible better packing of hydrophobic side chains (Qiang, Yau, Luo, Mattson, & Tycko, 2012).  
  
1.2.2. Oligomer Structure 
Amyloid oligomers are often thought of as fibrils which have not fully matured; however, 
recent structural data has demonstrated that this view is overly simplistic. In fact, the term 
“oligomer” is a very broad term and denotes a non-native, aggregated peptide structure which is 
not an amyloid fibril. Some oligomeric species may eventually end as an amyloid fibril, while 
others travel on an off-pathway reaction coordinate. The biochemical definition of an amyloid 
oligomer has been identified as an amyloid species reactive to the A11 antibody and OC- 
whereas fibrillar species are OC+ and A11- (Kayed, 2003).  
A variety of laboratories have demonstrated a diverse set of precursor or off-pathway 
structures to the amyloid fibril and referred to these unique species as aggregates (Kayed, 2003), 
micelles (Soreghan, Kosmoski, & and Glabe, 1994) , protofibrils (Harper, Liber, & Lansbury, 
1997) (Walsh, et al., 1999), prefibrillar aggregates (Bucciantini M. , et al., 2002), toxic amyloid-
β fibrillar oligomers (TABFO’s) (Stroud, Liu, Teng, & Eisenberg, 2012), ADDL’s (Lambert, et 
al., 1998), prefibrillar oligomers (PFO’s) (Glabe, 2008), globulomers (Yu, et al., 2009) and 
annular protofibrils (APF’s) (Kayed R. , et al., 2009). It is unclear which of these structures lie 
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on-pathway to the amyloid fibril, and whether any of them are overlapping species observed at 
different points along the aggregation pathway. Some of these structures lie on the reaction 
pathway to fibrils, and others lie off pathway (Necula, Kayed, Milton, & Glabe, 2007).  
Oligomers and protofibrils show some common structural similarity with mature amyloid 
fibrils. The two beta strand sections (~16-23 and 28-28) are connected by a short loop region. 
However in oligomers and protofibrils, the first strand is shorter than the first strand in mature 
fibrils and a shift takes place during maturation to elongate this strand into mature fibrils 
(Scheidt H. , Morgado, Rothemund, Huster, & Fandrich, 2011) (Scheidt, Morgado, & Huster, 
2012). Furthermore, Glu22 and Ile31 are closer in protofibrils than in mature fibrils (Scheidt, 
Morgado, & Huster, 2012). Huster and coworkers speculated that this structural rearrangement 
of intramolecular hydrogen bonds to intermolecular hydrogen bonds occurs in the last transition 
from protofibrils to mature amyloid fibrils. Beta-sheets appear antiparallel in oligomers and 
protofibrils, and parallel in mature fibrils as observed when using solid state NMR (Scheidt, 
Morgado, & Huster, 2012). X-ray diffraction studies of multimeric protein assemblies have 
shown peptides consisting of 2 densely packed beta-sheets with individual strands oriented with 
strands from one sheet anti parallel with the strands from the sheet immediately adjacent (Liu, 
Sawaya, Cheng, Zheng, Nowick, & Eisenberg, 2011). Often, beta-sheets appear antiparallel in 
oligomers and protofibrils and parallel in mature fibrils as observed by solid state NMR (Scheidt, 
Morgado, & Huster, 2012). 
While there have been an increasing number of reports published within the last five 
years of oligomeric structures, (Scheidt H. , Morgado, Rothemund, Huster, & Fandrich, 2011) 
(Moores, Drolle, Attwood, Simons, & Leonenko, 2011), a definitive x-ray diffraction or 3D 
NMR structure of an amyloid-β oligomer has yet to be resolved (Barz & Urbanc, 2012). 
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Protofibrils are believed to be the immediate precursors to mature amyloid fibrils and are 
longer and more linear than oligomers, but they lack the high order and periodicity of mature 
fibrils and are thinner and shorter than mature fibrils (Walsh, et al., 1999) (Fandrich, 2012). 
Molecular dynamics (MD) simulations conducted by Yu and colleagues show that the 
initial step in oligomerization is the formation of an amyloid dimer, the smallest neurotoxic 
oligomer. Once dimers are formed, they serve as building blocks for an annular ring of 
monomers forming an amyloid oligomer (Yu & Zheng, 2011) possibly leading to the species 
described as annular protofibrils (APF’s) as described by Glabe and coworkers (Kayed R. , et al., 
2009). These species may be identical to the ones identified by Bowers and colleagues as 
especially toxic tetramers, hexamers which can stack to form toxic dodecameric ion channels 
disrupting cellular homeostasis (Bernstein, et al., 2009). It is likely that these species were 
identical to those initially identified by Lal and colleagues as the cytotoxic commonality, linking 
the amyloid misfolding diseases by inducing ion channels (Quist, et al., 2005). 
These annular aggregates (APF’s) consist of a water filled channel or ion pore which may 
contribute to ion dyshomeostatis within the neuron (Connelly, et al., 2012). The hexomeric 
annular oligomer, as predicted and directly observed by Lal and colleagues, (Connelly, et al., 
2012), is believed to insert into the membrane to act as calcium channel as demonstrated by Lin, 
Quist and Arispe (Lin, Bhatia, & Lal, 2001) (Quist, et al., 2005) (Arispe, Pollard, & Rojas, 
1993). Its hexomeric structure was shown using MD simulations and correlates well with the 
observations of Bernstein and colleagues demonstrating the importance of dodecamers, a 
multiple unit of the hexomer in protein misfolding pathogenesis (Bernstein, et al., 2009). The 
membrane disrupting activities of these annular oligomers has been reviewed by Fandrich 
(Fandrich, 2012).  
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Molecular dynamics by Mu and colleagues predicted the structure of amyloid oligomers 
in a lipid membrane environment. Mu showed that the oligomers have a hydrophobic core and 
hydrophilic surface. As a result, Mu speculated that oligomerization is driven by hydrophobic 
effects with electrostatic effects contributing to stabilize the structure (Zhao, Chiu, Benoit, Chew, 
& Mu, 2011). 
While the bilevel dodecamer appears to be consistent from experimental data, Zheng and 
colleague predicted a single level, 12-mer structure using molecular dynamics simulations (Yu & 
Zheng, 2011) as shown in figure 3.  
  
 
Figure 3 - MD simulation of amyloid oligomer formation. Figure adapted with permission from 
(Yu & Zheng, 2011). 
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Eisenberg and coworkers prepared a novel species of amyloid oligomer named a toxic 
amyloid-β fibrillar oligomer (TABFO). TABFO’s share a mature cross-β structure where side 
chains penetrate adjacent β-sheets holding the sheets together (Stroud, Liu, Teng, & Eisenberg, 
2012). However TABFO’s are not short protofilaments. As a result of this structural similarity, 
TABFO’s are OC+, similar to amyloid fibrils, yet they cannot seed new populations of amyloid 
fibrils. The mean mass of TABFO’s is equivalent to 19 ± 4  amyloid-β monomers. 
Various reports have demonstrated oligomer diameters in excess of 50 nm (Broersen, 
Rousseau, & Schymkowitz, 2010) (Fandrich, 2012). Whether these species are an ordered 
oligomer or an amorphous globulomer is unclear. 
Similar, but not identical oligomeric structures are formed by Aβ40 and Aβ42. The 
addition of Ile41 and Ala42 at the C-terminus of Aβ42 contribute considerably to the folding of 
the peptide chain. These residues are hydrophobic and therefore contribute to the hydrophobic 
propensity of beta-sheet formation as well as reduce electrostatic contacts allowing a more 
diverse set of interactions with more distant residues within the protein (Côté, Laghaei, 
Derreumaux, & Mousseau, 2012).  
 Amyloid-β Neurotoxicity 
Amyloid-β toxicity was first identified in the 1980’s with the discovery that amyloid-β is 
the prime constituent in amyloid plaques (Allsop, Landon, & Kidd, 1983) (Glenner & Wong, 
1984) (Hardy & Allsop, 1991) (Masters, Simms, Weinman, Multlraup, McDonaid, & 
Beyreuther, 1985). However, the mechanisms of action of amyloid-β were not elucidated until 
the last two decades. 
Seven general methods of amyloid toxicity have been identified in the literature. (The 
chemistry of these mechanisms is explained later in this chapter):  
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1) Amyloid causes an inflammatory reaction with the cell membrane (Verdier & Penke, 
2004).  
2) Neuronal oxidative stress is caused by reactive oxidative species (ROS) (Mutisya, 
Bowling, & Beal, 1994).  
3) The binding of amyloid-β to metals such as copper, zinc and iron results in oxidative 
stress (Sayre, Perry, & Smith, 1999).  
4) Competitive binding of membrane receptors (Wang, Walsh, Rowan, Selkoe, & Anwyl, 
2004).  
5) Formation of ion channels alters cell homeostasis (Kayed, 2003) (Lin, Bhatia, & Lal, 
2001).  
6) The increased permeability of membranes by the thinning of the lipid bilayer 
(Sokolov, Kozak, Kayed, Chanturiya, Glabe, & Hall, 2006) (Hane, Drolle, Gaikwad, 
Faught, & Leonenko, 2011).  
7) Modification of DNA structure by attachment (Geng, Zhao, Ren, & Qu, 2010). 
In the past,  researchers believed that  amyloid plaques, made of mature amyloid fibrils, 
were the toxic species implicated in AD; however, it has become apparent recently that 
oligomers, rather than fibrils, are the toxic amyloid species. This has led some researchers to 
theorize that amyloid plaques (made of mature fibrils) are in fact a, “last ditch cellular attempt to 
wall off potentially toxic AB oligomers” (Grenough, Camarakis, & Bush, 2012). 
While the misfolding of Aβ42 has been shown to be causal to the pathogenesis of AD, 
attributing Alzheimer’s pathology strictly to the presence of Aβ42 is problematic. Firstly, it is 
unknown why amyloid deposits are focused on the synapse and are not uniform in the cerebral 
parenchyma, especially because amyloid-β is uniformly expressed and Aβ42 is a normal 
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constituent of all cerebrospinal fluid. Secondly, amyloid deposition increases with age, yet 
amyloid production does not. It appears that processes which clear amyloid deposits are 
diminished with age as are mechanisms to protect against redox effects (Bush & Tanzi, 2008). A 
difference between Aβ production and Aβ clearance is likely an underlying factor in the AD 
disease process (Grenough, Camarakis, & Bush, 2012). 
Even though there is only a two amino acid difference in the primary structure of Aβ40 
and Aβ42, there is a distinct aggregation pathway (Bitan, Kirkitadze, Lomakin, Vollers, 
Benedek, & Teplow, 2003) and toxicity (Dahlgren, Manelli, Stine, Baker, Krafft, & LaDu, 
2002). Aβ42 aggregates at a faster rate than Aβ40 making clearance of Aβ42 aggregates more 
problematic (Bush & Tanzi, 2008). While pathological Aβ42 concentration is only 10% that of 
Aβ40, Aβ42 is predominant in pathological amyloid plaques. An increase in the ratio of 
Aβ42:Aβ40 is associated with early onset AD because of a mutation of the amyloid precursor 
protein (APP) gene. This mutation results in an increased Aβ42:Aβ40 ratio, but not an increase 
in the total amount of Aβ produced. In addition, Aβ42 has been shown to be more neurotoxic 
than Aβ40, likely because of its higher aggregation propensity and its higher reactivity with 
metal ions (Bitan, Kirkitadze, Lomakin, Vollers, Benedek, & Teplow, 2003) (Bush & Tanzi, 
2008).   
Amyloid-β can aggregate into different oligomeric structures, each with varying levels of 
toxicities (Klug, Losic, Subasinghe, Aguilar, Martin, & Small, 2003). The structure of an 
amyloid tetramer determines whether an amyloid-β alloform becomes a pathological dodecamer 
or is non-pathological. Small folding differences of monomers are amplified by aggregation 
(Bernstein, et al., 2009). Amyloid-β has been shown to produce channel-like tetrameric and 
hexameric structures when incorporated into lipid membranes. Tetramers and hexamers appear 
24 
 
 
 
to be most stable in lipid membranes. Lal and colleagues predicted the presence of hexameric 
structures in a lipid environment using molecular dynamics simulations and demonstrated these 
predictions by observing images of amyloid-β in lipids with resolved channel-like structures of 
four and six subunits (Lin, Bhatia, & Lal, 2001). Amorphous amyloid plaques do not appear to 
be neurotoxic where compact amyloid deposits appear to have higher neurotoxicity (Klug, Losic, 
Subasinghe, Aguilar, Martin, & Small, 2003). Stable oligomers are expected to become highly 
neurotoxic and are fifty times more likely to induce neuronal apoptosis than amyloid fibrils 
consisting of wild-type Aβ42 (Sandberg, et al., 2010). Cross-linked amyloid-β oligomers are 
consistently more neurotoxic than fibrils (Ono, Condron, & Teplow, 2009) (Yu & Zheng, 2011). 
Trimers have a toxicity three times higher than that of monomers, where tetramers have a 
toxicity 13 times greater than monomers. Unfractionated cross-linked oligomers have a toxicity 
three times greater than that of monomers (Ono, Condron, & Teplow, 2009). The order of 
toxicity related to structure is tetramers > trimers > dimers > fibrils > monomers (Ono, Condron, 
& Teplow, 2009). The exposure of hydrophobic motifs in oligomers, rather than their size and 
secondary structure is the primary determinant of neurotoxicity (Campioni, et al., 2010). A 
higher crossing angle of beta sheets result in higher curvature forming pores by creating a hole 
along the helical axis of the toxic amyloid-β fibrillar oligomers (TABFO) (Stroud, Liu, Teng, & 
Eisenberg, 2012). TABFO’s are toxic to HeLa and PC12 cells at micromolar concentrations (0.5 
μM) (Stöhr, et al., 2012). 
The addition of metals such as Cu2+ appears to greatly increase the neurotoxicity of 
amyloid-β. Aβ42 fibrils are toxic to PC12 cells (40% viability) , whereas Aβ42 with Cu2+ ions 
added result in a viability of PC12 cells of only 4% (Sarell, Wilkinson, & Viles, 2010). 
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Post-translational pyroglutamylated forms of amyloid-β (pE-Aβ) are structurally distinct 
and more toxic than normal amyloid-β (1-42) on its own. pE-Aβ oligomerizes with Aβ42 to form 
low-n oligomers (LNO’s) which are far more neurotoxic than LNO’s made from amyloid-β on 
its own (Nussbaum, et al., 2012 ). pE-Aβ triggers tau dependent neuronal apoptosis that 
proliferate in a prion like manner (Nussbaum, et al., 2012 ). As a result, a small concentration of 
pE-Aβ radically increases the neurotoxicity of amyloid-β oligomers. 
Peroxidation of lipids is a major sign of elevated levels of oxidative stress in the brain 
which has been found in the brains of Alzheimer’s patients. This phenomenon is likely caused by 
reactive oxidative species such as free radicals resulting in increased apoptosis (Zhao, Long, Mu, 
& Yue Chew, 2012). Oxidative stress may also lead to abnormal protein structure and function 
leading to pathological symptoms (Abdul & Butterfield, 2007). Anti-oxidant foods such as 
walnuts and curcumin have been shown to prevent oxidative stress brought on by amyloid-β 
(Mathaiyah, Essa, Chauhan, & Chauhan, 2011). 
Up until the last decade, there was an active debate amongst researchers as to whether 
accumulated tau protein or amyloid plaques were causal to AD pathology. These two camps 
were whimsically referred to as the Tauists and the βAptists (Huang T.-H. J., 2001). Despite a 
decrease in the published literature supporting the tau protein hypothesis, a brief overview is 
warranted. Tau protein is important for the stability of the cytoskeletal and axonal transport as it 
controls microtubule assembly maintaining the structure of the cytoskeleton. The accumulation 
of phosphorylated tau leading to neurofibrillary tangles (NFT’s) has been shown to contribute to 
neuronal apoptosis (Lovestone & Reynolds, 1997). The aggregation of amyloid-β is implicated 
in signalling and mediating the hyperphosphorylation of tau leading to intracellular NFT’s 
(Hernendez, Gomex de Barreda, Fuster-Matanzo, Lucas, & Avila, 2010). In addition, amyloid 
26 
 
 
 
neurotoxicity is compounded by the expression of hyperphosphorylated tau (Nussbaum, et al., 
2012 ). 
 
1.3. Amyloid-β Aggregation 
The correct folding of a protein into a physiologically functional structure is not a sure 
thing: proteins may misfold and aggregate into a non-functional or even a toxic structure. Often, 
this aggregation is the result of an alpha helical structure misfolding into a β-sheet.  This misfold 
is referred to as the toxic amyloid fold which is responsible for amyloid aggregation and toxicity 
(Kayed, 2003). These beta sheets can then aggregate into non-functional oligomers or amyloid 
fibrils.  
1.3.1.  Amyloid-β Misfolding and Amyloidosis 
Amyloidosis is defined as an abnormal molecular process in which a protein,  normally in 
an alpha-helical state, unfolds, re-conforms in a β-sheet conformation and aggregates to form 
insoluble fibril-like structures forming pathogenic amyloid plaques (Serpell, 2000). These 
amyloid fibrils are then deposited either systemically or in specific organs, destroying 
surrounding cells through apoptosis (Johannson, 2005). Amyloid plaques, the visible end-
product of the amyloidosis process, can be observed by staining with the Congo Red dye and 
showing birefringence under polarized light. Despite significant research into the amyloidosis 
process, no clear reason has emerged on the formation and kinetics of this process (Carrell & 
Gootu, 1998). This amyloidosis process is implicated in at least twenty seven different 
pathologies, each one affected by the aggregation of a different protein. These diseases include 
the neuro-degenerative disorders Alzheimer’s, Huntington's, Parkinson's, and Creutzfeld-Jacob's.  
Although much research has been conducted on the conformational change of amyloid-β, 
a clear answer as to why this protein and other proteins misfold still eludes the research 
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community. While the question is often asked why some proteins misfold,  research has shown 
that any protein can misfold: the misfolding process is an intrinsic property of the polypeptide 
backbone (Bucciantini M. , et al., 2002) and is believed to be the structure associated with the 
global energy minimum of the protein folding free energy landscape (Percel, Hudaky, & Palfi, 
2007). So rather than “why do some proteins misfold?”, a more relevant question is, “why don’t 
all proteins misfold?”   
Amyloid-β fibril formation has been shown to involve an α-helix to β-sheet transition. 
However, not all proteins form amyloid deposits by this conformational change: α-synuclein has 
no defined structure in its native state, yet still forms amyloid fibrils (Johannson, 2005). Certain 
proteins show very similar secondary structures once the amyloid process is complete despite 
radically different primary structures. This suggests that the amyloidosis process for each 
different protein involves a different biochemical mechanism than ordinary protein folding 
mediated by side chain interaction (Booth, et al., 1997) such as a polypeptide backbone mediated 
process. In solution, amyloid-β readily transforms into a β-sheet conformation (Szyperski, 
Vandenbussche, Curstedt, Ruysschaert, Wuthrich, & Jan, 1998) despite the theoretical 
predictions that show that the helices are resistant to unfolding (Kovacs, Mark, Johansson, & van 
Gunsteren, 1995).    
The initial aggregation step of amyloid-β occurs with the 16-23 and 28-35 alpha helical 
regions forming beta strands and folding back on one another to “self-dimerize” into a double 
layer hairpin-like monomeric structure stabilized by hydrophobic interactions and a salt-bridge 
on residues D23-K28 (Sciarretta, Gordon, Petkova, Tycko, & Meredith, 2005) (Rauk, 2009).  
Following the initial misfold, the next step in the aggregation process is the dimerization 
of two monomers, the initial process resulting in neurotoxicity (Barz & Urbanc, 2012). MD 
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simulations conducted by the Urbanc and Zheng groups demonstrated that the formation of 
amyloid oligomers is driven by the shielding of hydrophobic residue side chains by the solvent. 
The extra two hydrophobic residues in Aβ42 results in a higher solvent exposure and therefore 
higher aggregation propensity (Barz & Urbanc, 2012) (Yu & Zheng, 2011). In addition, these 
MD simulations have shown that amyloid-β dimers are the smallest building blocks in higher 
ordered oligomers. During the aggregation process, these hairpin-like monomers dimerize and 
eventually aggregate into various amyloid structures, including oligomers, molten globules, and 
fibrils aligned in a parallel and antiparallel conformations (Ma & Nossinov, 2002). The stability 
(ie. propensity to dissociate) of larger oligomers in not a function of the size of the oligomer: 
dimers are less stable than oligomers  (Narayan, et al., 2012).  
Amyloid fibril formation has been described as a two-step process involving a nucleation 
phase and a growth phase. During the slow nucleation phase, alpha helical or random coil 
amyloid-β changes conformation into a beta sheet structure. Once this nucleus has formed, 
adding additional beta sheet monomers becomes thermodynamically favourable (Huang T.-H. J., 
2001) and the fibril grows in either width or length or both. Because of hydrophobicity of the 
peptide, the aggregation of amyloid-β in solution makes kinetics experiments difficult. 
The “Dock and Lock” mechanism of fibril elongation attempts to explain how monomers 
are added to a growing amyloid fibril. This mechanism posits that elongation is mediated by two 
distinct kinetic processes. In the first conformational selection phase (dock), there is a reversible 
process in which monomers are added to the amyloid seeds. During the second (induced fit 
optimization (lock) phase, additional monomers are added irreversibly in a time-dependent 
manner (Esler, et al., 2000) (Massi & Staub, 2001). 
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As a protein folds, misfolds or aggregates, it is said to flow down an energy landscape. 
Local minima correspond to stable states. The amyloid fibril occupies one of these minima, the 
oligomer another minima. Moving along different pathways is a function of the solvent 
properties (temperature, ionic strength, pH) and intrinsic structural  features of the peptide such 
as amino acid mutations. Concentration may also affect its location on the energy landscape 
(Chiti & Dobson, 2006) (Stefani, 2012). The aggregation side of the free energy landscape is 
poorly defined due to the inherent instability and dynamic nature of oligomeric structures which 
have similar free energies. In contrast, fibrils are far more defined and stable resulting in a more 
pronounced free energy landscape (Stefani, 2012). 
The tendency of proteins to assemble into fibrils is a general property of the polypeptide 
backbone (Bucciantini M. , et al., 2002) (Chiti & Dobson, 2009) (Nelson, Sawaya, Balbirnie, 
Madsen, Riekel, & Eisenberg, 2005) caused by the tendency of polypeptide chains to assemble 
into fibrils stabilized by inter-molecular hydrogen bonds between peptide bonds in parallel or 
anti-parallel structured beta-sheets referred to as a cross-beta structure (Stefani, 2012). When 
exposed to certain environments, peptides may externalize their normally buried polar side 
chains allowing interaction with the environment. This results in protein aggregations that are 
more energetically favourable, and different than those occurring in bulk solution (Suetherman & 
Belfort, 2005) (Stefani, 2012). Both double sheet and triple beta sheet conformations have been 
suggested for amyloid fibrils (Ma & Nussinov, 2012). Despite past orthodoxy that amyloid 
oligomers are merely small fibrils or intermediates along the fibril pathway, recent advances 
suggest that some annular oligomers, such as annular protofibrils may be structural end products 
of their own aggregation pathway as opposed to structural intermediates enroute to a fibrillar 
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structure (Kayed R. H., 2003) (Stefani, 2012) (Bitan, Kirkitadze, Lomakin, Vollers, Benedek, & 
Teplow, 2003). 
Work by Giles and colleagues showed that injecting  transgenic mice with amyloid-β 
initiated the aggregation process. The authors claimed that this was incontrovertible evidence 
that amyloid-β are in fact prions (Stöhr, et al., 2012). It is worthwhile to remember that amyloid-
β aggregates do seed further aggregates. Whether this qualifies these peptides to be classified as 
prions is a matter of current debate. It does however, explain why extensively researched 
amyloid vaccines have been unsuccessful thus far. 
Even though the primary structure sequence between Aβ42 and Aβ40 are very similar, 
the two alloforms oligomerize much differently. From conducting numerous cross-linking 
experiments, Teplow and colleagues were able to identify that Aβ42 oligomers appear as 
multiples (dodecamer) of small species such as hexamers by a method of self-association of 
smaller units (Bitan, Kirkitadze, Lomakin, Vollers, Benedek, & Teplow, 2003). Larger 
oligomers, such as dodecamers were found primarily in the Aβ42 alloform. At similar 
concentrations, oligomers of Aβ40 did not form, revealing why there is a difference between 
amyloid toxicity depending on which of the alloforms is present in pathological cases (Bitan, 
Kirkitadze, Lomakin, Vollers, Benedek, & Teplow, 2003).  
Research by Merzel and colleagues showed that the kinetics of amyloid-β aggregation 
may be a function of ionic strength: at low ionic concentrations, electrostatic repulsion between 
the monomer and the fibril allows for polymerization where the monomer binds the end of the 
fibril. At high ionic concentrations, hydrophobic interactions drives interaction at both the end of 
the fibril and the lateral edges making the fibril more broad (Zidar & Merzel, 2011).  
1.3.2. Evidence for Separate Aggregation Pathways 
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Earlier reports often assumed that the amyloid fibril pathway is a single pathway which 
travels through intermediates such as oligomers, protofibrils and finally to a full mature amyloid 
fibril. An increasing body of evidence suggests that “intermediate” species of amyloid-β are not 
actually intermediates, but rather lie along a separate reaction coordinate, with its divergence 
from the fibrillar pathway occurring early in the aggregation process. However, it is still a matter 
of debate whether oligomers, and perhaps which species of oligomers, are on-pathway products 
(grow by a direct addition of monomers) or off-pathway, meaning they occupy a minima on the 
free energy landscape of amyloid fibrils (Bitan, Kirkitadze, Lomakin, Vollers, Benedek, & 
Teplow, 2003) (Necula, Kayed, Milton, & Glabe, 2007) (Stefani, 2012) (Petkova, Leapman, 
Guo, Yau, Mattson, & Tycko, 2005). No standardized nomenclature has been developed for 
amyloid intermediates or off-pathway structures. While research by the Glabe group uses the 
terms fibrillar oligomer and prefibrillar oligomer, other terms found in the literature include 
protofibrils, unstructured oligomers (Bieschke, et al., 2012) among others. 
Small and colleagues used PAGE to observe different aggregation patterns in amyloid-β. 
Small showed that one of the pathways was inhibited by metal ions and slowly generates stable 
species detectable by PAGE. Along another pathway, unstable species that rapidly disaggregate 
are generated; these  are not detectable by PAGE. Neurotoxicity studies show that amyloid-β 
which is slow to aggregate is more neurotoxic than the unstable species which aggregates more 
rapidly (Klug, Losic, Subasinghe, Aguilar, Martin, & Small, 2003). 
Research by the Glabe laboratory has identified species of oligomers based on their 
reaction with antibodies (Glabe, 2008). Glabe has demonstrated that once the monomer misfolds, 
the aggregation pathway begins with a divergence depending on the conformation it adopts. The 
products along this reaction pathway include prefibrillar oligomers and fibrillar oligomers. 
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Products on this pathway are reactive to either antibody A11 or OC. Prefibrillar oligomers (PFO) 
are A11+ and OC-. These prefibrillar oligomers can then continue along their reaction pathway 
to form protofibrils and eventually amyloid fibrils. The second pathway, that of fibrillar 
oligomers (FO), is OC+ and A11- and represents fibril nuclei. The elongation of fibrils is a result 
of the addition of monomers until they become amyloid fibrils (Glabe, 2008). The fact that there 
is a difference in antibody binding to different oligomer structures suggests that there is a 
fundamental structural difference between the prefibrillar oligomer and the fibrillar oligomer 
(Glabe, 2008). However, Glabe and colleagues also showed that not all oligomers necessarily lie 
on the pathway to fibril formation (Necula, Kayed, Milton, & Glabe, 2007) (Kayed R. , et al., 
2009) (Chen & Glabe, 2006). β-sheet–rich spherical oligomers lie along the fibril reaction 
pathway whereas unstructured oligomers are off-pathway (Ahmed, 2010). The hypothesis that 
various species lie along different pathways is supported by the observation that at high 
concentrations of urea, oligomers do not yet form amyloid fibrils still form. Certain oligomeric 
species such as spherical oligomers are observed at intermediate times of incubation during 
amyloid fibrillogenesis resulting in the conclusion that oligomers lie along the fibrillization 
pathway (Glabe, 2008). Further research by Glabe demonstrated that amyloid fibrillar oligomers 
do not seed Thioflavin T (ThT) positive amyloid fibrils. These fibrillar oligomers nucleate 
soluble oligomers which are OC positive and ThT negative (Wu, et al., 2010). By using ThT 
fluorescence, Glabe showed that fibrillar oligomers seed other fibrillar oligomers rather than 
amyloid fibrils and the kinetics of fibrillar oligomer formation is faster than fibril formation. 
Glabe concluded that soluble fibrillar oligomers are distinct from prefibrillar oligomers and 
mature fibrils with distinct structural and antibody reactive properties.  
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 The work by Glabe is supported by observations by Dobson and Härd who used protein 
engineering to study the aggregation pathways of amyloid-β. Härd and colleagues found that 
amyloid-β can aggregate along at least two different aggregation pathways. By blocking amyloid 
fibril formation, toxic oligomers are transiently formed (Sandberg, et al., 2010). Härd deduced 
that the higher neurotoxicity of oligomers is a function of its aggregation pathway compared to 
the fibril forming pathway. By modifying the amyloid-β peptide, Härd demonstrated that a 
disulfide bridge between Cys21 and Cys30 prevented the formation of amyloid fibrils and 
formed stable oligomers which are indistinguishable from wild-type amyloid oligomers and 
contained dimeric and trimeric structures which have been shown to be neurotoxic. 
Hoshi and colleagues used fluorescence correlation spectroscopy and TEM to uncover a 
novel amyloid species referred to as amylospheroids (ASPD). The pathways to ASPD’s is off-
pathway to fibrils. ASPD’s initiate with trimerization as opposed to dimerization and their most 
toxic forms are 128 kDa 32-mer as opposed to the initial dimerization of fibrils (Matsumura, et 
al., 2012). ASPD’s are not incorporated during fibrillogenesis and have different morphology 
from amyloid derived diffusible ligands (ADDL’s) and protofibrils as well as  different 
immunoreactivity profiles of the oligomeric antibody A11. Hoshi and colleagues provided some 
evidence that ASPD’s are the amyloid species directly casual to neuronal apoptosis (Matsumura, 
et al., 2012). In contrast to fibrils, ASPD’s do not form at lower pH. The assembly of various 
species may not be a linear process, but rather the result of the integration of various kinetic 
pathways. 
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Figure 4 - Possible divergence pathway of fibrils and ASPD's. Figure reprinted with permission 
from  (Matsumura, et al., 2012). Copyright 2012, the Journal of Biological Chemistry. 
 
Molecular dynamics simulations by Shea and colleagues demonstrated a “rich diversity” 
of aggregation pathways (Bellesia & Shea, 2009). Shea demonstrated that these pathways occur 
via three mechanisms. The first is ordered oligomers assembling into fibrils, the second is the 
aggregation of on-pathway non-fibrillar aggregates; the third is the reorganization of amorphous 
aggregates into fibrils (Bellesia & Shea, 2009). All beta rich sequences resulted in non-fibrillar 
annular barrel-type structures (perhaps those observed by Lal (Connelly, et al., 2012) Glabe 
(Kayed R. , et al., 2009) or Teplow (Bernstein, et al., 2009) or fibrils. As the beta-sheet 
propensity of the peptide increased, the number of possible aggregation pathways was reduced. 
The barrel type structure appeared to be off-pathway and never evolved into fibrils. Furthermore, 
by increasing the flexibility of the peptide backbone, the number of possible end products is 
increased. 
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Theoretical predictions by Yu and Zheng demonstrated a unique conformation of 
amyloid oligomers which occur on a different reaction pathway than the fibrillar pathway, 
suggesting different kinetics between the two amyloid species (Yu & Zheng, 2011). The fibril 
pathway occurs as a two-step process with a lag phase in which nucleation occurs, and a growth 
phase associated with the elongation of the amyloid fibrils. Oligomers (called globulomers by 
Yu) on the other hand, form by interacting with other monomers and oligomers and occur rather 
quickly. Residues are packed in an out-of register fashion between the twisted beta strands. 
These globulomers have a measured diameter of 4nm with a molecular weight of 64 kDA 
corresponding to a 12-16 monomeric units/globulomers (Yu & Zheng, 2011). Yu determined the 
interaction energy of dimerization between the different species of amyloid aggregates and found 
that the parallel conformation dimer is more favoured than the out of register dimer conformation 
associated with the globulomers.  
  The aggregation pathway which amyloid-β travels appears to be concentration 
dependent. Aβ42 has been shown to form prefibrillar oligomers at concentrations below 30 µM 
while forming fibrils at higher concentrations. Tessier and colleagues demonstrated the 
conversion of a prefibrillar oligomer into an oligomer which is less toxic than the amyloid-β 
monomer and unable to disrupt the lipid bilayer. The authors proposed that peptide-lipid 
interaction is a function of the exposed hydrophobic segments (Ladiwala, et al., 2012).  
 By adding a novel amyloid antibody, KW1, to an incubation of amyloid-β, the addition of 
1% preformed fibrils to the monomeric solution resulted in a 50% decrease in the lag curve; 
however, adding preformed oligomers to the incubation solution resulted in no change in the lag 
curve (Morgado, et al., 2012). This indicates that KW1 can accelerate the aggregation of amyloid 
fibrils but not oligomers. 
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Lastly, Aβ40 and Aβ42 have been demonstrated to aggregate along separate pathways 
despite an identical hydrodynamic radius (Chen & Glabe, 2006). The initial folding structures of 
Aβ40 and Aβ42 are different and effect the peptides pathway to form higher order fibrillar 
structures. This difference is attributed to Aβ40 and Aβ42 having different aggregation pathways  
(Chen & Glabe, 2006). Data collected by Teplow and colleagues suggest that the difference in 
fibril assembly occurring between Aβ40 and Aβ42 begins immediately after peptide translation 
(Bitan, Kirkitadze, Lomakin, Vollers, Benedek, & Teplow, 2003). Further research by the Glabe 
lab demonstrated that Aβ42 tends to form trimers and tetramers with a higher free energy than 
Aβ42 which remains in monomeric forms (Chen & Glabe, 2006). In addition, ASPD’s from 
Aβ42 formed much faster than those from Aβ40 and were two orders of magnitude times more 
toxic (Matsumura, et al., 2012). 
 This difference in aggregation pathways between the two alloforms could be responsible 
for the pathological difference between the two alloforms: an overexpression of Aβ40 does not 
result in Alzheimer’s symptoms whereas low levels of Aβ42 results in amyloid pathology  (Chen 
& Glabe, 2006). This can be attributed to the difference in secondary structure between the two. 
Aβ40 is found to be largely in a monomeric form containing extensive random coil regions, but 
is not completely unfolded and likely adopts a two state unfolded monomer to monomeric model 
(Chen & Glabe, 2006). Consistent with the predictions made by Shea, as the beta-sheet content 
increases, the number of possible aggregation pathways decreases (Bellesia & Shea, 2009) 
leading to a higher probability of Aβ42 travelling along a pathogenic pathway.  
 
1.3.3. Aggregation Kinetics 
Amyloid aggregation follows a sigmoidal growth curve characteristic of nucleation 
dependent polymerization. Seeding the solution with preformed fibrils tends to result in a 
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hyperbolic growth curve (Hurshman, White, Powers, & Kelly, 2004). However hyperbolic 
curves have been demonstrated in some non-seeded experiments as well (Crespo, Rocha, Damas, 
& Martins, 2012). There are many different amyloid forming proteins each of which have their 
own individual kinetic and aggregation properties (Bellesia & Shea, 2009), however, the basic 
principles of aggregation kinetics apply to all of them. 
The conformational change of a protein from its native state is the initiating step in 
protein aggregation (Chiti & Dobson, 2009). As the peptide begins to aggregate, a critical 
nucleus is formed. Repeated observations that adding fibrillar seeds to monomeric solutions 
eliminates the lag phase in the sigmoidal growth curve creating a hyperbolic growth curve 
(Crespo, Rocha, Damas, & Martins, 2012) supports the hypothesis that the formation of a critical 
nucleus is the rate limiting step in fibril formation and is responsible for the lag phase of growth 
kinetics (Stefani, 2012). In addition to seeding aggregates in vitro, adding pre-formed fibrils has 
been shown to accelerate the deposition of amyloid oligomers leading some researchers to 
conclude that amyloid forming proteins such as amyloid-β are in fact prions (Stöhr, et al., 2012). 
MD simulations by Urbanc showed that when the primary sequence of Aβ40 is modified slightly 
to form a D23-K28 covalent bridge, fibrils formed at a rate three orders of magnitude faster than 
the wild type protein. The authors suggest that the increase in kinetics is a result of a bypass of a 
rate limiting nucleation process (Barz & Urbanc, 2012). 
Whether amyloid fibril formation is a one-step or two-step nucleation process is a 
question of contemporary debate and closely related to the debate of on- and off-pathway 
intermediates. Recently, Kashchiev and colleagues developed a model showing that the kinetic 
pathway is a function of both temperature and amyloid concentration in solution (Auer, 
Ricchiuto, & Kashchiev, 2012). Amyloid fibrillization can proceed in either  a one-step 
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nucleation pathway where monomers directly become fibrils or along a two-step nucleation 
pathway where monomers become oligomers which then become fibrils. The conclusions 
derived from this kinetic model agree with the phenomenological observations made by Glabe 
(Glabe, 2008). At lower concentrations (<20 µM), OC+ fibrils tend not to form, but rather A11+ 
unstable oligomeric structures (Ladiwala, et al., 2012). The critical concentration of an amyloid 
forming protein is the concentration at which the rate of fibril formation is equal to the rate of 
fibril dissolution (Andreu & Timasheff, 1986). The aggregation process is a function of the 
initial protein concentration and depends on whether the concentration is greater than or less than 
the critical protein concentration (Lomakin, Chung, Benedek, Kirschner, & Teplow, 1996). Fibril 
nucleation is much slower than oligomer formation because of the greater entropic barrier 
needing to be overcome during fibrillar self-assembly (Lansbury, Costa, Griffiths, Simon, & 
Auger, 1995). 
Hoshino and colleagues put forth a model for amyloid-β aggregation whereby the lag 
phase is caused by association events between amyloid-β molecules. Covalent disulfide linking 
between two separate peptides results in an increased local concentration leading to an increased 
rate of aggregation and an increase in the formation of ThT active aggregates (Yamaguchi, Yagi, 
Goto, Matsuzaki, & Hoshino, 2010). This state has a different morphology than amyloid fibrils 
even though it is ThT positive. These protofibrils aggregates are not the most thermodynamically 
stable, but occupy a kinetically trapped state. 
The pathway leading to amyloid fibrils is not a direct one. Monomers can rapidly become 
paranuclei which can oligomerize further to form beaded structures or protofibrils at a slower 
rate. Finally, the protofibrils can irreversibly become mature fibrils (Bitan, Kirkitadze, Lomakin, 
Vollers, Benedek, & Teplow, 2003).  
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Bernstein and colleagues showed how tetramers, hexamers and dodecamers all lie along 
the neurotoxic pathway (Bernstein, et al., 2009).  Figure 5  shows a cartoon of proposed different 
aggregation pathways. In the top random coiled pathway, the aggregates end up as non-fibrillar 
aggregates which bind to the A11 antibody. These aggregates are less structured than their 
fibrillar counterparts. The lower pathway travel along a β-sheet pathway with a neurotoxic fibril 
end product (Sandberg, et al., 2010). 
 
Figure 5 - Suggested amyloid aggregation pathway. Figure reprinted with permission from 
(Bernstein, et al., 2009). Copyright 2009, Nature Publishing Group. 
 
Work by Lindquist and colleagues (Krishnan, et al., 2012) demonstrated that in the 
multitude of amyloid pathways, certain pathways result in OC+ aggregates (fibrils) and other 
pathways in A11+ aggregates (oligomers). Labeling the peptide with these antibodies directs the 
aggregation pathway along its respective pathway. There is a direct pathway to amyloid fibrils, 
but many secondary pathways result in a local minima in the free energy landscape. 
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Figure 6 - Possible aggregation pathways. Figure reprinted with permission from (Krishnan, et 
al., 2012). Copyright 2012, National Academy of Sciences, USA. 
 
Observations by a number of groups have demonstrated that even if amyloid species 
proceed along one pathway, they can readily change conformation and follow another pathway. 
For example, prefibrillar oligomers (PFO’s) are A11+ and appear early in incubation. When 
exposed to hydrophobic-hydrophilic surfaces, or during longer incubation, PFO’s can form 
annular protofibrils (APF’s) which are circular PFO subunits and form pore forming ion 
channels (Kayed R. , et al., 2009). Fibrillar oligomers are A11- and OC+ and eventually seed 
amyloid fibrils and are thought of as small amyloid fibrils (Butterfield & Lashuel, 2010). During 
oligomer to fibril transition, there is a 90° rotation of the β-strands suggesting an intra- to inter-
molecular hydrogen bond conversion. It is believed that this switch occurs as protofibrils mature 
into mature amyloid fibrils (Scheidt, Morgado, & Huster, 2012). 
Different amyloid-β alloforms have different motifs, and as a result, different kinetic 
pathways (Côté, Laghaei, Derreumaux, & Mousseau, 2012). Despite similar primary structure, 
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Aβ40 and Aβ42 do not proceed along similar pathways. Aβ40 does not readily form typical 
amyloid fibrils: rather, it forms shorter protofibrils aggregates without any detectable lag period 
(Yamaguchi, Yagi, Goto, Matsuzaki, & Hoshino, 2010). A kinetic barrier for the formation of β-
sheet makes Aβ40 more prone to form along the coil pathway rather than a toxic oligomeric 
pathway. This may explain why Aβ42 is more toxic than Aβ40 (Sandberg, et al., 2010). Aβ42 
aggregates at a faster rate than Aβ40 because of a kinetic barrier in the Aβ40 pathway (Bitan, 
Kirkitadze, Lomakin, Vollers, Benedek, & Teplow, 2003) (Bernstein, et al., 2009). 
 Changes in kinetic properties of amyloid-β aggregation (ie. On rate) are not necessarily a 
function of thermodynamic effects (such as structural changes, solubility, etc). For example, the 
apoE3 gene reduces the rate of amyloidosis in Aβ40 without affecting the structure of the 
fibrillar end product (Evans, Berger, Cho, Weisgraber, & Lansbury, 1995). 
 Both the nucleation rate and the growth rate affect the fibrillization of proteins. Teplow 
and co-workers have argued that the terms “inhibition” and “promotion”  describing external 
agents are overly simplistic because an “inhibitor” may inhibit nucleation, thereby reducing the 
number of fibrils, resulting in longer fibrils (Lomakin, Chung, Benedek, Kirschner, & Teplow, 
1996). 
 Work by Roberts and colleagues (Ryan, Friedhube, Lind, Howlett, Masters, & Roberts, 
2012) examined the kinetics of Aβ42 fibril formation in the presence of 96 different amphipathic 
molecules. Compounds such as sodium salt of deoxycholic acid maximized fibril formation 
whereas sodium dodecyl sulfate (SDS) maximized oligomer formation. The authors suggest that 
the amyloid-β binding site contains at least one small molecule binding site which modulates 
peptide aggregation. Human serum albumin inhibits the kinetics of amyloid fibrillization by 
increasing the lag time associated with fibril formation acting somewhat analogous to 
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competitive inhibitor in the aggregation pathway (Stanyon & Viles, 2012). In addition, human 
serum albumin (HAS) reduces the total number of fibrils generated as reflected in the reduced 
fluorescence signal. The authors suggest that HSA binds to amyloid-β molecules trapping them 
in a non-fibrillar form effectively preventing them from forming fibrils. It is interesting to note 
that while the binding affinity of HSA to amyloid-β is unremarkable (Kd=5µM), the 
concentration of HSA in the cerebrospinal fluid (CSF) is 3µM resulting in a reduction of 
amyloid-β able to aggregate. 
1.3.4. Aggregation Statistical Mechanics 
Looking at the amyloid cascade hypothesis through the lens of energy landscape theory 
raises some interesting observations. Firstly, a sufficient amount of amyloid-β protein must be 
present for nucleation to occur above and beyond the “saturation point”, where the saturation 
point is the concentration at which, above, aggregation will occur. Secondly, a sufficient number 
of oligomers must be present and escape their free energy “reservoir” to support the elongation 
of fibrils. The protein diffuses down the free energy landscape as the aggregation process 
progresses with oligomers and fibrils occupying local or global minima (He, Giurleo, & Talaga, 
2010). Disordered free structures have a high free energy while mature fibrils occupy a lower 
free energy state. By probing their locations on the free energy landscape, toxic oligomers and 
the critical nucleus required for aggregation have different energy landscapes.  
There is a significant reduction in the free energy upon monomer to dimer conversion 
(Barz & Urbanc, 2012). The relationship between various amyloid intermediaries can be 
determined by probing their locations on the free energy landscape (He, Giurleo, & Talaga, 
2010). Different secondary structures (parallel vs. antiparallel) in amyloid fibrils result in 
different potential energies (Han, Wang, & Yang, 2008). The formation of higher order 
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structures is a function of the concentration of reservoir oligomers. Elongation of fibrils or the 
formation of higher order structure requires the depletion of the reservoir of intermediate 
structures. The filling of the reservoir with intermediates may be the rate limiting step in any 
aggregation process (He, Giurleo, & Talaga, 2010). It is generally agreed that the amyloid fibril 
occupies the global free energy minima and is therefore the most stable structure both in a 
vacuum and in aqueous environments (Stefani, 2012) (Perczel, Hudaky, & Palfi, 2007). In 
particular, double or multiple stranded fibrils are the most stable structures.  Theoretical work by 
Shea and colleagues showed that barrel-like aggregates have nearly identical potential energy as 
mature, triple layered fibrils (Bellesia & Shea, 2009). 
A more flexible peptide results in a greater diversity of structures. The effect of β-sheet 
propensity and temperature has the greatest impact on the final oligomeric or fibrillar structure. 
A lower temperature and a high propensity of β -sheet structures is associated with a higher 
probability of forming highly ordered, triple layered amyloid fibrils. Amorphous structures 
occupy the phase space where temperature is highest and β-sheet propensity is lowest (Bellesia 
& Shea, 2009). 
The aggregation process is driven by thermodynamics: once aggregation begins, there is 
no thermodynamic reason for the process to cease (Perczel, Hudaky, & Palfi, 2007) other than 
the structure finding a local minima. However, given the roughness of the free energy landscape, 
any increase in enthalpy would result in the protein coming out of its well, and further 
proceeding down the free energy landscape. 
There is no primary amino acid sequence that codes for the amyloid fibril, rather, the 
aggregation of proteins is an inherent property of the polypeptide backbone (Perczel, Hudaky, & 
Palfi, 2007).  
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Antiparallel structures are preferred to parallel structures in amyloid aggregates when 
metals are added (Han, Wang, & Yang, 2008). Using MD simulations, the potential energy of 
antiparallel structures is predicted to be approximately 25% lower than that of parallel structures. 
A greater proportion of hydrophobic residues exposed to the solvent correlate with 
increased propensity for aggregation. Aβ42 dimers showed a greater number of shallow local 
minima compared to Aβ40 (Barz & Urbanc, 2012). Aβ42 dimers show a greater structural 
diversity than Aβ40 (Barz & Urbanc, 2012). Using this reasoning, a mutation that induces  
aggregation would be expected to lower the energy barrier associated with aggregation (He, 
Giurleo, & Talaga, 2010). 
Talaga and colleagues used a statistical mechanical method to quantify the aggregation of 
β-lactoglobulin, an amyloid forming protein. Talaga defines the term ‘reservoir oligomer’ as a 
structure occupying a local energy minima. Sufficient energy is required for the structure to 
escape the reservoir ie. overcome an energy barrier (He, Giurleo, & Talaga, 2010). 
 
1.4. Amyloid-β-Metals Interactions 
The presence of metals in amyloid plaques has long been attributed to a link between 
amyloid fibril formation and metal ions. In fact, in times past, physicians even recommended that 
people shouldn’t cook in aluminum pans for fear of aluminum residues entering the body and 
making their way to the brain and inducing AD. Recent scientific advances have calmed the fears 
of gastronomers everywhere: cooking with aluminum pans has been disproven as contributing to 
Alzheimer’s disease. Amyloid-β has a unique affinity to metal ions such as copper and zinc 
coordinated at the imidazole groups of His6, His13 and His14 (Faller & Hureau, 2009)  (Hou & 
Zagorski, 2006) (Shin & Saxena, 2008) via a cross-linking action (Han, Wang, & Yang, 2008).  
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The brain uses  more oxygen than any other organ in the body; it accounts for 20% of 
oxygen consumption but only accounts for 2% of the body’s mass (Smith, Cappai, & Barnham, 
2007). Amyloid deposits are focused in the synapses and lamina media of the cerebrovasculature 
and are not distributed uniformly despite the fact that APP is uniformly expressed rendering the 
theory that elevated amyloid-β levels the sole determinant of amyloid deposition highly 
improbable (Bush & Tanzi, 2008). Concentrations of metals in the brain are regulated at the 
blood brain barrier (Grenough, Camarakis, & Bush, 2012). 
There appears to be a number of different mechanisms in which metal ions aggravate 
Alzheimer’s disease (Faller & Hureau, 2009). Copper tends to drive the aggregation of amyloid-
β towards the anti-parallel conformation which has a potential energy of approximately 25% 
lower than the parallel structure resulting in the formation of toxic oligomers rather than inert 
fibrils. Even sub-molar concentrations of copper ions released from synapses are sufficient to 
induce amyloid aggregation (Jun & Saxena, 2007) (Tougu, Karafin, & Palumaa, 2008). Redox 
active Fe(III) and Cu(II) have been shown to be neurotoxic via a Fenton reaction, while Zn(II) is 
believed to be neuroprotective or neurotoxic dependant on its concentration (Nair, Perry, Smith, 
& Reddya, 2010). Depending on concentration, zinc has been shown to stabilize amyloid 
oligomers preventing further aggregation into fibrils (Nair, Perry, Smith, & Reddya, 2010) or 
induce aggregation, but direct the aggregation pathway towards amorphous end products (Karr & 
Szalai, 2008). Cu(II) binding has Kd values several orders of magnitude lower than Zn(II) 
binding indicating a much stronger affinity (Faller & Hureau, 2009). 
Rat and mouse amyloid-β has substitutions that reduce the affinity for metals (Bush, 
Pettingell, & Multhaup, 1994) leading some researchers to speculate that this is why these 
animals do not have amyloid deposits with advanced age (Bush & Tanzi, 2008). 
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Aβ42 has a greater binding affinity for Cu(II) than Aβ40 providing another possible 
explanation of why Aβ42 may be more neurotoxic than Aβ40 (Curtain, Ali, & Volitakis, 2001). 
1.4.1. Chemistry of Amyloid-β-Copper Interactions 
The brain has many different ways to regulate free copper ions. These include circulating 
albumin to bind copper, rendering it unavailable for forming amyloid complexes (Hartter & 
Barnea, 1988) (Lutsenko, Bhattacharjee, & Hubbard, 2010), and the limited uptake of free 
copper across the blood-brain barrier (Choi & Zheng, 2009) (Eskici & Axelsen, 2012). 
His13 and His14 are the main ligands involved in metal coordination in amyloid 
aggregation. Cu binds to the imidazole ring of the histidine residues at the nitrogen atoms 
(Miura, Suzuki, Kohata, & Takeuchi, 2000). The specific atoms involved in binding metal ions 
are the N atom from the imidazole ring of His residues, N of the deprotonated amide of His, the 
O of the carboxyl group, N of the deprotonated amide of the main chain and O of water. Metals 
such as Cu(II) and Zn(II) can bridge peptide chains via tetrahedral coordination (Han, Wang, & 
Yang, 2008). Glu3, Glu11, Glu23, Asp1, Asp7, Asp23 and Tyr10 may also be involved in metal 
complexing (Nair, Perry, Smith, & Reddya, 2010) (Han, Wang, & Yang, 2008). Asp1 has been 
shown to form stable complexes with the His residues and Cu(II) however, Asp1 does not bind 
Cu(II) if there is any His binding (Azimi & Rauk, 2011). Cu(II) is more efficient in histidine 
binding than Fe(III) which is more efficient than Zn(II) (Cu>Fe>Zn) explaining why Cu(II) 
displays higher levels of peptide-metal complexing (Nair, Perry, Smith, & Reddya, 2010) than 
the other two metal ions. Copper binding to amyloid-β is dependent on pH with an increasing 
affinity with a drop in pH (Syme, Nadal, Rigby, & Viiles, 2004). 
Various laboratories have shown that Cu(II) affinity towards amyloid-β varies from 
attomolar (Atwood, et al., 2000) to micromolar (Garzon-Rodriguez, Yatsimirsky, & Glabe, 
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1999). The difference in environmental conditions may account for some of these differences 
(Tougu, Tiiman, & Palumaa, 2011). Cu(I) appears to bind Cu with much higher affinity 
(femtomolar) then Cu(II) (Feaga, Maduka, Foster, & Szalai, 2011) (Azimi & Rauk, 2011). 
There has been considerable controversy in the literature regarding the effects of Cu(II) 
ions as a function of their concentration. Substoichiometric levels of Cu(II), which are 
physiologically relevant,  increase amyloid neurotoxicity (Sarell, Wilkinson, & Viles, 2010). 
However, as the concentration of Cu increases, the aggregation pathway tends to form 
neurotoxic non-fibrillar aggregates such as protofibrils and ADDL’s (Eskici & Axelsen, 2012). 
The potential energy of an amyloid-β dimer coordinated with Cu(II) is lower in an anti-
parallel conformation compared to parallel. This difference is attributed to the difference in 
potential energies of the secondary structures and the planar structure of the metal bridge bonds 
in antiparallel structures which serve to further stabilize the structure. It is unlikely that Cu(II) is 
involved in parallel β-sheet structures because the Cu associated His13 and His14 residues would 
lie on opposite sides of the β-sheet and would be unable to interact with copper (Eskici & 
Axelsen, 2012).The formation of a bridge induced by metal binding results in a drop in the 
potential energy from -36.40 kcal/mol to -405 kcal/mol with Zn (II) binding and -281 kcal/mol 
with Cu (II) binding stabilizing the peptide structure (Han, Wang, & Yang, 2008). 
The cleaving of APP is a function of γ-secretase and β-secretase activity. The cleavage 
site determines whether the amyloid-β will have a propensity to aggregate (Aβ42) or not (Aβ40). 
The presence of copper is one of the factors (via other copper binding proteins) that influences 
the cleaving sites of the secretases (Thinakaran & Koo, 2008). APP has a copper binding domain 
at 124-189 and 376-554 which lies outside the domain cleaved for amyloid-β (Eskici & Axelsen, 
2012). The copper binding domain of APP demonstrates a Kd value of 10nM indicating a strong 
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affinity for Cu (Smith, Cappai, & Barnham, 2007). Figure 7 shows the three possible 
coordination geometries of the APP protein. 7A shows a 5 coordinate geometry of a crystal 
structure of the Cu binding domain. Figure 7B shows a tetrahedrally distorted square planar 
geometry in APP. 7C shows square planar coordination geometry in amyloid-β involving His6, 
His 13, and His14 (Eskici & Axelsen, 2012). 
 
Figure 7- APP-Cu coordination geometries. Figure reprinted with permission from (Eskici & 
Axelsen, 2012). Copyright 2012, American Chemical Society. 
 
1.4.3. Chemistry of Amyloid-β-Zinc Interactions 
The amyloid-β zinc coordination is similar to that of the amyloid-β copper coordination. 
Reddya and colleagues demonstrated a 1:2 stoichiometry of Zn:histidine residues with an 
octahedral structure (Nair, Perry, Smith, & Reddya, 2010) likely made up of 4-6 ligands 
including His6, His13, His14 and possibly Asp1 (Faller & Hureau, 2009). However, other side 
chains such as Asp and Glu and the hydroxyl group of Tyr may contribute to Zn binding affinity 
(Nair, Perry, Smith, & Reddya, 2010). Zn can destabilize and break the loop region formed by 
Asp23 and Lys28 by forcing these residues into conformations where salt bridge formation is not 
favourable (Mayeux, Tang, & Mehta, 1999) while leaving the cross-β structure of fibrils intact 
(Mithu, Sarkar, Bhowmik, Chandrakesan, Maiti, & Madhu, 2011). Amyloid-β forms a cross-β 
structure regardless of whether or not exposed to Zn. Zn ions bring more order to the side chains 
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of the histidine residues at the metal binding site. Furthermore, Zn removes the salt bridge at 
Asp23 and Lys38 by altering the side chain conformation into non-bridge forming conformations 
which may result in the higher neurotoxicity of amyloid-β when exposed to high concentrations 
of Zn. Mutants with ill-defined salt bridges have been shown to be more neurotoxic than salt 
bridge forming wild type (Mithu, Sarkar, Bhowmik, Chandrakesan, Maiti, & Madhu, 2011). 
Some reports have shown that Zn at concentrations below 10mM reduces amyloid-β 
toxicity by destabilizing toxic intermediates (Garai, Sahoo, & Maiti, 2007) while  higher 
concentrations of Zn appears to increase toxicity by increasing aggregation (Lovell, Xie, & 
Markesbury, 1999). 
1.4.2. Effect of Metals on Amyloid-β Aggregation 
Extensive research has been conducted on the effect of metals on amyloid-β aggregation 
by  Bush (Bush & Tanzi, 2008), Faller (Faller & Hureau, 2009), and Smith (Bonda, Lee, Blair, 
Zhu, Perry, & Smith, 2011) all of which have shown that both Cu(II) and Zn(II) accelerate 
amyloid-β aggregation (Ha, Ryu, & Park, 2007). Amyloid aggregation starts instantly when 
amyloid-β is in the presence of Cu(II) (Pedersen, Østergaard, Rozlosnik, Gammelgaard, & 
Heegaard, 2012) compared to a lag period in the absence of copper. 
Both metal ions disrupt the formation of fibrillar forms of amyloid with some 
concentrations completely abolishing the formation of amyloid-β. Hou and Zagorski have shown 
that after amyloid-β binding to Cu(II) ions, the amyloid-β peptide undergoes rapid aggregation, 
but does not form fibrils (Hou & Zagorski, 2006). Some groups have not reported fibril growth 
in the presence of Cu(II), but rather amorphous precipitates (Ha, Ryu, & Park, 2007) (Tougu V. , 
et al., 2009) likely the result of using higher concentrations of Cu(II) (Innocenti, et al., 2010). 
The effects of the metals on amyloid aggregation are largely a function of the concentration of 
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the peptide and metal ion. In dilute conditions, rapid fibril formation was detected in a copper 
environment, however, at higher concentrations, no fibrils were detected (Sarell, Wilkinson, & 
Viles, 2010). Even substoichiometric concentrations of metal ions induce and accelerate amyloid 
aggregation: substoichiometric levels of Cu(II) doubles the rate of fibril nucleation and 
elongation (Sarell, Wilkinson, & Viles, 2010). At micromolar concentrations of amyloid-β Cu(II) 
does not form cross linked species with amyloid-β, and coordination geometry in the monomer 
and fibril is identical ruling out copper bridging to form cross-linked amyloid-β (Sarell, 
Wilkinson, & Viles, 2010). Substoichiometric concentrations of Cu(II) (between 0.2 and 0.4 mol 
eq) show the largest effect on the growth rates of fibrils (Sarell, Wilkinson, & Viles, 2010). Viles 
and colleagues suggest that substoichiometric levels of Cu(II) nucleate fibrils formation and 
suggested that the binding of Cu(II) increases the isoelectric point approaching physiological 
levels inducing self-association.  
Cu(II) increases the nucleation and elongation rate of fibril formation. For Aβ40, there is 
predominantly a reduction in lag time with the addition of Cu(II). For Aβ42, lag times are not 
affected as greatly, but rather, there is an increase in the elongation rates (Sarell, Wilkinson, & 
Viles, 2010). Fibrils formed in Cu(II) solution are able to seed fresh fibrils in non-copper 
solutions with an associated reduction in lag time (Sarell, Wilkinson, & Viles, 2010). Zn(II) ions 
completely inhibit amyloid fibril formation at 3µM. Cu(II) ions form an intramolecular complex 
with amyloid-β whereas Zn(II) forms an intermolecular complex cross-linking between  the two 
histidine residues on multiple amyloid-β peptides (Minicozzi, et al., 2008) (Faller & Hureau, 
2009) (Sarell, Wilkinson, & Viles, 2010). Acidic conditions aggravate the effects of Cu on the 
aggregation of amyloid-β (Bin, Chen, & Xiang, 2013). 
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The ratios of copper and amyloid-β are different in different tissues (Eskici & Axelsen, 
2012). Physiologically, the concentration of copper is much greater than the concentration of Aβ: 
Cu concentrations in CSF are in the order of 0.1-4.0 µM (Bogden, Troiano, & Joselow, 1977) 
whereas the concentration of amyloid-β is in the order of nM (Oe, et al., 2006). In extracellular 
fluid, the concentration of amyloid-β is 10% of that in CSF (Cirrito, et al., 2003)  while copper 
concentrations are up to 2 orders of magnitude higher (Kardos, Kovacs, Hajos, Kalman, & 
Simonyi, 1989). In extracellular fluid, the concentration of amyloid-β is approximately one tenth 
the concentration in CSF (Cirrito, et al., 2003); however, some reports have shown that copper 
concentrations may be as high as 100 µM (Kardos, Kovacs, Hajos, Kalman, & Simonyi, 1989). 
Micromolar concentrations of synapse released copper is sufficient to induce amyloid-β 
aggregation (Ha, Ryu, & Park, 2007) (Tougu, Karafin, & Palumaa, 2008). Fibrils tend to form in 
the extracellular fluid as opposed to the CSF. It is worth to note that in the ECF, the 
concentration of amyloid-β is lower and the Cu:Aβ ratio is higher (Eskici & Axelsen, 2012). 
Metal ions induce amyloid-β insertion into lipid vesicles. In the absence of metal ions, the 
peptide is only able to insert at pH values below 5.5 (Curtain, Ali, Smith, Bush, Masters, & 
Barnham, 2003). 
Heegaard and colleagues reported on the aggregation kinetics of amyloid-β in a copper 
environment (Pedersen, Østergaard, Rozlosnik, Gammelgaard, & Heegaard, 2012). The 
concentration of Cu:Aβ ratio is a major determinant of the aggregation pathway. Heegaard, along 
with previous researchers reported that three different kinetic pathways can occur for amyloid-β 
in a copper environment. The first pathway occurs at low ratios of Cu(II):Aβ form by the 
complexes quickly forming a critical nucleus followed by the slow addition of peptide-metal 
complex to form an amyloid fibrils (Bush, Pettingell, & Multhaup, 1994) (Sarell, Wilkinson, & 
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Viles, 2010). These fibrils may slowly form amorphous aggregates. The second pathway 
involves the formation of amyloid fibrils in the presence of copper (Ha, Ryu, & Park, 2007). At 
equimolar concentrations, there is a fast irreversible aggregation into peptide-metal oligomers 
which slowly bind together resulting in amorphous aggregates leading to spherical oligomers. 
The third pathway, as identified by Heegaard, alters the kinetic pathway of amyloid-β  and 
develops into both fibrillar and oligomeric forms of amyloid-β. As the Cu(II):Aβ ratio increases, 
the pathway is shifted from fibrillar to non-fibrillar indicating a destabilizing effect of Cu(II) on 
the structure of amyloid aggregates (Pedersen, Østergaard, Rozlosnik, Gammelgaard, & 
Heegaard, 2012). The third pathway (at high Cu(II):Aβ ratios) is similar to the second pathway, 
but there is a fast reversible process that adds additional copper molecules to the oligomer 
increasing the Cu(II):Aβ ratio to 1.4:1 (Pedersen, Østergaard, Rozlosnik, Gammelgaard, & 
Heegaard, 2012). In the presence of copper, fibrils grow by the addition of monomers to an end 
of a fibril which eventually bundle into full mature fibrils stabilized by inter-fibrillar interactions. 
Agitation of the solution increases the kinetic rate of formation (Tougu, Tiiman, & Palumaa, 
2011). 
Heegaard reported that at higher Cu(II):Aβ40 ratios, 65% of the peptide aggregated 
within 2 hours. After this initial aggregation, the rate decreased so that after 50 hours of 
incubation, there was still a detectable amount of monomeric peptide (Pedersen, Østergaard, 
Rozlosnik, Gammelgaard, & Heegaard, 2012). It is believed that the aggregation of Cu:Aβ 
complex is the rate limiting step as opposed to the formation of the amyloid-metal complexes 
themselves. Analysis of Cu:Aβ kinetics indicates that the peptide-metal complex aggregates in a 
two-phase kinetic fashion. At supra-equimolar ratios, the Cu:Aβ ratio in aggregates has been 
shown to be 1.4:1, implying another binding site is present in aggregates, whereas at Cu:Aβ <1, 
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the ratio appears to be 1:1. Even in the presence of Cu(II), shorter Aβ16 peptides do not 
aggregate because they are missing the critical 23-27 sequence needed for self-assembly 
(Balbach, et al., 2002) (Pedersen, Østergaard, Rozlosnik, Gammelgaard, & Heegaard, 2012). The 
thermodynamic equilibrium between oligomers and monomers is a function of the peptide 
concentration to the power of the number of monomers per oligomer (Tougu, Tiiman, & 
Palumaa, 2011).  
Copper has been shown to decrease the hydrophobic residues exposed to the surface 
(thereby forcing them towards the center of the peptide) possibly explaining why Cu:Aβ 
demonstrate increased solubility in aqueous solutions (Chen, Liuo, Yu, Cheng, & Cen, 2011). 
Zn ions can promote aggregation, but may not be neurotoxic. The late Dr. Mark Smith 
has frequently commented that this aggregation can serve as a neuroprotective mechanism, 
whereas the toxic peptide aggregates further along its pathway to form inert aggregations (Smith, 
Cappai, & Barnham, 2007). Cu(II) ions can inhibit Zn(II) induced aggregation (Suzuko, Miura, 
& Takeuchi, 2001) (Tougu, Tiiman, & Palumaa, 2011). 
A number of important findings can be noted from the available literature. Monomeric 
amyloid-metal complex can be formed with synaptic Cu and Zn ions. All known structures 
(monomeric, oligomeric, fibrillar) of amyloid-β can bind metals. Fibrillar amyloid-metal 
complexes are resistant to metal chelator likely because the metal ions are trapped inside the 
fibrillar structure. Cu ions can generate ROS in the presence of H2O2 and other reducing agents 
(Tougu, Tiiman, & Palumaa, 2011). 
1.4.3. Redox Effects of Metals Contributing to Neurotoxicity 
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The presence of oxidative stress in the Alzheimer’s brain has been universally 
acknowledged3 , but it is still unclear whether the oxidative stress is a cause of Alzheimer’s 
symptoms or just a consequence (Eskici & Axelsen, 2012). Numerous effects of oxidative stress 
brought on by the generation of reactive oxidative species (ROS) have been identified. These 
include an increased level of protein, lipid and DNA oxidation in the brain, resulting in 
deleterious cell signaling and function, decreased production of cytochrome C oxidase, and the 
formation of inflammatory cytokines including interkeukin-6 (Jomova, Vondrakova, Lawson, & 
Valko, 2010). Oxidative stress plays a role in the normal process of human aging (Doraiswamy 
& Finefrock, 2004) (Pearl, 1928). 
Oxidative stress to the brain is one of the earliest signs of Alzheimer’s disease (Smith, 
Numomura, Zhu, Takeda, & Perry, 2000) demonstrated by the presence of oxidatively damaged 
macromolecules and inflammation preceding the presence of amyloid aggregations (Zhu, Lee, 
Perry, & Smith, 2007) (Pimplikar, 2009). The binding of copper to amyloid-β correlates with the 
generation of hydrogen peroxide (Bonda, et al., 2010) (Bonda, Lee, Blair, Zhu, Perry, & Smith, 
2011). There is a minority opinion advocated by researchers such as Atwood and Smith who 
have proposed that amyloid plaques act as a metal “reservoir” intended to trap metals that, if not 
trapped, would catalyze oxidative reactions (Atwood, et al., 2012). In essence, the formation of 
amyloid plaques is a compensatory mechanism to remove ROS rather than a pathological 
mechanism. This hypothesis is the minority view (Eskici & Axelsen, 2012), but may have some 
merit because trace metals are embedded deep within amyloid fibrils (and therefore plaques) 
unable to interact with their environment and produce ROS. Smith and colleagues argue that the 
removal of amyloid-β as proposed by numerous groups may in fact have a deleterious effect on 
the symptoms of Alzheimer’s disease since there would no longer be an agent removing reactive 
3 See extensive list of references in (Eskici & Axelsen, 2012). 
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oxygen from the system (Atwood, et al., 2012). However, the majority of evidence supports the 
hypothesis that amyloid-β peptides promote oxidative stress mediated by metals such as Cu(II) 
bound to amyloid-β (Eskici & Axelsen, 2012).  
The effect of free radicals and oxidative damage to the brain influenced by amyloid-β is 
extensive. A free radical is a molecule containing one or more unpaired electrons allowing them 
to react readily. In biological systems, species derived from oxygen are the most common free 
radicals (Cadenas & Davies, 2000). The oxidative injury associated with AD is mediated by 
H2O2 which, via a Fenton reaction, produces the OH radical which is highly reactive. H2O2 is 
membrane permeable and is able to react with reduced metal ions such as Cu(II) and Fe(II) to 
produce OH. The hydroxyl radical is able to initiate a number of biochemical reactions including 
post translational protein modifications, DNA damage and lipid peroxidation (Markesbury & 
Lovell, 2007). The brain has natural defense systems for scavenging excess H2O2 such as 
catalase, glutathione peroxidase, and superoxide dismutase, which may be rendered inoperative 
by the sheer amount of H2O2 generated by the amyloid-metal complex (Bush & Tanzi, 2008). 
Cerebral content of oxidative stress inducing agents such as Cu and Fe have been documented to 
be elevated in post mortem examination of brains of Alzheimer’s patients (Jomova, Vondrakova, 
Lawson, & Valko, 2010). Copper-amyloid binding leads to the production of ROS. If no other 
molecule is involved in oxidation, it is the amyloid-β side chains which may become oxidized 
(Puglielli, Freidlich, & Setchell, 2005). The binding of amyloid-β, especially the Aβ42 alloform 
(Huang, Cuajungco, & Atwood, 1999), to metal ions Cu(II) or Fe(III) produces H2O2 by a double 
electron transfer reaction, reducing the metal ions in favour of O2 oxidation (Tabner, Turnbull, & 
El-Agnaf, 2002) (Dikalov, Vitek, & Mason, 2004) which is mediated by Met35 and Tyr10 
(Barnham, Haeffner, & Ciccotosto, 2004). Oxidation of Tyr10 can result in stable, but highly 
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neurotoxic forms of amyloid-β (Atwood, et al., 2004). The electron implicated in the reduction of 
the metal ion could be from amyloid-β, from Met35 or from reducing agents such as dopamine 
and ascorbate (Opazo, et al., 2002). H2O2 can also be formed by the cycling of metals bound to 
amyloid-β using electron donors without oxidation of the peptide. The reducing agents 
implicated are sterols such as cholesterol and long-chain fatty acids (Murray, Sindoni, & 
Axelsen, 2005).  The chemistry of H2O2 and OH•  production proceeds by Fenton and Haber-
Weiss reactions as outlined below (Markesbury, 1997) (Liochev, 1999). 
The reduction of the metal ion proceeds along by the reaction,  
Aβ + M(n+1)+  Aβ + Mn+ 
Where M is the metal and n the charge. Oxygen is reduced via the reaction, 
 Mn+ + O2  Mn+1 + O2- 
The production of hydrogen peroxide proceeds by, 
O2- + O2- + 2H  H2O2 + O2 
Fenton chemistry mediates the reaction between metals and hydrogen peroxide to 
produce hydroxyl radicals, 
Mn+ + H2O2  OH• + OH- + O2 
Lastly, Haber-Weiss chemistry reacts oxygen with hydrogen peroxide to produce free 
radicals, 
O2- + H2O2  OH• + OH- + O2 
From this chemistry, it appears that metals are required to produce ROS in Alzheimer’s 
disease by oxidizing another moiety (Smith, Cappai, & Barnham, 2007). 
While there is some controversy over whether or not amyloid-β has a neuroprotective 
effect, this effect tends to be dependent on the in vivo concentration of amyloid-β. Nanomolar 
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concentrations appear to have a neuroprotective effect (Whitson, Selkoe, & Cotman, 1989) while 
micromolar concentrations appear to induce neurotoxicity via oxidative mechanisms (Ueda, 
Fukui, & Kageyama, 1994). Cu(II) ions tend to increase amyloid toxicity while Zn(II) decrease 
toxicity (Cuajunco, et al., 2000). Viles and colleagues have identified two reasons why toxicity is 
enhanced in amyloid-β in the presence of Cu(II) ions. The first is that monomeric amyloid-β 
binds substoichiometric Cu(II) at the cell surface generating H2O2 and hydroxyl radicals leading 
to lipid peroxidation compromising cell integrity. The second reason is that copper near the 
neuronal synapse may promote aggregation of monomeric amyloid-β causing increased 
cytotoxicity (Sarell, Wilkinson, & Viles, 2010). If the pathogenesis of the metals hypothesis of 
Alzheimer’s disease was as simple as the generation of ROS by copper, it would be expected that 
neurotoxicity would be a function of metal concentration. However, Viles and colleagues 
showed that smaller concentrations of Cu(II) ions are more toxic than metal solutions 50 times 
more concentrated. This provides evidence that the ability of Cu(II) to promote amyloid 
aggregation has a major role in the etiology of Alzheimer’s disease beyond that of simply 
forming ROS (Sarell, Wilkinson, & Viles, 2010). 
 
1.5. Alzheimer’s Disease Pharmaceuticals 
The following possible strategies have been identified to prevent the aggregation of 
amyloid-β (Härd & Lendel, 2012) (Sokolov, Kozak, Kayed, Chanturiya, Glabe, & Hall, 2006):  
1) Stabilizing or sequestering the native state of the protein.  
2) Stabilizing or promoting off pathway aggregates which may have reduced toxicity.  
3) β-sheet breakers than end fibril elongation or stop aggregation.  
4) Disassembling amyloid aggregates.  
5) Preventing oligomer-cell membrane interactions.  
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6) Preventing amyloid induced membrane thinning.   
In addition, the promotion of clearance mechanisms have recently shown promise 
(Cramer, et al., 2012). 
Currently there are only five pharmaceuticals used to treat AD which are approved by the 
Food and Drug Administration. All have limited efficacy- none reverse the course of disease 
progression or result in any sustained delay of symptoms (Karran, Mercken, & Stooper, 2011) 
(Skaat, Chen, Grinberg, & Margel, 2012). The first four are acetylcholinesterase inhibitors 
(donepezil, galantamine, rivastigmine, tacrine) and the  fifth is memantine, an N-methyl D-
aspartate (NMDA) antagonist. These medications relieve some of the symptoms associated with 
AD, but do not alter the course of the illness or provide any curative mechanism (Neugroschl & 
Sano, 2010). 
1.5.1. Mechanism of Action 
Cholinesterase inhibitors combat amyloid toxicity by slowing the degradation of 
acetylcholine after release at the synapse. Memantine prevents overstimulation of the NMDA 
glutamate receptors (Mattson M. , 2004). Both acetylcholinesterase inhibitors and memantine, 
often used together, have shown moderate effects on cognitive function and behavioural scores 
(Roberson & Mucke, 2006). Many AD patients also take antipsychotics and antidepressants to 
manage psychiatric issues associated with AD. Non-steroidal anti-inflammatories (NSAID) have 
been demonstrated to have some anti-Alzheimer’s benefits (Townsend & Pratico, 2005). 
Another possible strategy for  the treatment of Alzheimer’s disease involves compounds 
that can prevent the misfolding and aggregation of amyloid-β. A number of these beta sheet 
breakers have been identified with limited success in clinical trials. Methylene Blue has been 
demonstrated to inhibit the aggregation of both amyloid-β (Necula, Kayed, Milton, & Glabe, 
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2007) and tau (Wischik, Edwards, Lai, Roth, & Harrington, 1996). The anti-leprosy drug 
rifampicin has been identified to inhibit amyloid aggregation. The mechanism of action is 
believed to be related to its ability to scavenge free radicals and stabilize amyloid oligomers 
(Härd & Lendel, 2012) (Li, Zhu, Ranjamani, & Uversky, 2004). The dye Orange G inhibits fibril 
formation, but does not inhibit the formation of amyloid oligomers (Necula, Kayed, Milton, & 
Glabe, 2007). The research group of Arvi Rauk has synthesized a few novel peptides referred to 
as SG1 and SG2 (Roy, 2010). These peptides have the potential to prevent any further 
aggregation by binding to the amyloid-β self-recognition site and therefore interfering with the 
dimerization of the peptide. Other inhibitors are based on the actual amyloid-β peptide, but the 
terminals are modified to prevent their aggregation. Shin and colleagues tested a multitude of 
steryl benzene derivatives which have excellent binding affinities to amyloid fibrils and 
oligomers preventing further aggregation (Lee, et al., 2012) (Lee V. , 2002). Ferulic Acid, an 
antioxidant inhibits fibril formation and mitigates amyloid toxicity (Ono, Hirohata, & Yamada, 
2005). Curcumin, common in tumeric, has been demonstrated to directly bind small amyloid 
oligomers preventing further aggregation. Curcumin is also a powerful antioxidant suppressing 
oxidative damage and inflammation (Yang, et al., 2005). Epidemiological studies have shown a 
correlation between tumeric consumption and reduced risk for AD (Ganguli, et al., 2000). 
Phenolic compounds such as myricetin and rosmarinic acid have been shown to inhibit amyloid 
aggregation. These compounds have been demonstrated to reduce synaptic dysfunction by 
blocking early assembly processes (Ono, et al., 2012). Dimers, trimers and tetramers have all 
been demonstrated to be cytotoxic (Ono, Condron, & Teplow, 2009) leading some researchers to 
suggest that pharmaceuticals should be targeting monomeric forms of amyloid-β to ensure that 
dimerization does not occur (Ono & Yamada, 2011). Results obtained by Yamada and 
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colleagues showed that at lower ratios (5:2) of Aβ42:myricetin, there was a moderate inhibition 
of oligomerization with the elimination of pentamers and hexamers and tetramers. At higher 
ratios (1:4 Aβ42:myricetin) there was no inhibition of oligomerization. A similar result was 
observed for rosmarinic acid (Ono, et al., 2012). Yamada and colleagues concluded that the 
following phenolic compounds inhibit amyloid oligomerization with decreasing efficacy: 
myricetin, rosmarinic acid, nordihydroguaiaretic acid (NDGA), furulic acid (FA), curcumin with 
NDGA and FA having similar efficacies (Ono, et al., 2012). Engineered polymer nanoparticles 
have been demonstrated to slow the transition from random coil to β-sheets of Aβ40 slowing 
fibrillization kinetics (Skaat, Chen, Grinberg, & Margel, 2012). The rate of fibrillization 
decreased, but fibrils still formed eventually. This inhibition is attributed to hydrophobic 
interactions between the double phenylalanine residues of the nanoparticles and residues of 
amyloid-β aggregates. Another possible mechanism proposed by researchers is that instead of 
attempting to inhibit amyloid fibril formation, fibril formation could be promoted so that toxic 
oligomers would not be formed, or if formed, would quickly develop into a low toxicity reservoir 
in the form of fibrils (Bieschke, et al., 2012).  
Polyphenols, such as resveratrol, have been demonstrated to have extensive antioxidant 
and anti-inflammatory properties and inhibit amyloid fibril formation and reduce cell death 
induced by amyloid-β (Riceevans, Miller, Bolwell, Bramley, & Pridham, 1995) (Jang & Surh, 
2003). 
Three mechanisms of action have been identified for amyloid-β targeted immunotherapy. 
The peripheral sink hypothesis states that binding of monomeric amyloid-β in the blood to 
antibodies alters the transport of amyloid-β across the blood-brain barrier (BBB). The second 
hypothesis is that antibodies may cross the BBB to alter the aggregation process. Lastly, 
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antibodies that bind fibrils can trigger Fc-mediated phagocytosis to clear plaques (Härd & 
Lendel, 2012). 
Amyloid immunotherapy is currently the subject of intense research. A number of 
antibodies are in late clinical trials (Pul, Dodel, & Stangel, 2011). However, it has come to light 
that many of these pharmaceuticals, while successful in laboratory trials, are failing and in some 
cases even increase, the toxic effects of amyloid-β (O'Nuallain, Hrncic, Wall, Weiss, & 
Solomon, 2006) (Lord, Gumucio, Englund, Sehlin, Sunquist, & Soderberg, 2009). These 
deleterious effects have been attributed to the suggestion that amyloid-β are in fact prions and the 
body cannot develop an immunity to them (Stöhr, et al., 2012). Cognitive improvements in mice 
models were demonstrated following passive immunizations with amyloid antibodies (Bard, et 
al., 2000) suggesting antibodies could cross the blood brain barrier and clear amyloid via 
phagocytosis by microglia. Antibodies specific to the N-terminus only recognize and promote 
amyloid clearance (Bard, Barbour, Cannon, Caretto, Fox, & Games, 2003) correlating with 
previous observations that the N-terminus is not part of the core of amyloid fibrils and therefore 
accessible to binding (Petkova, et al., 2002). Macao and colleagues demonstrated that the novel 
ZAβ3 affibody clears Aβ from the brain of the D. melanogaster fly (Luheshi, Hoyer, Barros, 
Härd, Brorsson, & Macao, 2010). 
The use of statins to prevent AD is based on the hypothesis that amyloid uses cholesterol 
as scaffolding on neuronal membranes. If cholesterol is removed, perhaps amyloid binding to 
membranes in minimized. However, a meta-analysis demonstrated that the use of statins to 
prevent AD is not supported by concrete evidence (Zhou, Teramukai, & Fukushima, 2007). 
Docosahexanoic Acid (DHA) is an omega-3 polyunsaturated fatty acid found in 
relatively high quantities in fish. AD patients have been shown to have lower plasma DHA levels 
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leading to studies showing that patients with very mild cognitive decline benefit from the 
consumption of omega-3 fatty acids. There was no effect on patients with moderate levels of 
cognitive decline (Freund-Levi, Eriksdotter-Jonhagen, & Cederholm, 2006). 
Studies of efficacy of ginkgo biloba in reducing AD demonstrated no statistically 
different results between patients given ginkgo biloba and those given a placebo (Dekosky, 
Williamson, & Fitzpatrick, 2008). 
Both red wine (Wang, Ho, & Zhao, 2006) and resveratrol was shown to reduce amyloid 
plaque formation in transgenic mice (Karuppagounder, Pinto, Zu, & al, 2009). 
Melatonin has been demonstrated to mitigate the toxic effects of amyloid-β in vitro 
(Zatta, Tognon, & Carampin, 2003) by preventing free radical formation caused by amyloid-
metal interactions. Furthermore, melatonin demonstrated a reduction in fibril formation (Cheng, 
Feng, Zhang, & Zhang, 2006) and reduction in oxidative stress in mice models. 
The use of Human Serum Albumin is currently in a phase 2 clinical trial. HSA has been 
shown to bind free amyloid “removing” it from the system (Stanyon & Viles, 2012). In addition, 
HSA is able to freely pass through the blood brain barrier. 
PBT2, an 8-hydroxyquinoline derivative of clioquinol, has been shown to reduce levels 
of Aβ42 in the CSF, but not serum concentrations. There was some improvement in cognitive 
measures (Lannfelt, et al., 2008). 
The amyloid-β degrading enzyme neprilysin is regulated by the phosphorylation state of 
the intracellular domain. In turn, neprilysin modulates extracellular concentrations of amyloid-β. 
Saido and colleagues have proposed that enhancing the cell surface activity of neprilysin either 
by activating phosphatases or inhibiting the kinase responsible for phosphorylation is a possible 
method of reducing amyloid-β aggregation (Kakiya, et al., 2012).  
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A variety of treatment strategies have been proposed which are related to amyloid-β: the 
inhibition of the β- or γ- secretases or promotion of the α-secretase which would alter the 
primary structure of the toxic Aβ42 alloform, inhibiting aggregation, promoting amyloid 
degrading proteases such as neprilysin and immunotherapy (Citron, 2004) (Citron, 2010). Myr 
can act as a β-secretase inhibitor that reduces cellular amyloid-β production in vitro (Shimmyo, 
Kihara, Akaike, Niidome, & Sugimoto, 2008). 
1.5.2. Current Research 
Research by Ravindranath and colleagues has demonstrated a remarkable effect of the 
Withania  root on the reduction of levels of amyloid-β and improvement of cognitive function in 
laboratory mice within 14-21 days (Sehgal, et al., 2012). The authors attribute this effect to the 
up-regulation of liver lipoprotein receptor related protein (LRP) and protease neprilysin 
enhancing clearance of amyloid-β.  
Desferrioxamine (DFO) an approved drug for iron overload disease has demonstrated to 
slow the progression of AD. These effects have been attributed to its metal chelating properties 
which clear metals from the brain preventing the formation of free radicals and thus neuronal 
oxidative damage (Liu, Men, Perry, & Smith, 2010). 
A recent clinical trial has been completed for the monoclonal antibody, solanezumab with 
mixed results: although cognitive decline decreased in patients with mild cognitive decline, no 
statistically significant results have been obtained for patients with moderate cognitive decline 
(Health, 2012). These results suggest than solanezumab will join the list of failed Alzheimer’s 
drugs making an effective treatment even more elusive (Kambhampaty, 2012). 
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1.6. Atomic Force Spectroscopy 
Atomic force spectroscopy is a process used to measure extremely small forces using the 
atomic force microscope or optical tweezers. Interest in this technique was piqued when Strunz 
and colleagues used an atomic force microscope to pull the two complementary strands of DNA 
apart and measured the unbinding force of each base pair separating (Strunz, Oroszlan, Schafer, 
& Guntherodt, 1999). Other force spectroscopy experiments have measured antibody-antigen 
unbinding forces (Riener, et al., 2003), protein unfolding forces (McAllister, et al., 2005) (Harris, 
Song, & Kiang, 2007) (Schlierf & Rief, 2006), and peptide-lipid interactions (Rico, Oshima, 
Hinterdorfer, Fujiyoshi, & Scheuring, 2011), to name a few.  
Using single molecule force spectroscopy, the substrate is typically chemically modified 
to attract one half of the system being studied (i.e. one peptide terminus). The cantilever is 
chemically modified to attract the other half of the system, which may be another peptide or the 
other terminus of a protein. The cantilever is lowered and the two peptides (or other molecules) 
are allowed to bind. The cantilever is then retracted and a force as a function of distance 
recorded. Typically, an experiment will involve hundreds or thousands of such approaches and 
subsequent retractions yielding a much smaller fraction of actual rupture events. This fraction is 
termed the experimental yield. Rupture forces are placed in a histogram and statistics of the force 
distributions are taken.  
1.6.1. Effect of Mechanical Manipulation on Binding Kinetics 
As a chemical system proceeds along a reaction coordinate from states A  B, it must 
overcome an energy barrier of height ΔG located at a location xβ from A, the initial state. 
Thermal fluctuations in the system allow individual molecules to overcome this activation barrier 
in order for the chemical reaction to complete. The rate at which molecules overcome this energy 
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barrier is referred to as the association rate (also referred to as the on-rate). Similarly, thermal 
fluctuations can cause the reaction to occur in reverse and molecules to proceed back to A at the 
dissociation rate (also referred to as the kinetic off rate). 
Generally, receptor-ligand systems interact non-covalently and their kinetics are similar 
to covalently bound compounds. Assume two interacting molecules, X, and Y. X and Y bind 
together to form a complex XY. However during the course of the reaction, X and Y are not 
completely consumed in favour of product XY. Rather, the reaction lies at some equilibrium 
where X, Y and XY are all present. This reaction is represented by the equation:  
      koff 
X + Y            XY 
kon 
 
Where koff is the kinetic off (dissociation) rate and kon is the kinetic on (association) rate. 
By determining these two kinetic rates, the affinity of two molecules can be determined by the 
equilibrium dissociation constant, Kd = koff/ kon. 
By increasing the heat in the system, the thermal fluctuations are greater, and generally, 
the reaction speed is increased in an Arrhenius-like fashion. However, temperature is not the 
only variable which increases reaction kinetics: the mechanical force separating the two 
molecules have also been shown to change both the height of the energy barrier and the kinetic 
off rate (Merkel, Nassoy, Leung, Ritchie, & Evans, 1999).   
As force is applied to a receptor-ligand complex, the height of the energy barrier 
decreases as a function of the force applied and distance from the energy barrier in accordance 
with the equation (Dudko, Hummer, & Szabo, 2006), 
𝑈(𝑥) =  𝑈0(𝑥)− 𝐹𝑥 
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Figure 8- Effect of force on energy barrier. Figure reproduced with permission from (Friddle, 
2008) 
 
As shown in figure 8, the free energy surface, U(x), is equal to the intrinsic free energy 
surface U0(x), and reduced proportional to the force, F. 
By conducting AFS at a variety of loading rates, the intrinsic energy barrier and kinetic 
off rates can be established. 
1.6.2. Surface Chemistry 
Force spectroscopy requires both the substrate and the tip to be chemically modified for 
the system to bind on one terminus to the substrate and the other terminus to the cantilever tip. 
Protocols for the modification of the surfaces vary from simple (Schwaiger, Kardinal, 
Schleicher, Noegel, & Rief, 2004) to complex (Guo, Lad, Ray, & Akhremitchev, 2009). In one 
common surface modification protocol, a polyethylene glycol (PEG) linker is bound to the 
substrate via a silanated surface modification. This linker provides extra space between the 
surfaces (substrate and tip) and the system to be studied, preventing damage to the system. A 
typical set up is shown in figure 9 below. 
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In our lab we modified the protocol 
developed earlier (Yu, Malkova, & Lyubchenko, 
2008). The protocol begins by freshly cleaving 
mica and cleaning a Bruker MLCT AFM tip by 
placing the tip in an ethanol bath for 15 minutes, 
washing in water and drying in a gentle stream of 
nitrogen. The tip is placed under UV light for 30 
minutes to remove any remaining organic matter. 
 All immersions are done by cutting the cap 
off a centrifuge microvial and placing the 
appropriate liquid (HEPES, ethanol, etc) into the 
caps. The caps are then placed inside of a petri 
dish. After the appropriate liquid was placed into 
the caps, curved blunt nose tweezers are used to 
lift the cantilever chips out of their storage 
container and into the appropriate liquid taking 
care to ensure the cantilever chip is completely 
immersed in the liquid prior to releasing the grip 
on the tweezers.   
Aminopropyl silatrane (APS) which was 
synthesized in accordance with (Shlyakhtenko, 
Gill, Filonov, Cerovac, Lushnikov, & Lyubchenko, 
Figure 9- Surface chemistry cartoon. 
Figure reprinted with permission from 
(Hane, Tran, Attwood, & Leonenko, 
2013). 
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2003) and dissolved in water at a concentration of 167µM.. Both surfaces are silanated by 
immersing the tip and mica in APS.  
When APS is allowed to react with the mica and water, the silicon covalently binds with 
the oxygen atoms on the mica surface preparing the surface for a hetrobifunctional crosslinker 
(such as N-hydroxysuccinimide-PEG-maleimide) (Shlyakhtenko, Gill, Filonov, Cerovac, 
Lushnikov, & Lyubchenko, 2003). 
 The mica and tip are further modified by placing them in a solution of N-
hydroxysuccinimide-PEG-maleimide (NHS-PEG-mal) at a concentration of 167µM in 
dimethylsulfoxide (DMSO) for a period of 3 hours. Depending on the manufacturer, NHS is also 
referred to as succinamide valerate (SVA). Both tips and mica are washed with DMSO and dried 
under a gentle stream of nitrogen. 
 Cys-amyloid-β (1-42) (Anaspec, Freemont, CA) is prepared by dissolving the peptide to 
a concentration of 1 mg/mL in DMSO. The cys-amyloid-β is diluted in HEPES (pH 7.4, 50 mM, 
150mM NaCl) for a final peptide concentration of 20nM. An equal volume of 200nM tris(2-
carboxyethyl)phosphine (TCEP) is added to the amyloid solution to prevent aggregation and the 
solution is stored for 10-15 minutes. The amyloid-β is centrifuged for 15 minutes at 15k RPM 
driving high molecular weight peptides to the bottom of the centrifuge tube. Amyloid-β near the 
top of the tube is removed and allowed to soak the tips and mica for 30 minutes. The tips and 
mica are rinsed 3 times with HEPES. To prevent unwanted binding events to unreacted 
maleimide groups, the surfaces were immersed in beta-merceptoethanol, a short chain thiol 
ethanol which quenches unreacted maleimide groups. The surfaces are rinsed with HEPES and 
are ready for force spectroscopy in HEPES solution.  
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1.6.3. Conducting Force Spectroscopy Experiments 
Once surface chemistry is complete, the tip and mica are loaded into the atomic force 
microscope. The AFM cantilever is calibrated using the thermal noise method as directed by the 
manufacturer to calculate the cantilever spring constant. Typical force spectroscopy settings are 
Igain 40, pgain 0.0048, set point 10 nN, relative set point 0.9. Approach and retract speeds are in 
the order of nanometers/sec to micrometers/sec and will vary greatly during dynamic force 
spectroscopy. A 0.5 second pause is set to allow the peptides to bond to one another. Usually 900 
force curves are taken per 100 µm area with a 30x30 grid (30 points taken in each row, with 30 
rows sampled).  
Experimental yield (number of binding events/number of binding attempts) varies from 
2.5% to 30% depending on conditions. Sample force curves are shown below. As the tip is 
retracted from the sample, if a binding event occurs, the tip is deflected. A worm like chain 
(WLC) fit can be used to model a variety of natural phenomenon including the extension of 
polymers and the bending of structural beams under load. At molecular rupture, the cantilever no 
longer is subjected to any force and the cantilever returns to a neutral position. The WLC model 
envisions an isotropic continuously flexible rod. The deflection of the WLC model is in 
accordance with the following equation. 
𝐹𝑙𝑝
𝑘𝐵𝑇
= 14 �1 − 𝑥𝐿𝑐�−2 −  14 + 𝑥𝐿𝑐 eq. 1 
Where F is the force, lp is the persistence length of the polymer, kB is Boltzmann 
constant, T the absolute temperature, x is the length of stretching and Lc the contour length 
(Bustamante, Marko, & Smith, 1994). The persistence length is a method of quantifying the 
stiffness of a polymer. If the length of a polymer is less than its persistence length, the polymer 
acts as a flexible elastic rod. If the length of the polymer is greater than its persistence length, its 
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properties cannot be described dynamically. The contour length of a peptide is the maximum 
length the peptide can physically be extended. 
 
Figure 10 - Sample force curve showing an approach, retract and rupture of a chemical bond. 
Figure reprinted with permission from (Hane, Tran, Attwood, & Leonenko, 2013). 
 
1.6.4. Data Analysis 
Once data are collected, JPK data processing software is used to analyze the force curves. 
Force curves are zeroed so the distant approach and retract line is on the x-axis. The force curve 
is smoothed and the vertical deflection is calibrated using the sensitivity settings collected during 
cantilever calibration. A WLC model is then applied to the force curve. The software calculates 
the rupture force, contour length, loading rate and persistence length (JPK Instruments AG, 
2007). Rupture forces are recorded in a spreadsheet and histograms are plotted. We can obtain 
the mean and median of the force curves to determine the most probable unbinding force but 
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using a Gaussian fit to the histograms or a probability density function yields a more rigorous 
result.  
1.6.5. Dynamic Force Spectroscopy 
Dynamic force spectroscopy (DFS) is a variation of atomic force spectroscopy whereby 
the retraction velocity, and therefore the loading rate is changed to obtain a force spectra as a 
function of the loading rate as shown in figure 11. DFS may be used to extract kinetic or 
thermodynamic information about protein unbinding or unfolding events such as the kinetic off 
rate and the height and width of the energy barriers (Hinterdorfer & Dufrêne, 2006) (Allison, 
Hinterdorfer, & Han, 2002). This kinetic information can then be used to elucidate 
thermodynamic information about the protein such as the free energy of an unbinding barrier and 
the location of this barrier along a reaction coordinate. DFS utilizes the AFS technique, but 
instead of a single set of data being collected at a given speed and thus loading rate, unbinding 
forces at multiple loading rates are collected. The loading rate is the spring constant of the 
cantilever multiplied by the retraction speed. The “apparent” loading rate is obtained by 
obtaining the slope of the cantilever position with respect to time, dx/dt, at the rupture event and 
multiplying by the cantilever spring constant.  
To extract kinetic data from the unbinding experiments, a number of analytical models 
have been proposed to fit the experimental data.  While the Bell-Evans model (Evans & Richie, 
1997) (Evans E. , 2001) is the oldest and most highly cited model, an argument can now be made 
questioning the interpretation of some experimental results which have utilized this model 
(Friddle, Noy, & De Yoreo, 2012).  
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1.6.6. Bell-Evans Model 
The Bell-Evans model is the most cited method of extracting kinetic information from 
DFS data. The origins of the Bell-Evans theory began with the work by Bell in 1978 (Bell, 1978) 
who proposed a phenomenological method for the analysis of the adhesion of cells to other cells. 
The Bell-Evans model was the result of Evans’ adaptation of the work introduced by Bell in 
1978 (Bell, 1978) and adapted for atomic force spectroscopy (AFS) (Evans & Richie, 1997) 
(Evans E. , 2001). This model posited that the rupture force between two cells was proportional 
to the natural logarithm of the loading rate during retraction. In 1997, Evans and Richie built 
upon Bell’s model to extract kinetic information from the dissociation of individual 
macromolecules such as proteins (Evans & Richie, 1997). The theoretical work developed by 
Evans and Richie became known as the Bell-Evans model. 
The Bell-Evans model is based on the assumption that for non-covalent bonds, molecules 
in solution bond and dissociate continuously when no force is force applied to them. By 
introducing a force field to the system, there is a reduction in the ratio of bound-to-free 
molecules. The mean lifetime of one of these non-covalent bonds is referred to as τoff. If the bond 
is pulled apart faster than τoff, the bond resists rupture (Evans E. , 2001). On a single molecule 
level, we can deduce that as a force is applied quicker to the molecules (the loading rate), the 
unbinding force required to dissociate the bond is increased. The rate constant of this 
dissociation, koff, is given by the equation koff = 1/ τoff.  
Every metastable chemical system contains some thermodynamic energy barrier which 
needs to be overcome in order for a reaction to proceed along the reaction coordinate. If an 
external force is applied to this system, the energy landscape barrier is reduced and therefore τoff 
is decreased. If we conduct multiple experiments, we can obtain a most probable rupture force at 
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a given loading rate. By repeatedly conducting this experiment at loading rates with difference of 
orders of magnitude and plot the most probable rupture force on a log scale of loading rates, the 
most probable unbinding force at each loading rate is obtained (Evans E. , 2001). An example of 
such a loading rate plot is shown in figure 11.  
 
Figure 11- Most probable rupture force as a function of loading rate. 
 
When the most probable unbinding force is determined from plotting all unbinding events 
at a given loading rate on a histogram, and the most probable unbinding force is plotted against 
the loading rate on a log scale, a straight line results, the slope of which is the location of the 
transition barrier, xβ,  and the y-intercept being the height of the energy barrier, ΔG (Evans E. , 
2001). Using Bell-Evans equation (eq.1) (Evans & Richie, 1997) (Evans E. , 2001), 
𝐹 (𝑟) =  �𝑘𝐵𝑇
𝑥𝛽
� ln 𝑟 𝑥𝛽
𝑘0 𝑘𝛽𝑇 eq. 2 
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where F(r) is the most probable rupture force, kB, Boltzman’s constant, T, temperature in 
Kelvin, xβ, the location of the energy barrier, r, the loading rate, and k0 the off rate constant at 
zero force. Once k0  is determined, ΔG can be calculated using following equation (eq.2) (Evans 
& Richie, 1997) (Evans E. , 2001). 
−∆𝐺 = 𝑘𝐵𝑇 ln 𝑘0ℎ𝑘𝐵𝑇 eq. 3 
 Some DFS experiments yield multiple slopes of the rupture force plots. Common 
orthodoxy interprets this as an additional energy barrier to be overcome however this paradigm 
has recently come under heavy criticism (Kim, Palermo, Lovas, Zaikova, Keana, & Lyubchenko, 
2011) (Evans E. , 2001) (Friddle, Noy, & De Yoreo, 2012). 
1.6.7. The Dudko-Hummer-Szabo Model 
While the Bell-Evans model has received widespread acceptance within the force 
spectroscopy research community, it has received criticism that its assumptions are overly broad 
(Hummer & Szabo, 2003) (Dudko, Hummer, & Szabo, 2006). A number of groups have 
suggested modifications to the Bell-Evans model. The most commonly accepted DFS analysis 
technique which corrects for the inadequacies of the Bell-Evans model is that proposed by 
Dudko, Hummer and Szabo (Dudko, Hummer, & Szabo, 2006) which in turn is based on the 
work solely by Hummer and Szabo  (Hummer & Szabo, 2003) based on Kramers’ kinetic 
diffusion model of gases (Kramers, 1940).  
Both the Bell-Evans model and Dudko-Hummer-Szabo models can be reduced to a 
similar expression, 〈𝐹〉~(ln𝑣)𝑎, where 〈𝐹〉 is the average rupture force of an ensemble of 
measurements, v the pulling speed, and a, an arbitrary exponent equal to 1 in the Bell-Evans 
model (Evans & Richie, 1997), ½ by Garg (Garg, 1995) and 3/2 by the Hummer-Szabo model 
(Hummer & Szabo, 2003).  
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Modifying the Bell-Evans model above, Szabo and colleagues determined an arbitrary 
exponential scaling constant to obtain the equation (eq.4) (Dudko, Hummer, & Szabo, 2006), 
𝜏(𝐹) =  𝜏0 �1 − 𝑎𝐹𝑥𝛽∆𝐺 �1−1 𝑎� 𝑒∆𝐺�1−�1−𝑎𝐹𝑥𝛽∆𝐺 �1 𝑎� � eq. 4 
Where τ is the bond lifetime, a is a power scaling factor corresponding to ½ for a cusp-
like barrier, 3/2 for a linear-cubic barrier, and 1 for a recovery of the Bell-Evans  model.  
Szabo and colleagues reduced the Bell-Evans model to its approximate limit using a 
stochastic model of a spring (Hummer & Szabo, 2003) and used Kramers’ theory of diffusion 
(Kramers, 1940) to determine kinetic constants. Szabo and colleagues later updated this model 
by adding an exponential constant of 1/2 to create a cusp-like model to better approximate 
kinetic parameters such as the kinetic off rate and location of the energy barrier (Dudko, 
Hummer, & Szabo, 2006).  
The Bell-Evans model assumes that koff(F) scales linearly with exp(Fxβ), so k(F)=k0eFxβ. 
However, this assumption has been shown to be an oversimplification (Dudko, Hummer, & 
Szabo, 2006): this phenomenological approximation holds as ΔG∞, but with ΔG of realistic 
values the unbinding process can be better modeled using Kramer’s theory of diffusive barrier 
crossing. The Dudko-Hummer-Szabo model modifies the Bell-Evans model above and applied 
Kramer’s theory to extract more rigorous kinetic and thermodynamic parameters (Hummer & 
Szabo, 2003) (Dudko, Hummer, & Szabo, 2008).  
The loading rate during a rupture event has been estimated as 𝑟 = 𝑘𝑐𝑣 where r is the 
loading rate (N/s), kc the cantilever spring constant (N/m) and v the retract velocity (m/s). Dudko 
showed that the molecular linker can be incorporated into the loading rate calculation (Dudko, 
Hummer, & Szabo, 2008). Dudko and colleagues showed that the loading rate of two molecules 
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connected by a linker following worm like chain (WLC) dynamics can be modelled by equation 
5: 
𝑟(𝐹) = 𝑣 � 1
𝑘𝑐
+  2𝛽𝐿𝑐𝑙𝑝�1 + 𝛽𝐹𝑙𝑝�3 + 5𝛽𝐹𝑙𝑝 + 8�𝛽𝐹𝑙𝑝�5 2� �
−1
 
eq. 5 
Where v is the retraction velocity, Lc is the contour length, β is kBT-1, and lp is the 
persistence length of the system consisting of the linker and peptide. The persistence length is the 
length at which, when greater, the system deforms in a classical manner. The first term within 
the brackets represents the cantilever’s contribution to the loading rate and the second term 
represents the molecular linker’s contribution to the loading rate. The addition of the two terms is 
multiplied by the retraction velocity.  
 The bond lifetime, τ(F), is approximated by the equation 6: 
𝜏(𝐹) ≅  �𝜋2 (〈𝐹2〉 − 〈𝐹〉2)�1 2�
𝑟(𝐹)  eq. 6 
Where 〈𝐹2〉 is the mean squared rupture force at a given loading rate r(F).  
1.6.8. Friddle-De Yeoreo Reversible Binding Model 
In the past, it has often been assumed that multiple slopes on the rupture force – loading 
rate plot was to be interpreted as multiple energy barriers. Often DFS experiments result in 
apparent multiple slopes in the unbinding force/loading rate plots (Merkel, Nassoy, Leung, 
Ritchie, & Evans, 1999). Given early avidin-biotin experiments and their known multiple 
unbinding properties, experiments on simpler systems have also interpreted these non-linearity’s 
as complex systems with multiple kinetic barriers with some barriers occurring at impossible 
distances of significantly less than 1 Å (Friddle, Noy, & De Yoreo, 2012). 
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Recently De Yoreo and colleagues challenged the assumption made by these earlier 
models that no reversible binding occurs during force experiments and that multiple spectra are 
the result of different energy barriers resulting from the mechanically induced deformation of the 
protein structure (Friddle, Noy, & De Yoreo, 2012). By challenging this assumption, De Yoreo 
was able to explain away some of the more peculiar conclusions reached by previous groups 
such as the complexity of very simple system and energy barriers of orders of magnitude less 
than 1 Å. As De Yoreo so aptly stated, “If fitting is the only criterion, then the multi-barrier 
hypothesis can never be rejected, because this segmented approach can be tailored to fit any 
force spectrum.” 
De Yoereo and colleagues attribute the phenomenon of multiple “slopes” to reversible 
binding at low loading rate- a very plausible scenario (Seifert, 2002) or fluctuations of several 
independent interactions (Seifert, 2000) (Erdmann & Swartz, 2004).  
In the Friddle-De Yoreo interpretation, a system of two bodies being pulled apart passes 
through two phases: an equilibrium phase at lower pulling velocities where the molecules can 
rebind, and a kinetic phase at higher loading rates where molecules unbind irreversibly. The 
equilibrium phase is associated with a shallow slope and the kinetic phase, a steeper slope. Both 
cases result in the system moving through two states – an equilibrium state characterized by a 
finite force and a kinetic state where the system displays a weak dependence on loading rate, F ~ 
ln v. 
The force at which the dissociation rate and the association rate cross is given by the 
equilibrium equation,  
𝑓𝑒𝑞 = �2𝑘𝑐∆𝐺 eq. 7 
78 
 
 
 
Where kc is the spring constant of the cantilever and ΔG the height of the activation 
barrier. 
The unbinding force, F(r), is approximated by the equation, 
〈𝐹(𝑟)〉 ≅ 𝑓𝑒𝑞 +  𝑓𝛽 ln�1 +  𝑟𝑒−𝛾𝑘𝑜𝑓𝑓�𝑓𝑒𝑞�𝑓𝛽� eq. 8 
Where γ is Euler’s constant, 0.577. The thermal force scale, fβ is given by the expression 
fβ=kBT/xβ. koff(feq) is the dissociation rate at the equilibrium force, feq, the force at which the 
system transitions from the equilibrium regime to the kinetic regime. F(r) is the mean rupture 
force as a function of the loading rate, r, corrected for the effect of the PEG linkers as 
demonstrated in (Dudko, Hummer, & Szabo, 2008). 
From fβ, the width of the energy barrier, xβ, can be calculated as, 
𝑥𝛽 = 𝑘𝐵𝑇𝑓𝛽  eq. 9 
 The dissociation rate at force F, koff (F) is given by the function, 
𝑘𝑜𝑓𝑓(𝐹) = 𝑘0 exp�𝛽�𝐹𝑥𝛽 − 1/2𝑘𝑐𝑥𝛽2�� eq. 10 
The association rate (on-rate), kon(F), is given by the function,  
𝑘𝑜𝑛(𝐹) = 𝑘𝑜𝑛(0) exp �−𝛽𝑘𝑐2 � 𝐹𝑘𝑐 − 𝑥𝛽�2� 
𝑘𝑜𝑛(𝐹) = 𝑘0 exp �𝛽 �∆𝐺 − 𝐹22𝑘𝑐�� 
eq. 11 
 
1.6.9. Eliminating Errors in Force Spectroscopy Experiments 
Force spectroscopy data analysis assumes that for every rupture event, only one pair of 
molecules bind. In reality this assumption is often not true. On occasion, two molecules bind 
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simultaneously resulting in abnormally high forces shifting force histograms high.  The 
determination of the number of double ruptures is given by the equation, 
𝑃 = 1 − �1
𝜌
− 1� 𝑙𝑛 � 11 − 𝜌� eq. 12 
where P is the probability of a multiple rupture event and ρ is the experimental yield of the 
experiment (Tees, Waugh, & Hammer, 2001).  
 It is accepted practice to truncate the highest rupture forces from the force histogram. For 
example, if we conduct 1500 approaches yielding 125 usable force curves the resulting 
experimental yield, ρ=0.083. We calculate the probability of obtaining simultaneous multiple 
unbinding events. In accordance with the above equation P=0.0425 The number of unbinding 
forces which are likely a double unbinding event is 125 x 0.0425 = 5.3. Truncating these 5 
highest rupture forces from the rupture force histogram and excluding them from data analysis is 
an accepted practice within the force spectroscopy field (Evans, Halvorsen, Kinoshito, & Wong, 
2009).  
 Akhrimitchev has suggested other ways to minimize the probability of multiple bond 
ruptures. These include a low peptide surface density (achieved by using nanomolar peptide 
solutions), using sharp AFM tips, using crosslinkers exceeding 20nm in length to facilitate 
identifying multiple bond ruptures, and using cantilevers with high spring constants for 
experiments where high rupture forces are anticipated (Karacsony & Akhrimitchev, 2011). 
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Chapter 2 
Research Objectives 
 
2.1. Objectives of Research 
This research began with an objective of probing the binding forces of amyloid-β 
peptides, and testing the effects of copper ions and inhibitors on amyloid-β unbinding as well as 
determining the height and width of the  energy barrier of amyloid-β dimerization. These 
objectives have been met. 
In this work, I show the forces involved in the unbinding of an amyloid-β dimer with and 
without the mediating effects of copper ions. I expand on these force experiments by probing the 
kinetics and thermodynamics of the initial dimerization and aggregation process on a single 
molecule level and comparing a variety of dynamic force spectroscopy models. Lastly, I 
demonstrate the effect of amyloid aggregation inhibitors on the unbinding force of the amyloid 
dimer.  
2.2. Hypothesis 
I hypothesize the following explanation of the etiology of Alzheimer’s disease: the 
normal body produces a normal amount of amyloid-β cleaved from the amyloid precursor 
protein. These amyloid-β monomers are routinely cleared by the body as a normal part of 
recycling proteins. Certain individuals have genetic mutations that allow the body to produce 
abnormally high amyloid peptide or disproportionately high levels of AB42 to AB40. As these 
individuals age, the ability of the body to clear amyloid is hindered and these monomers 
aggregate. People with genetic mutations in APP, PSEN1 or PSEN2, APOE4 are at additional 
risk for AD because the inability to clear AB is compounded by excess AB production.  In 
addition, aging and unidentified genetic factors allow the accumulation of trace amounts of metal 
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ions such as copper. The increase in metal ions leads to higher amyloid-amyloid affinity 
accelerating the kinetics of amyloid aggregation and lowering the free energy required for the 
initial dimerization of the amyloid peptide.  
Once oligomers have formed, the oligomers thin the neuron membrane or produce small 
ion channels in the membrane disrupting regular cell function. The addition of metals, while 
already accelerating amyloid aggregation, further compounds the progression of AD by 
destroying the neuronal membrane by lipid peroxidation. 
Specific to the experiments I have proposed, I make the following hypothesis’: 
Adding trace amounts of metals will result in higher amyloid-amyloid unbinding forces. 
Amyloid aggregation is characterized by a sinusoidal aggregation curve with a lag phase prior to 
appreciable aggregation. The higher amyloid-amyloid unbinding forces correlate with a decrease 
in the lag time associated with amyloid aggregation. The lag phase is characterized by the 
amyloid overcoming an energy barrier during the dimerization process. 
Amyloid oligomers and amyloid fibrils lie on separate pathways. An amyloid dimer can 
dimerize in a variety of different conformations including a β-hairpin and N-terminal-N-terminal. 
The conformation of this dimer determines the pathway the amyloid will take- either destined to 
become an oligomer or destined to become a fibril.  
Adding metals to the system will result in the peptide to travel along an oligomeric rather 
than fibrillar pathway. 
Adding metals to the system lowers the activation barrier and deepens the free energy 
well associated with dimerization, thereby accelerating the aggregation kinetics.  
Adding amyloid aggregation inhibitors to the system will result in no dimerization of the 
amyloid peptide, preventing any further aggregation. 
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2.3. Relevance of Research 
Alzheimer’s disease affects 12 million people worldwide. By 2050, this figure is destined 
to triple to nearly 36 million people. Alzheimer’s patients do not suffer alone - the estimated 
health care costs by 2050 are estimated of approaching $1.1 trillion. Despite millions of dollars 
in funding and millions of man-hours spent on research, the best Alzheimer’s treatments so far 
only delay the onset of symptoms of by a few months. 
Copper has long been implicated in AD. By understanding the single molecule 
interactions in a copper environment, researchers may be able to target metal chelators more 
efficaciously, perhaps by using our AFS based screening technique.  
Our attempt to standardize dynamic force spectroscopy (DFS) experiments will allow 
researchers to compare data obtained from single molecule force spectroscopy (SMFS) 
experiments using the same data analysis techniques. 
The research contained within this thesis addresses the issues surrounding AD etiology at 
its very initial stages – the point where two amyloid-β peptides bind to form a neurotoxic dimer. 
By understanding what molecular events occur during the progression of AD on a single 
molecule level, other researchers may eventually be able to develop therapeutic strategies to slow 
the progression of AD.   
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Chapter 3 
Cu(2+) Affects Amyloid-β (1-42) Aggregation by Increasing 
Peptide-Peptide Binding Forces 
 
This chapter is reprinted with permission from Hane, et al. PLoS ONE. (2013). 
The link between metals, Alzheimer’s disease (AD) and its implicated protein, amyloid-β 
(Aβ), is complex and highly studied. AD is believed to occur as a result of the misfolding and 
aggregation of Aβ. The dyshomeostasis of metal ions and their propensity to interact with Aβ has 
also been implicated in AD. In this work, we use single molecule atomic force spectroscopy to 
measure the rupture force required to dissociate two Aβ (1-42) peptides in the presence of copper 
ions, Cu2+. In addition, we use atomic force microscopy to resolve the aggregation of Aβ formed. 
Previous research has shown that metal ions decrease the lag time associated with Aβ 
aggregation.  We show that with the addition of copper ions the unbinding force increases 
notably. This suggests that the reduction of lag time associated with Aβ aggregation occurs on a 
single molecule level as a result of an increase in binding forces during the very initial 
interactions between two Aβ peptides. We attribute these results to copper ions acting as a bridge 
between the two peptide molecules, increasing the stability of the peptide-peptide complex. 
Author Contributions: 
• Designed Experiments: Zoya Leonenko, Francis Hane 
• Performed Experiments: Francis Hane, Gary Tran, Simon Attwood 
• Analyzed Data: Francis Hane, Gary Tran, Simon Attwood 
• Wrote the Manuscript: Francis Hane, Simon Attwood, Zoya Leonenko 
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3.1. Introduction 
The mechanism for Aβ misfolding has not yet been identified. The initial misfolding of 
amyloid-β onto itself occurs through the folding of amino acid sequences 16-23 onto 28-35 to 
form a β-sheet structure (Rauk, 2009). It is now accepted that the oligomers, which may form 
along a distinct pathway, are more neurotoxic than the relatively inert amyloid fibrils (Arispe, 
Pollard, & Rojas, 1993) (Lin, Bhatia, & Lal, 2001) (Necula, Kayed, Milton, & Glabe, 2007). 
Despite extensive research, the mechanism of action of Aβ is not clearly understood.  
The factors affecting AD are diverse and their interrelatedness remains elusive. Genetic 
factors (Bertram & Tanzi, 2005), metals (Bush & Tanzi, 2008), and vascular deficiencies (Roy & 
Rauk, 2005) have been found to be associated with AD. Also, the Alzheimer’s afflicted brain has 
been shown to suffer from severe oxidative stress (Markesbury, 1997) and inflammation 
(Akiyama, Barger, Barnum, Bradt, & Bauer, 2000). In post-mortem brains of AD patients, 
amyloid plaques were laden with trace metals such as copper, zinc, and iron at concentrations up 
to 400 μM, 1 mM, and 1 mM, respectively (Lovell, Xie, & Markesbury, 1999). Extensive 
research has been conducted on the role of metal ions in the formation of reactive oxygen species 
(ROS), and amyloid-metal complexes that increase amyloid toxicity by ultimately promoting 
apoptosis (Huang, Cuajungco, & Atwood, 1999) (Jomova, Vondrakova, Lawson, & Valko, 
2010) (Liu, Men, Perry, & Smith, 2010) (Sayre, Perry, & Smith, 1999) (Smith, Numomura, Zhu, 
Takeda, & Perry, 2000).  
Aβ aggregation begins with a lag phase at which point the peptide progressively 
aggregates to form nucleation seeds (Harper, Liber, & Lansbury, 1997). The addition of metal 
ions has been shown to reduce the lag phase associated with Aβ aggregation (Sarell, Wilkinson, 
& Viles, 2010). Aβ has been shown to bind metal ions, such as copper, zinc, and aluminum, 
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yielding amyloid-metal complexes with varying effects (Lovell, Xie, & Markesbury, 1999) 
(Curtain, Ali, Smith, Bush, Masters, & Barnham, 2003). The binding of Aβ to copper allows the 
peptide to insert into lipid membranes more readily (Curtain, Ali, Smith, Bush, Masters, & 
Barnham, 2003), while aluminum-Aβ complexes have been shown to disrupt lipid membranes 
(Suwalsky, Bolognin, & Zatta, 2009). 
The binding site of copper is believed to lie within the N-terminal portion of the peptide. 
Specifically, there is a salt bridge formed utilizing metals, such as zinc and copper, 
predominantly through a His(13)-metal-His(14) conformation as well as bridges with His(6) 
(Faller & Hureau, 2009) (Azimi & Rauk, 2011). 
Previous research has shown that copper binds to these His co-ordination sites with 
greater affinity than zinc (Nair, Perry, Smith, & Reddya, 2010) and significantly stabilizes Aβ 
aggregates (Han, Wang, & Yang, 2008). The binding of copper causes Aβ to become redox 
active, which significantly contributes to the oxidative stress prevalent in AD (Rauk, 2009) 
(Markesbury, Oxidative stress hypothesis in Alzheimer's disease, 1997). The reduction of Cu2+-
amyloid complexes to Cu+-amyloid complexes has been shown to produce hydrogen peroxide 
(Hewitt & Rauk, 2009) that in turn leads to the formation of pro-apoptotic lipid peroxidation 
products, such as 4-hydroxynonenal, which ultimately induces neuronal cell apoptosis (Jang & 
Surh, 2003). Thus, the binding of copper to Aβ not only increases neurotoxicity, but it has also 
been demonstrated to have kinetic and thermodynamic implications (Huang, Cuajungco, & 
Atwood, 1999).  
In this work, we study the effect of copper ions on the peptide-peptide rupture force of 
the Aβ (1-42) peptide. We show that when copper ions are added to the Aβ force spectroscopy 
environment, the rupture force increases dramatically, which correlates with a higher rate of 
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aggregation shown by AFM imaging. This is the first single-molecule study which shows that 
Cu2+ increases the force of interaction between two single Aβ peptides; thus, affecting further 
aggregation. 
3.2. Experimental Procedures 
We used a widely accepted method of binding proteins through N-terminus to PEG 
heterobifunctional cross linkers (Allison, Hinterdorfer, & Han, 2002) (Hinterdorfer & Dufrêne, 
2006), an experimental setup as previously described (Kim, Palermo, Lovas, Zaikova, Keana, & 
Lyubchenko, 2011). Detailed protocols are described in appendix A of this thesis. Briefly, the 
experimental procedures are outlined below. 
3.2.1. Tip and Surface Modification 
Bruker MLCT AFM cantilevers were cleaned by soaking in ethanol for 15 minutes, 
washed in ultrapure water and dried in a gentle stream of nitrogen and placed under UV light for 
30 minutes. Mica was freshly cleaved. 3-aminopropyltriethoxy silane (APS) was synthesized as 
previously described (Shlyakhtenko, Gill, Filonov, Cerovac, Lushnikov, & Lyubchenko, 2003). 
The structure of APS was confirmed using NMR spectroscopy. The mica and cantilever were 
then immersed in 167μM APS for 30 minutes, rinsed with ultrapure water and dried under a 
gentle stream of nitrogen. The mica and cantilever were then placed in a 3400MW Polyethylene 
Glycol (PEG) solution (167μM in DMSO) (Laysan Bio, Alabaster GA) for 3 hours, than rinsed 
with DMSO.  The cantilever and mica were washed and stored in HEPES buffer (50mM HEPES, 
150mM NaCl, pH 7.4). We specifically chose HEPES buffer because of the absence of metal 
ions. 
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3.2.2. Aβ (1-42) Preparation and Surface Binding 
Cys-Aβ (1-42) was purchased from Anaspec (Fremont, CA) and prepared in DMSO at a 
concentration of 1mg/mL. The Aβ stock solution was then diluted in HEPES buffer to a final 
concentration of 20nM. An equal volume of 200nM tris(2-carboxyethyl)phosphine (TCEP) was 
added to the dilute peptide solution to prevent aggregation. The Aβ solution was stored for 15 
minutes and then centrifuged at 14000 RPM for 15 minutes to move monomeric forms to the top 
of the solution to ensure primarily monomeric forms of the peptide were used. The mica and 
cantilevers were soaked in the dilute Aβ solution for 30 minutes. The Aβ was rinsed with HEPES 
buffer, and the mica was treated for 10 minutes with β-mercaptoethanol to react with any 
available maleimide groups so as to prevent false rupture events. Both cantilever and mica were 
washed three times with HEPES buffer, and stored in HEPES buffer until use. 
3.2.3. Atomic Force Spectroscopy 
A JPK Nanowizard II atomic force microscope was used for all measurements. 
Cantilever spring constants were measured using Hutter’s thermal noise method (Hutter & 
Bechhoefer, 1993), which requires both the normal sensitivity and the thermal resonance spectra. 
The sensitivity was obtained from the gradient of the contact portion of a force-displacement plot 
acquired on a mica surface. The thermal spectrum was obtained using the JPK software. The 
voltage response of the cantilever deflection measured using the photodiode was converted to 
units of force by multiplying by the normal sensitivity and the spring constant. Mica coated with 
Aβ as described earlier was placed on the stage in the liquid cell and immersed in HEPES buffer. 
A series of force curves were taken with an approach and retract velocity of 400 nm/s. A dwell 
time of 0.5 seconds was set to allow peptide-peptide binding events. For a single experiment 
approximately 1000 force curves were recorded, out of which approximately 10% of these 
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showed specific unbinding events. Each experiment was repeated four times with a different 
cantilever and substrate.  For each repeat experiment at least 100 force curves were analyzed, a 
similar binary distribution was observed and representative experiments are presented. Solutions 
of Cu2+ (purchased from Sigma-Aldrich) in HEPES buffer were prepared at a concentration of 
20nM and were added to the liquid cell for applicable experiments. 
3.2.4. Force Curve Analysis 
JPK data analysis software was used to analyze force curves. A worm like chain (WLC) 
fit was obtained for each force curve and rupture forces were obtained. Rupture force histograms 
were fitted with a sum of two Gaussian distributions, and minimized using the Levenberg-
Marquardt non-linear least squares fitting routine in Matlab. Errors quoted for the most probable 
rupture force are evaluated as the standard deviation of each distribution, divided by the square 
root of the effective number of counts for each distribution (estimate of standard error). The 
effective number of counts was approximated by multiplying the total number of data points by 
the area fraction of the given Gaussian distribution. 
3.2.5. Amyloid Incubation for AFM Imaging 
Aβ (1-42) (purchased from rPeptide, Bogarta, GA) was pre-treated according to the 
Fezoui procedure (Fezoui, Hartley, Harper, Khurana, & Walsh, 2000) to ensure the monomeric 
form. The peptide solutions were prepared by adding HEPES buffer and either Cu2+ ions or an 
equal amount of buffer to produce the copper and control samples, respectively. The final 
concentration of amyloid-β (1-42) was 55 μM, and the final concentration of Cu2+ was 5.5 μM, 
which yielded a 10:1 amyloid-Cu2+ molar ratio. The solutions were incubated at room 
temperature for 1 hour, 6 hours and 24 hours. 50 μL aliquots were placed onto freshly cleaved 
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mica at the respective times for a 5 minute adsorption period. Excess amyloid solution was then 
washed with milliQ water and dried with a gentle stream of N2 gas. 
3.2.6. AFM Imaging 
The mica slides with adsorbed amyloid were placed in a JPK Nanowizard II atomic force 
microscope and imaged in air in Intermittent Contact mode using cantilevers purchased from 
NanosensorsTM (Non-contact/Tapping™ mode - High resonance frequency; non-coated; tip 
radius <10nm). All images were taken with a line rate of 0.5Hz, and the gains were adjusted to 
yield maximum image quality. 10x10μm and 5x5μm images were taken, and subsequently 
analyzed using JPK Data Processing Software. Each experiment was repeated at least twice and 
at least 3 images for each sample. 
3.3. Results 
We used a combination of single molecule atomic force spectroscopy and atomic force 
microscopy to probe the single molecule interactions of Aβ in the presence of Cu2+ ions. 
Statistical analysis was completed on force curves to determine the most probable rupture force 
and Gaussian curve width. Figure 9 illustrates a schematic of the force spectroscopy 
experimental set up. Notice that Aβ has been bound to both the tip and substrate through APS 
and a PEG linker, via a cys residue at the N-terminus.  
Figure 12 shows a series of histograms of rupture events. For our control experiment 
without any copper added, we observed double Gaussian peaks centered on 66±1 pN and 132±4 
pN. These figures are shown in Table 1. With the addition of copper, a much higher mean 
rupture force was observed, with copper yielding rupture forces with double Gaussian peaks at 
83±3 and 164±5 pN and mean rupture force of 178.9±7 pN. 
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 Gaussian Peak 1 
± SE  (pN) 
Gaussian Peak  
2 ± SE (pN) 
Mean Rupture 
Force (pN) 
Experimental 
Yield (%) 
Aβ Control 66±1 132±4 125.2±5 14.3 
Cu2+ added 83±3 164±5 178.9±7 14.2 
Table 1 - Statistical Data of Force Spectroscopy Experiments 
 
 
Figure 12- Histograms of rupture forces showing the distribution of forces required to rupture 
the peptide-peptide complex without copper (A) and with copper (B). Fits to the data are 
Gaussian distributions, the peaks of which represent the most probable rupture force. 
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Figure 13 shows sample force curves obtained with and without copper and occurring 
within both the higher and lower Gaussian peaks shown in figure 12. 
 
Figure 13- Representative force curves.  Force curves showing rupture forces of an Aβ 
dimer without (A) and with (B) copper added at a retraction rate of 400 nm/s. Curves are shown 
as force vs. piezo z-displacement. 
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Figure 14 shows AFM images of amyloid aggregates formed in solution with and without 
copper ions added for incubation times of 1 hour, 6 hours and 24 hours. We observed oligomeric 
amyloid species with a mean height of  3.13 nm after an hour of incubation without copper, as 
seen in figure 14A.  After 6 hours, the control experiment (figure 14B), revealed the formation of 
a mixture of oligomeric species, and short fibrils that had a mean height of 4.5 nm. At 24 hours 
of incubation (figure 14C), Aβ aggregated to dominantly fibrillar species with a mean height of 
7.2 nm. The observed fibrils at 24 hours were significantly longer than those observed at 6 hours, 
extending up to 3 μm. Figures 14D-14F are representative images of the various structural 
conformations of the Aβ aggregates in the presence of one tenth Cu2+ molar concentrations under 
the respective times.  Large amorphous aggregates with a mean height of 9.3 nm were formed 
after 6 hours, which coincided with the formation of the short fibrils as found in the respective 
control. After 24 hours, these unique aggregates remained the dominant species, and the 
populous fibrils that were observed in the control were not present. 
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Figure 14- AFM images of amyloid-metal aggregates. AFM images of Aβ incubated 
without copper for periods of 1hr (A) 6hr (B) and 24hr (C), and with copper at a 10:1 molar 
ratio for 1hr (D), 6hr (E), and 24hr (F). The lateral scale bar is 1 µm. 
 
3.4. Discussion 
In a recent report, Sarell and colleagues (Sarell, Wilkinson, & Viles, 2010) attributed the 
increase in aggregation of Aβ with substoichiometric levels of Cu2+ to charge neutralization 
caused by the binding of copper ions to the copper binding site at the histidine residues resulting 
in a peptide more prone to self-association. In this work, we present for the first time 
measurements of the initial single molecule interaction between two Aβ peptides in the presence 
of Cu2+ ions. We show that with the addition of copper, the unbinding (rupture) force increases 
notably. The increase in unbinding force is consistent with the findings of other groups showing 
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a reduction of lag time in amyloid aggregation when copper is added to the system (Huang, 
Atwood, Moir, Hartorn, & Tanzi, 2004). This suggests that the reduction of lag time associated 
with Aβ aggregation occurs on a single molecule level as a result of the very initial dimerization 
interactions between the peptides. 
The rate of aggregation of aggregation-prone proteins, such as Aβ (1-40) and α-
synuclein, has been shown to be a function of the mean rupture force between two peptides 
(McAllister, et al., 2005) (Yu, Malkova, & Lyubchenko, 2008).  It has been established that the 
acceleration of aggregation is the result of a decrease in the lag time associated with amyloid 
nucleation (He, Giurleo, & Talaga, 2010). Although the mechanisms involved during this lag 
time have previously been unclear, it is believed that the lag time is a result of the development 
of a significant amyloid nucleus onto which other peptides can bind to. We suggest that a 
reduction in lag time may occur as a result of the very initial nucleation process: the dimerization 
of two Aβ peptides.  
The common theory of the aggregation of Aβ involves the oligomer cascade hypothesis 
(Hardy & Higgins, 1992). According to the oligomer cascade hypothesis, monomeric species 
form a dimeric nucleation site. Additional monomers are added to this nucleus to progressively 
form larger oligomers, protofibrils and finally, mature amyloid fibrils (Hardy & Higgins, 1992). 
This paradigm has recently come under review and a serious argument can now be made that 
pathological oligomers and inert fibrils may form along separate pathways (Yamaguchi, Yagi, 
Goto, Matsuzaki, & Hoshino, 2010). Necula and colleagues have suggested that several different 
oligomeric species may form following the misfolding of the Aβ monomer (Necula, Kayed, 
Milton, & Glabe, 2007). Only one of these oligomers may eventually form fibrils, with other 
oligomers remaining in the most stable oligomeric state. He and colleagues studied the amyloid 
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forming β-lactoglobulin protein and have suggested a bifurcation of its amyloid pathway at the 
16mer point, where the aggregate may continue as an oligomer or begin to form a protofibril 
(He, Giurleo, & Talaga, 2010). Based on our data, we propose that, for Aβ, the divergence of this 
pathway begins much earlier: at the initial dimerization of the two Aβ peptides, where the 
structure of the initial dimer varies and determines the pathway followed.  In our control 
experiments without copper, we observe two distinct force peaks most likely associated with 
different dimer configurations, possibly parallel and anti-parallel for two amyloid peptides 
interacting with each other at the self-recognition site as proposed by Tjernberg (Tjernberg, 
Naslund, Lindquist, Johannsson, Karlstrom, & al, 1996) and illustrated in figures 15A and B. The 
anti-parallel dimer configuration (figure 15A) is the more stable of the two stabilized by salt 
bridges at each end (Mothana, Roy, & Rauk, 2009), and therefore, we assign this configuration 
to the stronger force observed (peak two, figure 12A).  The first weaker force (peak one, Figure 
2A) more likely corresponds to the parallel configuration (Figure 15B). 
Our interpretation of the data collected is consistent with the results of Pedersen and 
colleagues (Pedersen, Østergaard, Rozlosnik, Gammelgaard, & Heegaard, 2012). Pedersen used 
bulk measurements of Aβ aggregation under the influence of Cu2+ and concluded that copper 
alters the aggregation pathway of Aβ. The interpretation of our data is consistent with Pedersen’s 
conclusions. Our results build on this data and propose a structural model which is consistent 
with the observations provided by our groups. 
The addition of copper ions significantly increases the unbinding forces of Aβ peptides, 
at the same time the two distinct peaks shift to a higher value (figure 12B). It was also apparent 
that though there is a shift in the two Gaussian peaks, the proportion of the number of binding 
events in the first peak to the second peak decreases when copper is added to the environment. 
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Based on our hypothesis that there are at least two different conformations of the Aβ dimer, we 
believe that the addition of copper increases the probability of Aβ to dimerize in a conformation 
correlating with the second peak, corresponding to a larger binding force. Given these 
differences in unbinding forces, we suggest that both the parallel and anti-parallel dimer 
conformations become stabilized by Cu2+ ions, which results in the shift of these peaks to higher 
forces. Considering the possibility of Aβ-Aβ binding both with and without Cu2+ ions, we 
suggest four possible complexes that can be formed in this case: Aβ-Aβ parallel, Aβ-Cu-Aβ 
parallel, Aβ-Aβ anti-parallel, Aβ-Cu-Aβ antiparallel. Our hypothesis is further supported by 
recent theoretical work by Mousseau (Côté, Laghaei, Derreumaux, & Mousseau, 2012) and 
Urbanc (Barz & Urbanc, 2012). Using molecular dynamics simulations, both groups 
independently demonstrated that Aβ (1-42) can dimerize in multiple conformations along 
multiple pathways. It stands to reason that different dimer conformations have different 
unbinding forces. 
We considered alternative explanations to our hypothesis to explain the presence of two 
most probable force peaks. We considered that two distinct dimers are rupturing at the same time 
yielding one much larger force. Based on the probability of a binding and unbinding event, we 
applied the method proposed by Akhremitchev (Karacsony & Akhrimitchev, 2011) to determine 
the probability of two or more peptides being located in the same area and rupturing 
simultaneously. For our highest yielding experiments, where the most rupture events happened 
for a given number of approaches, we calculate this probability to be p=0.12. Consistent with 
previous analysis methods, the force curves with the (pn, n = number of force curves) highest 
rupture forces were discarded and not included in the rupture force histograms. Over several 
thousand collected force curves, we did indeed observe some double, and even triple, binding 
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events. However, given the inhomogeneity of the length of the PEG linkers, these events were 
identified by two force curves with the distance between them being a function of the difference 
in PEG linkers rather than one large force curve. Given our statistical observations, we conclude 
that any double unbinding event masquerading as a single force curve is so improbable as to be 
negligible, and certainly would not approach the greater than 50% of force curves that occur at 
the higher force. 
Our second alternative explanation for the presence of these double force peaks is that 
instead of a monomeric peptide being bound at the end of the PEG linker, aggregation has 
occurred prior to attachment to the PEG linker and an amyloid oligomer was in fact bound at the 
end of the PEG linker. We closely followed the procedure developed by the Lyubchenko group, 
who repeatedly showed that when treated as noted in our methods and kept in such a dilute 
solution, Aβ will not aggregate (Kim, Palermo, Lovas, Zaikova, Keana, & Lyubchenko, 2011). 
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Figure 15- Schematic diagram of Aβ dimers with and without copper. Without copper, 
the most favorable conformation of the Aβ dimer involves an anti-parallel conformation (A). 
With the addition of copper,  Aβ adopts a parallel dimer conformation (B) stabilized by the 
occupied copper binding sites (C). 
 
Figure 16 shows plausible conformations of Aβ dimer with and without copper 
assembled from stable Aβ42 monomer structures (Raffa & Rauk, 2007). Each monomer has an 
internal antiparallel β-sheet between residues 18-21 and 30-33. The dimers are assembled by 
juxtaposition of the self-recognition site residues 18-21 in antiparallel (A, C) and parallel (B, D) 
orientation.  Both orientations bring His6, His13 and His14 of each monomer into close 
proximity, requiring little reorientation to bind Cu2+ ions (filled green circles). Figure 16 A and B 
show plausible assemblies for the Aβ-Aβ complexes in antiparallel and parallel conformations 
without copper. Figure 16 C and D show two possible structures for Aβ-Cu-Aβ in anti-parallel 
and parallel conformations, respectively.  The variety of possible structures and the strengthening 
99 
 
 
 
of each binding event by Cu2+ results in the broad distribution of unbinding forces we observed 
in the presence of Cu2+ ions (figure 12B). 
 
Figure 16 - Schematic diagram of Aβ dimers with and without copper assembled from 
stable Aβ42 monomer structures (Raffa & Rauk, 2007). Each monomer has an internal 
antiparallel β-sheet between residues 18-21 and 30-33. The dimers are assembled by 
juxtaposition of the self-recognition site residues 18-21 in antiparallel (A, C) and parallel (B, D) 
orientation.  Both orientations bring His6, His13 and His14 of each monomer into close 
proximity, requiring little reorientation to bind Cu2+ ions (filled green circles). Proposed 
schematics are courtesy of A. Rauk, unpublished data, created using Raswin software.   
 
Our AFM imaging shows that after 6 hours of incubation in the presence of copper, no 
amyloid fibrils were found in a significant amount. Rather, we observed large amorphous 
structures that indicate the presence of a copper-dependent Aβ aggregation pathway distinctive 
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from the aggregation pathway without Cu2+ which leads to fibril formation. The dominance of 
these amorphous amyloid aggregates in the presence of copper ions is consistent with previously 
published images of amyloid aggregation in the presence of Cu2+  (Ha, Ryu, & Park, 2007) 
(Innocenti, et al., 2010).  
Trace amounts of metal ions have been shown to decrease the lag time associated with 
aggregation (Huang, Atwood, Moir, Hartorn, & Tanzi, 2004). Previously, it has been unclear 
why only substoichiometric amounts of metal ions were needed to reduce the lag time, and thus, 
increase aggregation. We believe that the reduction of lag time associated with amyloid 
aggregation in the presence of copper is a result of the very initial dimerization process 
immediately forming an aggregation nucleus which other peptide can bind onto. 
In summary, we demonstrated that unbinding forces of two Aβ peptides without Cu2+ 
have two distinct force peaks, likely associated with parallel and anti-parallel configurations, and 
resulted in  amyloid fibril formations as demonstrated by AFM imaging.  The addition of Cu2+ 
ions resulted in a shift to higher force distributions and a higher proportion of unbinding events 
occurring in the higher force. As seen by the AFM imaging, this distinct force profile is 
correlated with the formation of amorphous aggregates. We assign this effect of Cu2+ to the 
strengthening of binding between two individual Aβ peptides and disruption of fibril formation 
pathway at a single molecule level.   
3.5. Conclusions 
In conclusion, we report that copper increases peptide-peptide binding forces at a single 
molecule level and changes aggregation observed at the microscale. Therefore, single molecule 
peptide-peptide interaction defines a pathway for amyloid aggregation. This finding leads to a 
better understanding of the role of biometals in the mechanism of amyloid fibril formation. 
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Chapter 4 
Effect of Aggregation Inhibitors on Amyloid-β Peptide 
Unbinding Force 
 
This chapter has been adapted from a manuscript which has been accepted for publication in the 
journal Biosensors and Bioelectronics.  
Alzheimer’s disease is a neurodegenerative disease with no known cure and few effective 
treatment options. The production of pharmaceuticals which prevent the aggregation of amyloid-
β has long been a goal of researchers. The principal neurotoxic agent is an oligomeric form of the 
amyloid-β peptide and one of the treatment options currently being studied is the inhibition of 
amyloid aggregation. In this work, I tested a novel pseudopeptidic aggregation inhibitor 
designated as SG1 designed by the Rauk group. SG1 has been designed to bind at the amyloid-β 
self-recognition site and prevent amyloid-β from misfolding into beta sheet. I used atomic force 
spectroscopy, a nanoscale measurement technique, to quantify the binding forces between two 
single amyloid peptide molecules. I demonstrated that single molecule atomic force spectroscopy 
can be used to assess the effectiveness of amyloid aggregation inhibitors by measuring the 
experimental yield of binding and can potentially be used as a screening technique for quick 
testing of efficacy of inhibitor drugs for amyloid aggregation.  
Author Contributions: 
• Designed Experiments: Zoya Leonenko, Arvi Rauk, Francis Hane 
• Performed Experiments: Francis Hane, Brenda Lee, Anahit Petoyan 
• Analyzed Data: Francis Hane, Brenda Lee, Anahit Petoyan 
• Wrote the Manuscript: Francis Hane, Zoya Leonenko, Arvi Rauk  
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4.1. Introduction 
AD is a complex disease associated with a number of potential factors including aging 
(Bertram & Tanzi, 2005), genetics (Bertram & Tanzi, 2005), metals dyshomeostasis (Bush & 
Tanzi, 2008), protein-lipid interactions (DiPaolo & Kim, 2011), vascular disorders (Roy & Rauk, 
2005), and loss of acetylcholine receptors (Whitehouse, et al., 1986). Pharmaceutical therapies 
have focused on attacking underlying factors associated with Alzheimer’s (Roberson & Mucke, 
2006). For example, γ-secretase inhibitors have been developed in an attempt to stop the cleaving 
of amyloid-β from its precursor protein, the amyloid precursor protein (APP) (Citron, 2004). 
Despite extensive research and funding, no therapy has yet been shown to reverse the symptoms 
associated with Alzheimer’s in human trials, and even the most efficacious therapies are not 
curative, but only delay the onset of symptoms (Neugroschl & Sano, 2010).  
Aβ begins its pathological aggregation by misfolding into an internal beta sheet between 
the amino acids 17-23- and 28-35. The amino acids (24-27) form a beta-hairpin to allow the 
peptide to fold back on itself (Petkova, et al., 2002) (Sciarretta, Gordon, Petkova, Tycko, & 
Meredith, 2005). After misfolding into a hairpin, the peptide may bind to another Aβ peptide, 
acting as a nucleus for further peptide aggregation. The self-recognition site (17-23) (Tjernberg, 
Naslund, Lindquist, Johannsson, Karlstrom, & al, 1996) is responsible for the aggregation of Aβ 
into dimers and higher oligomers. Blocking this site effectively prevents the misfolding and 
subsequent aggregation.  In the absence of sufficient peptide clearance, this aggregation leads to 
the formation of toxic amyloid aggregates (Harper, Liber, & Lansbury, 1997). 
The Aβ sequence (13-23), which incorporates the self-recognition site, has been a target 
for amyloid aggregation inhibitors (Mothana, Roy, & Rauk, 2009) which are designed to have a 
high affinity for the self-recognition site and “block” the peptide from self-dimerization. Rauk 
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and co-workers developed a series of pseudopeptidic novel amyloid inhibitors that bind to and 
act on this self-recognition site (Mothana, Roy, & Rauk, 2009) (Roy, 2010). These inhibitors 
consist of a series of modified amino acids including methylated amino acids. A structure of SG1 
is show in figure 18b. These inhibitors were synthesized and tested using a combination of 
circular dichroism and thioflavin T fluorescence assay to look for evidence of peptide 
aggregation. These methods have a characteristically low throughput because a period of 24 
hours or more is needed for the peptide to aggregate into a recognizable form to determine the 
effect of the inhibitor on the aggregation properties. We used atomic force spectroscopy to test 
the efficacy of a synthetic amyloid inhibitor termed SG1 (figure 18) and demonstrated that SG1 
reduces the number of binding events between two Aβ peptides by as much as 81%. In addition, 
we used atomic force microscopy and molecular dynamics simulations for comparison with AFS 
data and demonstrated with all these methods that the aggregation of Aβ is greatly reduced in the 
presence of SG1.   
4.2. Experimental Procedures 
To follow the effect of SG1 on Aβ aggregation and fibril formation, AFM was used in 
both imaging mode and force spectroscopy mode.  To measure single molecule binding forces 
between peptides, AFM was used in force spectroscopy mode, in which the AFM probe, with an 
Aβ peptide attached to it was moved repeatedly towards and away from the mica surface, also 
bound with peptides, and the interaction force was measured as a function of probe-sample 
separation at pN resolution. For these experiments attachment of the Aβ peptide to both AFM 
probe and the surface is required. Except as noted, we used chemical modification protocols as 
previously described (Hane, Tran, Attwood, & Leonenko, 2013) and in appendix A of this thesis. 
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4.2.1. Preparation of SG1 Inhibitor Solution 
SG1 was synthesized using fmoc-chemistry method (Roy, 2010). SG1 was lyophilized 
and stored in powdered form in -20 °C. When ready for experimental use, SG1 was dissolved in 
HEPES buffer (50 mM, 150 mM NaCl, pH 7.4). A 2 µM stock solution was prepared using serial 
dilutions. From the stock solution, final aliquots of 20 nM, 40 nM and 200 nM were prepared for 
experimental force spectroscopy experiments.  
4.2.2. AFM Imaging of Amyloid-β and SG1 incubated in solution 
Aβ (1-42) was purchased in lyophilized powder from rPeptide (Bogart, GA), pretreated 
according to the Fezoui procedure (Fezoui, Hartley, Harper, Khurana, & Walsh, 2000) to ensure 
monomeric form. The Aβ was dissolved in HEPES buffer (20 mM HEPES and 100 mM NaCl, 
pH 7.4) and was immediately used to prepare the sample solutions at a final concentration of 110 
μM Aβ (1-42). The inhibitor SG1 was added at a 1:1 molecular ratio of SG1 to Aβ. The control 
solution had no inhibitor added. Solutions were incubated at 1, 6, and 24 hours at room 
temperature. After each incubation period, 100 μL of each solution was deposited onto freshly 
cleaved mica slides and incubated at room temperature for 5 minutes. Mica slides were then 
rinsed 5 times with 50 μL aliquots of distilled H2O, dried for 2 minutes with a gentle stream of 
nitrogen gas and imaged in air in intermittent contact mode using JPK Nanowizard II AFM. We 
used silicon AFM probes (VISTA), with a spring constant of 40 N/m, resonance frequency of 
300 kHz, and an aluminum reflex coating. Multiple 50x50 μm images and 5x5 μm images were 
collected from each sample at a resolution of 2048x2048 pixels and used for statistical analysis. 
AFM images were analyzed to extract the size of oligomers, size of fibrils and the oligomer to 
fibril ratios using JPK image processing software and ImageJ v.1.43 software.  
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4.2.3. Molecular Dynamics Simulations 
The initial structures of SG1, Aβ (13-23), Aβ (13-23)-Aβ (13-23), and SG1-Aβ (13-23) 
were obtained as described earlier (Mothana, Roy, & Rauk, 2009).  The monomeric Aβ receptor 
model, Aβ(13-23), was acetylated at the N-terminus, residue 13 (His13) and N-methylated at 
residue 23 (Asp23). The SG1-SG1 dimer was determined as described previously (Mothana, 
Roy, & Rauk, 2009). All MD simulations were performed using the Gromacs 4.5 suite of 
software (Berendsen, van der Spoel, & van Drunen, 1995). Previously, the free energy 
perturbation technique called "Atomic Force Microscopy" or AFM was used to calculate the free 
energy of binding of different complexes (Mothana, Roy, & Rauk, 2009).  The binding results 
presented in this work were reevaluated with the more accurate technique, "Umbrella Sampling," 
in which selected frames along the AFM potential curves are re-equilibrated and re-assembled 
into complete potential curves by the "Weighted Histogram Analysis Method" (WHAM).  Each 
dimer had thirty windows and each window was equilibrated for 20ns with force constant 1000 
kJ/ (mol nm2) at physiological pH (7.4) and temperature (310 K). 
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Figure 17- Schematic of Force Spectroscopy Experiment. A schematic of the 
experimental setup of force spectroscopy experiments, showing Aβ bound to the substrate and 
AFM tip via the PEG linker with aggregation inhibitor SG1 in the aqueous solution. A silanated 
surface is modified with NHS-PEG-maleimide. A cysteine residue is bound to the N-terminus of 
Aβ peptide to act as a binding site for the maleimide group of the linker molecule. 
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4.3. Results 
A schematic of the experimental set up is shown in figure 17 with one Aβ peptide bound 
to the tip and another to substrate via intermediate PEG linkers.  
Amyloid aggregation inhibitor SG1 binds to the Aβ self-recognition site (17-23), 
preventing the dimerization and further aggregation of Aβ. By binding to this site, the inhibitor 
physically prevents the two structured sections from coming into contact and forming the 
prerequisite hairpin. In figure 18a, the structure of most stable conformation of Aβ  (13-23) is 
shown, which is  folded conformation,  stabilized by intramolecular H-bonds between Glu22 and 
the amido N-H of residues Val18 - A21.  The most stable conformation of SG1 is a β-strand 
(figure 18b). SG1 is designed to make an antiparallel beta sheet with the self-recognition site, 
Aβ (17–23). The structure of the SG1 peptide shown in figure 18a was obtained by MD 
simulations and the binding between SG1 and Aβ (13-23) fragment responsible for beta-sheet 
formation was calculated. When SG1 binds to Aβ, N-methylation at one edge of the beta strand 
ensures that SG1 cannot propagate a beta sheet from that edge.  Figure 18c shows the complex 
formed as a result of binding between SG1 and Aβ (13-23), which is predominantly an 
antiparallel β-sheet.  
Figure 18d shows free energy curves for the dissociation of the Aβ (13-23) dimer, the 
SG1/Aβ (13-23) complex and the SG1 dimer obtained from MD simulations. The estimated free 
energies of dissociation are 62, 56, and 40 kJ/mol, respectively.   
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Figure 18- Molecular Dynamics Simulations Showing Mechanism of Action of SG1: a) 
the structure of Aβ (13-23) in its most stable conformation. b) the structure of SG1 in its most 
stable conformation (β-strand): SG1=Ac-dab-O-(Me)L-F-(Me)F-LP-bA-COOH where 
dab=diaminobutyric acid, O=ornithine, (Me)L=N-methylleucine, (Me)F=methylphenylalanine, 
and bA= β-alanine; c) The structure of the complex of SG1 (gold) and Aβ (13-23) (magenta). 
The complex is predominantly an antiparallel beta sheet. d) Free energies of dissociation 
(∆Gdiss) in kJ/mol, of Aβ(13-23)-Aβ(13-23), SG1-Aβ(13-23) and SG1-SG1. All form antiparallel 
dimeric complexes. 
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Using AFS we measured unbinding forces and observed a noticeable reduction in the 
experimental yield in the presence of SG1 (from 24% in control experiment to 11.2% with 
equimolar concentrations SG1). Higher inhibitor concentrations of 40 nM and 200 nM resulted 
in experimental yields of 7.9% and 6.9% respectively. 
A typical force curve is shown in figure 19a, with adhesion peak in the withdraw part of 
the force plot (blue). The unbinding event starts at a ~65nm which correlates with the length of 
two PEG linkers (each ~35nm). MD data as shown in figure 18d do not include a PEG linker and 
separation is therefore considerably less. 
Figure 19b and 19c display the results of a typical experiment with mean rupture force 
shown (figure 19c) and the experimental yield of this experiment (19b). While a significant 
reduction in the experimental yield was observed as a function of inhibitor concentration (figure 
3b), a quasi-linear increase in the unbinding force was also observed at higher concentrations of 
SG1 (figure 19c). This experiment was repeated four times. Each time, the addition of SG1 
resulted in a decrease in experimental yield. Other experiments (data not shown) resulted in 
decreases from 3.1% to 0.5%, 8.8% to 6.1% and 36.3% to 23.4% with the addition of inhibitor 
SG1. 
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Figure 19 a). Typical unbinding force curve. The tip approaches the surface (red) until 
the AFM senses a repulsive force resulting from the tip interacting with the sample. The tip is 
then retracted (blue). As the tip is retracted, an interaction between the two molecules is 
measured until there is a sudden rupture at which point the cantilever returns to its original 
unbent position. If a binding event occurs, the retraction plot shows adhesion peak; b). 
Dependence of experimental yield of binding on concentration of SG1 inhibitor; c) Rupture force 
dependence on inhibitor concentration. 
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The effectiveness of the inhibitor was also validated by atomic force microscopy 
imaging. SG1 was added into the Aβ solution and after incubation for 1, 6 and 24 hours, the 
aggregates that were formed in solution were deposited on mica and imaged by AFM (figure 20) 
in air. In the absence of inhibitor, typical amyloid fibrils grew in width and length as a function 
of incubation time. When the aggregation inhibitor SG1 was added, a reduction in the number of 
fibrils was observed especially at earlier incubation times of 1 and 6 hours. We define the 
oligomer qualitatively as any of small globular structures not resembling a long fibrillar form. 
Other authors have referred to these structures as Aβ derived diffusible ligands (ADDL) 
(Lambert, et al., 1998), or prefibrillar oligomers (Glabe, 2008). Fibrils formed with inhibitor 
present were considerably smaller in length and width than the fibrils observed in the control 
samples. A statistical analysis of height distribution for Aβ control shows that the mean 
aggregate heights for 1, 6, and 24 hours were very similar: 6.47, 7.00, and 6.39 nm, respectively. 
For samples with SG1, the mean aggregate heights were changing with time: 3.13, 5.17, and 7.87 
nm for 1, 6 and 24 hours, respectively.  
The size of fibrils increased as a function of time for control samples. When SG1 
inhibitor was added, fibril growth was considerably slower, and fibrils produced were shorter. 
The mean fibril lengths for amyloid-beta as 262, 571, 715 nm at 1, 6 and 24 hrs respectively. For 
the SG1 sample, we calculated mean fibril length of 83, 193, and 301 nm at 1, 6, 24 hrs 
respectively. We analyzed the images to deduce oligomer to fibril ratio (figure 21a). After 1 hour 
of incubation, both the control sample and the SG1 sample showed twice as much oligomers 
compared to fibrils. As incubation time increased, the control sample showed a large increase in 
the fibril/oligomer ratio to 10.3 indicating that there were 10 times as many monomers in fibrillar 
form than the oligomeric form. At 24 hours of incubation, the fibril to oligomer ratio increased to 
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12.5. With the SG1 present, the fibril to oligomer ratio was much lower:  0.5 at 1h and increased 
to only 9.7 after 24 hours of incubation (figure 21a). 
 
Figure 20 - AFM images of Amyloid Fibril Formation with and without Inhibitor. Aβ 
only (A, B, C) and Aβ with inhibitor SG1 incubated for 1, 6 and 24 hours respectively (D, E, F) 
and representative cross sections. SG1 and Aβ concentrations were both identical at 110 μM. 
After incubation for 1, 6, and 24 hours (images from left to right) at room temperature, 100 μL 
aliquots of each solution were deposited on freshly cleaved mica for 5 minutes, washed, dried 
and imaged in air. Below each image a cross-section is shown, indicating the height of the 
aggregates. The scale bar is equal to 1 µm.  
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Figure 21- Analysis of AFM images. a) Fibril to oligomer ratio and b) Fibril length as a function 
of incubation time and presence of inhibitor. 
 
4.4. Discussion 
The goal of this study was to demonstrate that amyloid aggregation inhibitor SG1 can be 
used to slow the aggregation of the Aβ peptide. In addition, we wanted to show the potential of 
using AFS for quick testing of inhibitor drugs for amyloid fibril formation before they go to 
cellular, animal studies or clinical trials.  
The first step in any aggregation process is the formation of a critical nucleus which 
begins with the dimerization of two molecules. If this initial process can be inhibited, 
aggregation will not occur, or at least the lag time associated with aggregation will increase or 
the aggregation rate will be lowered to allow for physiological clearance mechanisms to clear 
aggregates before they accumulate and become neurotoxic.  
In past AFS experiments, the unbinding force itself has been used to characterize binding 
of molecules (Hinterdorfer & Dufrêne, 2006). In this work we show that the most useful 
parameter for testing inhibitors is the experimental yield of binding/unbinding events. Our 
objective was to determine a binary process: “binding” or “no-binding” event. We demonstrate 
that the greatest reduction in amyloid dimerization occurs when a small concentration (20 nM) of 
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SG1 inhibitor is present in the solution, followed by further reductions (though not to the same 
magnitude with increasing inhibitor concentrations (figure 19b). In correlation with experiments, 
the MD data demonstrate that SG1 binds to Aβ (13-23) fragment, a self-recognition part of 
Aβ (1-42),  a slightly less strongly than Aβ binds to itself, but significantly stronger than SG1 
binds to itself.  The N-methylation pattern of SG1 ensures that when it binds at the self-
recognition site of Aβ, it prevents the amino acid domains (16-22) and (29-35) from binding with 
one another- the initiating event of the aggregation cascade. An ideal inhibitor will result in no 
Aβ dimerization (no binding), but there is a limit to the inhibitor concentration able to bind to a 
very sparse coverage of surface bound peptides. The reason there are still amyloid-amyloid 
binding events in the inhibitor environment is because the inhibitor has not bound all available 
Aβ peptide.  As the inhibitor concentration increases, the probability of an inhibitor molecule 
coming into contact with a surface or tip bound Aβ peptide increases. The difference between 40 
nM and 200 nM concentrations of inhibitor is only 1% experimental yield making the inhibitor 
concentration dependence appear asymptotic. The AFM images in figure 20 show that some 
aggregation is still observed even with inhibitors present. Furthermore, we noticed that higher 
inhibitor concentrations resulted in an increase of unbinding force. From MD simulations we 
conclude that SG1 induces a conformational change in Aβ, converting the self-recognition region 
into a beta strand.  This conformational change costs energy, making the calculated binding 
affinity less than the actual interaction between two beta strands. Once the energy cost has been 
paid, further interaction may appear to be stronger. This may cause the increase of the unbinding 
forces that we observe experimentally with the increase of concentration of SG1.   
The analysis of AFM images indicates that the structure of the oligomers that were 
different when SG1 was present. Without the inhibitor, Aβ forms characteristic oligomers of 
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beta-sheet structure which grow in length to form long fibrils. When the inhibitor was present, 
characteristic Aβ-Aβ arrangement was disturbed, which resulted in the observation of different 
heights of oligomers and less fibril growth (figures 20 and 21).  Extensive evidence suggests that 
the dimerization and further nucleation of an amyloid oligomer is the rate limiting step in the 
fibrillization process (Stefani, 2012). Our AFM data indicate that SG1 may not slow the 
nucleation of Aβ but rather inhibit the polymerization of oligomers into amyloid fibrils with 
beta-sheet structure. Thus, all three factors, the change in the unbinding force, the reduction of 
experimental yield of binding, and the decrease of fibril formation indicate that the SG1 inhibitor 
successfully suppresses the typical pathway of Aβ-Aβ interaction, which results in characteristic 
(Aβ-Aβ) unbinding forces and formation of fibrils and oligomers with β-sheet structure.  
Alzheimer’s disease does not usually occur as a result of excessive production of Aβ, but 
rather the ability of neurons to clear the peptide prior to aggregation is impaired (Mawuenyega, 
et al., 2010). Our data demonstrates that the addition of SG1 to a solution of Aβ slows the 
aggregation of Aβ possibly allowing the body’s natural clearance mechanisms to “catch up”. The 
slowing of aggregation may be sufficient for the physiological clearance of amyloid aggregates 
before they become pathological.   
Previous methods used to test the effectiveness of amyloid inhibitors required several 
hours of preparation, followed by running an SDS-PAGE gel (Lee, et al., 2012), or incubation (in 
the case of AFM imaging) (Gestwicki, Crabtree, & Graef, 2004). In the case of single molecule 
AFS, a set of chemically modified cantilevers and substrates can be prepared in advance, and 
once the cantilever is loaded into the AFM  two sets of experiments (control and inhibitor test) 
can be conducted within about 30 minutes. In this work we have shown a good correlation 
between experimental data obtained with force measurements (AFS), AFM imaging and 
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molecular dynamics simulations, which demonstrated that the SG1 synthetic inhibitor disrupts 
the typical Aβ-Aβ nucleation pathway.  
4.5. Conclusions 
We conclude that synthetic inhibitor SG1 successfully disrupts the typical Aβ 
aggregation pathway by inhibiting binding of individual Aβ peptide molecules. Single molecule 
atomic force spectroscopy can be used to test compounds which act as specific competitive 
inhibitors for amyloid fibril formation. Notably, we were able to test the efficacy of SG1 
inhibitor in only 30 minutes. This approach can potentially be used by the pharmaceutical 
industry as a high throughput screening technique to rapidly test various inhibitors for amyloid 
aggregation as well as a wide variety of other drug candidates which block the interaction of two 
molecules. 
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Chapter 5 
Comparison of three competing dynamic force spectroscopy 
models to study binding forces of amyloid-β (1-42) 
 
This chapter has been adapted from a manuscript which has been submitted to the journal Soft 
Matter for publication. 
A number of different models have been proposed to explain the increase in rupture force 
as a function of loading rate including the Bell-Evans model, Dudko-Hummer-Szabo, and the 
Friddle- De Yoreo. In this work I compare these three models by applying them to extract the 
free energy parameters of Aβ42 dimerization. I show that correcting the loading rate for the 
effect of the PEG linker is imperative to obtaining accurate kinetic rate information. 
Author Contributions: 
• Designed Experiments: Zoya Leonenko, Francis Hane 
• Performed Experiments: Francis Hane 
• Analyzed Data: Francis Hane, Simon Attwood 
• Wrote the Manuscript: Francis Hane, Simon Attwood, Zoya Leonenko 
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 5.1. Introduction 
Single molecule force spectroscopy (SMFS) is a nanoscale biophysical technique used to 
probe the unbinding of individual molecules or the unfolding of a polymer such as a protein 
(Florin, Moy, & Gaub, 1994) or nucleic acids (Liphardt, Dumont, Smith, Tinoco, & Bustamante, 
2002). A number of competing analytical models have been developed to extract the parameters 
such as the dissociation rate at zero force (also called the off rate), k0, and the thermodynamic 
parameters, xβ and ΔG, which are the width and height of the energy barrier, respectively 
(Bizzarri & Cannistraro, 2010). These parameters are fundamental to the understanding of the 
kinetics and thermodynamics of the interaction of a pair of molecules and allow the comparison 
of kinetics between different systems and factors which may affect the affinity of two molecules. 
k0 is a rate constant which is the inverse of the bond lifetime, τ0, and measures the rate at which 
two molecules dissociate at zero force. The kinetic association rate (also referred to as the on 
rate), kon, is the rate at which two molecules associate. By relating these two rates, the 
dissociation constant kD, can be defined as kD=koff/kon (Bizzarri & Cannistraro, 2010).  
In this work we use atomic force spectroscopy to extract unbinding force data for 
amyloid-β (1-42). We present a comparative analysis of the three models described (Bell-Evans, 
Dudko-Hummer-Szabo, Friddle-De Yoreo) in a variety of iterations to our AFS data to extract 
kinetic and thermodynamic data about the rupture of the amyloid-β dimer in an attempt to 
provide some standardization to the analysis of force spectroscopy experiments. 
5.2. Experimental Procedures 
We used the protocol as described previously (Hane, Tran, Attwood, & Leonenko, 2013). 
For a single experiment approximately 1000 force curves were recorded, out of which 
approximately 5-10% of these showed specific unbinding events. 5 data sets were collected each 
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 using a different cantilever chip. 3 data sets were collected with the same cantilever and 2 others 
were collected with a softer cantilever.  
5.2.1. Force Curve Analysis 
JPK data analysis software was used to analyze force curves. Software functions were 
used to smooth the force curves, level the x-axis, set both axis to 0 and obtaining the tip sample 
separation, z, to correct for cantilever deflection. A worm-like-chain (WLC) fit was obtained for 
each force curve and rupture forces were obtained. Data was truncated using Poisson statistics to 
eliminate force curves that were likely the result of simultaneous multiple unbind events as 
described in (Karacsony & Akhrimitchev, 2011). These rupture forces were plotted as 
histograms at the different collected loading rates and fitted with a Gaussian distribution to 
determine the most probable rupture force. Errors quoted for the most probable rupture force are 
evaluated as the standard deviation of each distribution, divided by the square root of the 
effective number of counts for each distribution (estimate of standard error).   
Kinetic and thermodynamic parameters k0, ΔG and xβ were extracted using a number of 
different dynamic force spectroscopy models. 
5.2.2. Extraction of Kinetic Data – Bell-Evans Model 
Kinetic parameters for the uncorrected Bell-Evans model were calculated by plotting the 
most probable rupture force (obtained from histograms) against the natural logarithm of the 
loading rate calculated by multiplying the cantilever spring constant kc, by the retraction 
velocity, v. A straight line was fit to the data using a least squares regression model using Origin 
v. 9.0 software. The software returned values of R2 and χ2 for linear and non-linear fits, 
respectively, to indicate the quality of the fit to the experimental data. The calculated slope and 
the y-intercept of this line were used to extract k0, ΔG and xβ using the Bell-Evans. In another 
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 iteration of the application of this model, we corrected the loading rate for the effect of the PEG 
linkers by applying equation 5 as described in (Dudko, Hummer, & Szabo, 2008) to calculate the 
corrected loading rate and reapplied the above described procedure to obtain k0, ΔG and xβ. In 
the third iteration, we aggregated the results of all our force curves and equally divided the data 
into 8 bins according to their corrected loading rates. The most probable rupture force and mean 
corrected loading rate were calculated for each bin and plotted (fig 23C&D). Once again, we 
applied the Bell-Evans model to determine k0, ΔG and xβ. In the last iteration of the application 
of this model (referred to as aggregate data), the results of all force curves were plotted (about 
500 force data points) and the Bell-Evans model applied to the all force plot data points.  
5.2.3. Extraction of Kinetic Data – Dudko-Hummer-Szabo Model 
All force curves were collected and binned into 8 bins according to their corrected 
loading rate as described above. We plotted the natural logarithm of the corrected loading rate of 
each bin vs. the rupture force of each bin, to obtain the bond lifetime versus rupture force 
relationship as show in figure 23B. The Dudko-Hummer-Szabo model was fit to the data using a 
Levenberg-Marquardt fitting algorithm using the software’s user defined non-linear fitting 
function. The bond lifetime, τ0, ΔG and xβ, were returned by the software. k0 was determined by 
the inverse relationship k0=1/τ0.  
5.2.4. Extraction of Kinetic Data – Friddle-DeYoreo Model 
Rupture force, F(r) versus corrected loading rate, r, data points were binned and plotted 
as described above (fig 23C&D). We fit the Friddle-De Yoreo reversible binding equation to 
these data points and extracted parameters equilibrium force, feq, thermal scaling factor, fβ, and 
dissociation rate, koff(feq) at the equilibrium force. These parameters were then used to calculate 
parameters ΔG, xβ, and k0 using the equations used in (Friddle, Noy, & De Yoreo, 2012). In the 
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 last iteration of the application of this model, we plotted all force curve data points 
(approximately 500 data points) and fit the Friddle-De Yoreo model to the entirety of our data to 
obtain the parameters from the fitting of the Friddle-De Yoreo equation to this data set. 
5.3. Results 
Force curves were collected at a variety of retraction velocities and plotted as histograms 
with respect to the average loading rate, 𝑟(𝐹) = 𝑣 𝑘𝑐, here kc  is the cantilever spring constant 
and v the retraction velocity (figure 22). The most probable rupture force as a function of loading 
rate is consistent with our previous reports (Hane, Tran, Attwood, & Leonenko, 2013). We noted 
that the distribution of our unbinding forces contained within our histograms broaden with 
increasing loading rate which is consistent with theoretical models and experimental models 
(Dudko, Hummer, & Szabo, 2008).  
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Figure 22- Rupture force histograms and Gaussian fit at corrected loading rates of 1950 pN/s, 
9860 pN/s, 23900 pN/s and 51900 pN/s. 
 
5.3.1. Bell-Evans Model
We plotted the most probable rupture forces against the uncorrected loading rate 
(retraction velocity (nm/s) multiplied by cantilever spring constant (nN/m) (figure 23A). A least-
squares linear fit was calculated to best approximate a straight line through the data points 
(figure 23A). This line through the data when placed on a natural logarithm scale is consistent 
with what is predicted by Evans (Evans E. , 2001). Parameters of the line were calculated by the 
graphing software and calculated as a slope of 2.84 x 10-11 and an intercept of 5.34 x 10-10. We 
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 applied the Bell-Evans model to these line parameters to calculate the following parameters: 
xβ=143 pm, k0=240.3 s-1, and ΔG=24.0 kBT (figure 23A). 
5.3.2. Dudko-Hummer-Szabo Model 
Using the equation 6, we calculated the bond lifetime, τ(F) for each bin with mean force, 
F. We calculated the natural logarithm of τ(F) and plotted this against the rupture force, F, as 
shown in figure 23B. We applied the Dudko-Hummer-Szabo model (equation 4) and fit this 
equation to our data (Dudko, Hummer, & Szabo, 2008). Applying the Dudko-Hummer-Szabo 
cusp model to our data of the rupture of two Aβ42 peptides, we extracted parameters of xβ=205 
pm, k0=0.68 s-1, and ΔG=7.7 kBT. 
5.3.3. Friddle-De Yoreo Model 
To obtain kinetic parameters using the Friddle-De Yoreo model (Friddle, Noy, & De 
Yoreo, 2012), we plotted the mean unbinding force 〈𝐹(𝑟)〉 as a function of the loading rate for 
each set of loading rates as shown in figures 23C&D. The Friddle-De Yoreo reversible binding 
equation was fit to the data and parameters koff, feq and fβ were calculated (figure 23C&D). The 
equilibrium force, feq, was calculated to be 38.4 pN. Thermodynamic parameters xβ and ΔG were 
obtained by rearranging equations 7-9. Using the Friddle-De Yoreo model, we obtained values of 
k0 = 11.1 s-1, xβ = 104 pm and ΔG = 7.5 kBT. 
A summary of kinetic parameters extracted using different models is given in table 1.  
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Figure 23- A - Rupture force vs. loading rate using the Bell-Evans model. Most probable 
rupture forces are plotted against the uncorrected loading rate. Each data point corresponds to 
the mean rupture force for an experiment conducted at a given retraction velocity. Retraction 
velocity is converted to loading rate by multiplying by the cantilever spring constant. A straight 
line Bell-Evans model is fit to the data and the y-intercept and slope is calculated. The adjusted 
R2 value was calculated as R2 = 0.911. B  - Bond lifetime vs. rupture force fit with the Dudko-
Hummer-Szabo model (green) applied to all force curves binned into 8 bins in accordance with 
corrected loading rate. χ2 = 0.031. C & D - Aβ unbinding experimental data fitted with the 
Friddle-De Yoreo reversible binding model (blue) and the Bell-Evans model (red). Data and 
analysis are identical, but C is on a linear scale and D is on a log10 scale. All data points are 
binned linker-corrected loading rates. The data used in this graph are identical to that shown in 
figure 23A, however all force curves were sorted in order of corrected loading rate and binned 
into 1 of 8 bins according to the corrected loading rate. R2 = 0.973 for the Bell-Evans (red) 
model and R2 = 0.979 for the Friddle-De Yoreo (blue) model. 
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DFS Model xβ (pm) ΔG (kBT) k0 (s-1) τ0 (s) 
Bell-Evans (uncorrected 
for PEG linkers) 
143±16.9 24.0±3.6 240.3±36.5 0.00416±0.0006 
Bell-Evans (loading rates 
corrected for PEG linker) 
143±16.4 27.3±4.1 8.44±1.2 0.112±0.02 
Bell-Evans (binned - 
loading rates corrected)  
138±9.7 27.5±2.5 7.14±0.6 0.14±0.01 
Bell-Evans (aggregate 
data) 
136±9.4 27.4±2.5 7.55±0.7 0.132±0.01 
Dudko-Hummer-Szabo 
(cusp model) 
205±51.7 7.7±0.2 0.68±0.4 1.47±0.9 
Friddle-De Yoreo  
(binned data) 
104.2±19.3 7.50±2.7 11.1±7.4 0.090±0.06 
Friddle-De Yoreo 
(aggregate data) 
98.9±19.6 7.83±3.0 12.5±8.5 0.080±0.05 
Table 2- Comparison of kinetic and thermodynamic parameters using different force 
spectroscopy models. Different iterations of each model are described in the experimental 
procedures section. 
 
5.4. Discussion
Comparing the results of these different models and their various iterations, a few 
important observations stand out. Firstly, a large variation in the dissociation rates between those 
models which do not correct for the effect of the PEG linker and those that do shows that 
correcting the loading rate for the effect of the PEG linker is very important for determining 
accurate dissociation rates although it is minimally important for determining thermodynamic 
parameters. Secondly, the Friddle-De Yoreo and Dudko-Hummer-Szabo model show similar 
energy barrier heights, ΔG. Lastly, the width of the energy barrier, xβ, is similar for all models. 
It appears that no two models provide near sufficiently similar results to definitively rule 
out the third model. So which model provides the most rigorous results? Clearly any model that 
does not account for the effect of the linker molecule is bound to calculate dissociation rates 
126 
 
 
which are erroneous by several orders of magnitude. We also believe that a model which relies 
on fewer assumptions is superior to a model which relies on the assumption of the absence of 
rebinding during pulling.  
Given the variance between SMFS experiments conducted under identical conditions, we 
suggest that the scientific value of SMFS is not to obtain absolute kinetic and thermodynamic 
parameters of a given system, but rather serves as a tool to compare two or more different 
experiments or how a variable affects these parameters. 
Early force spectroscopy experiments were conducted on the avidin-biotin system, a 
system known to have complex (ie more than one) binding conformation (Merkel, Nassoy, 
Leung, Ritchie, & Evans, 1999) (Livnah, Bayer, Wilchek, & Sussman, 1993). When force 
spectra were collected for this system, multiple lines of best fit were found which were plausibly 
interpreted as multiple energy barriers with each barrier corresponding to a different method of 
unbinding. However this interpretation remained popular even though some systems are much 
simpler than the avidin-biotin complex such as peptides on steel (Landouksi & Dupres, 2011). It 
is highly unlikely that these systems contain the complex kinetics of the avidin-biotin receptor-
ligand pair. Much of this force spectroscopy data have been interpreted as a complex energy 
landscape containing multiple barriers even when the system involves very simple binding such 
as peptide to steel (Landouksi & Dupres, 2011) or when the energy barrier is shown to be sub-
angstrom by multiple orders of magnitude (Berquand, et al., 2005). Friddle and colleagues 
provided an alternate interpretation to account for the exponential shape of the rupture force plot 
which does not require multiple fits to straight lines as the Bell-Evans model does. 
While we do not claim that the  Bell-Evans model lacks accuracy or rigour for a simple 
system, we share the concerns noted by Friddle and believe that many reports have “over-
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interpreted” the Bell-Evans model and calculated multiple energy barriers where none can 
plausibly exist, such as at sub-Angsrom length scales.  
In summary, we report that three models we used (corrected for the linker effect) give 
comparable results for xβ and k0, while ΔG parameter correlates well between Dudko-Hummer-
Szabo and Friddle-De Yoreo models but differs for the Bell-Evans model. Despite some 
variation in results due to applying different models, SMFS experiments are very useful to 
measure the binding forces, as well as to extract kinetic and thermodynamic parameters of the 
system. These studies are especially useful to evaluate the effect of various factors on binding 
events. Although a careful consideration of the analytical model applied to fit experimental data 
should be made to make a correct comparison.  We share the opinion of De Yoreo in that 
multiple slopes in the force-loading rate plots are likely the result of rebinding events and not a 
multiple energy barrier, especially in simple systems, such as the one we have studied. 
5.5. Conclusions 
Our data demonstrate that correcting the loading rate for the effect of the linker 
molecule is imperative for accurately determining dissociation rates. Furthermore, our 
data show that SMFS experiments are best suited in comparing two different experiments 
as opposed to obtaining absolutely values. Following the comparison of these DFS 
models, we share the concerns raised by De Yoreo and colleagues that multi-sloped plots 
are the result of rebinding events as opposed to multiple energy barriers in most simple 
systems. 
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5.6. Supplementary Information 
 
5.6.1. Bell-Evans Calculations 
 
The Bell-Evans equation (Evans E. , 2001) is expanded to obtain a similar form to the 
straight line equation y=mx+c,  
𝐹(𝑟) =  �𝑘𝐵𝑇
𝑥𝛽
� ln 𝑟 + �𝑘𝐵𝑇
𝑥𝛽
� ln 𝑥𝛽
𝑘𝑜𝑓𝑓 𝑘𝐵𝑇 
Therefore when F(r) is plotted against ln r, the slope of the best fit line equals �𝑘𝐵𝑇
𝑥𝛽
� and 
the y-intercept equals  
�
𝑘𝐵𝑇
𝑥𝛽
� ln 𝑥𝛽
𝑘𝑜𝑓𝑓 𝑘𝐵𝑇 . 
All values are converted to standard units, N and N/s. The location of the energy barrier, 
xβ is determined by the equation, 
𝑥𝛽 = 𝑘𝐵𝑇𝑚  
Where m is the slope of the line. koff was determined by rearranging the equation. 
𝑘𝑜𝑓𝑓 = 𝑥𝛽𝑘𝐵𝑇 𝑒𝑐𝑥𝛽/𝑘𝐵𝑇 
Where c is the y-intercept. 
Once koff is determined, we applied the following equation to determine the height of the 
energy barrier, ΔG (Evans, Halvorsen, Kinoshito, & Wong, 2009). 
𝑘𝑜𝑓𝑓 (𝐹) =  �𝑘𝐵𝑇ℎ � 𝑒−𝛥𝐺−𝑥𝛽𝐹𝑘𝐵 𝑇  
Rearranged, ΔG can be determined as 
−∆𝐺 = 𝑘𝐵𝑇 ln 𝑘0ℎ𝑘𝐵𝑇 
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Where h is Plank’s constant. For our purposes, we used kBT as units for ΔG. 
5.6.2. Error Analysis 
 
For the Bell-Evans model, errors were determined by the square root of the sum of the 
squares of the standard error (Taylor, 1997). For example, the standard error of xβ was calculated 
as follows: 
Since xβ is a function of the slope, m, 
𝑥𝛽 = 𝑘𝐵𝑇𝑚  
With m being the slope of the line using a least squares fit of the data points, the standard 
error of xβ is given by the equation, 
𝛿𝑥𝛽
𝑥𝛽
= ��𝛿𝑚
𝑚
�
2 + �𝛿𝑇
𝑇
�
2
 
The standard error of the slope, m, was calculated using the graphing software. The 
standard error of the temperature was negligible, but still used and estimated as 1 K. 
The standard error for all parameters using the Dudko-Hummer-Szabo model (Dudko, 
Hummer, & Szabo, 2008) were calculated using Origin v 9.0. 
Hutter’s thermal noise method (Hutter & Bechhoefer, 1993) of cantilever spring constant 
calculation typically results in a standard error of 10-20% (JPK Instruments AG, 2009). To 
calculate the standard errors for the Friddle-De Yoreo model (Friddle, Noy, & De Yoreo, 2012), 
a 15% error was estimated for the cantilever spring constant. Since ΔG is a function of the 
cantilever spring constant and feq, the standard error in ΔG was estimated as 
𝛿∆𝐺 = ∆𝐺��𝛿𝑓𝑒𝑞
𝑓𝑒𝑞
�
2 + 0.152 
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The remainder of standard errors were calculated in a manner similar to the Bell-Evans 
model. 
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Chapter 6 
Conclusion 
 
6.1. Overview of Results 
 
In this work, I used a combination of atomic force microscopy and atomic force 
spectroscopy to study the single-molecule interactions of two amyloid-β peptides, the very initial 
step in the aggregation of amyloid-β leading to amyloid oligomers, fibrils, and eventually, 
symptomatic Alzheimer’s disease. I demonstrated that copper increases the unbinding force of 
amyloid-β and makes it more difficult for the brain to naturally clear amyloid oligomers. This 
phenomenon is attributed to the different conformation an amyloid-β takes when copper is 
involved in the system creating and mediating a stronger bond between the two amyloid-β 
peptides resulting in the observation that the presence of copper increases the unbinding force 
between the two peptides. 
For the first time, I used AFS to test the use of an inhibitor on a peptide binding complex. 
I tested the use of an amyloid aggregation inhibitor named SG1 as a potential candidate for 
preventing the aggregation of amyloid oligomers. By showing that the experimental yield of 
atomic force spectroscopy (AFS) experiments drops drastically with SG1 as part of the system, 
SG1 prevents amyloid-β peptides from self-dimerizing and forming dimers, the initial step is 
Alzheimer’s pathogenesis. This method of testing potential pharmaceutical compounds can be 
used as a high throughput screening device for testing inhibitors and promoters of any receptor-
ligand system. 
Lastly, I compared the free energy parameters of amyloid-β dimerization using a variety 
of different models: the Bell-Evans, Dudko-Hummer-Szabo, and Friddle-deYoreo. The field of 
single molecule force spectroscopy has suffered from a lack of standardization and an “over-
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interpretation” of many data resulting in absurd conclusions. My data showed that a model which 
excludes the effect of the linker molecules produces results which are erroneous by several 
orders of magnitude. Furthermore, our data supported the observations made by Friddle in that at 
lower loading rates, the force-loading rate plot is considerably shallower than at higher loading 
rates and connected by a curved region. Our data leads us to conclude that the Friddle-De Yoreo 
model provides a superior interpretation to that commonly provided by groups using the Bell-
Evans model. Lastly, I propose that rather than using these DFS models to determine absolute 
quantitative values, these models are best used to determine a difference in kinetic parameters 
when an experimental variable, such as the presence of metal ions, is altered.  
6.2. Future Research 
 
Often, good research yields more questions than answers. The results of these 
experiments are no different. This project was the first involving single-molecule force 
spectroscopy in the Leonenko lab. Thankfully, a considerable portion of the experiments 
conducted were successful and yielded statistically valid results. This project has further 
possibilities - a considerable number of additional experiments can be conducted relating to the 
results of this thesis. I proposed additional experiments: 
1) What is the effect on the kinetic and thermodynamic parameters when an amyloid 
fibril promoter or inhibitor is added to the system? Molecules such as Methylene Blue have been 
demonstrated to inhibit amyloid aggregation. I hypothesize that since the dimer conformation is 
different between OC+ and A11+ oligomers, there would be a difference in the free energy 
landscape. 
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2)What is the effect of metal ions, Cu, Zn, and Fe on the affinity of two amyloid-β 
peptides? Since Cu increases the unbinding force between two peptides, I hypothesize that the 
binding affinity of these two peptides also increases.  
3) Are there binding sites within a neuron that have a higher affinity for amyloid-β? By 
growing neuron cells in vitro and placing these cells on the combined AFM/fluorescence stage 
and a peptide on the cantilever tip, force mapping could be conducted to find if there are areas 
with higher affinity for AB.  
4) Are aggregates formed in an SG1 environment OC+ or A11+? Are they neurotoxic? 
We could further characterize the aggregates formed with SG1 and determine their neurotoxic 
properties. 
Given the expertise gained in the lab of Prof. Leonenko in the field of SMFS, these 
questions could very well be answered in a continuation of this research program by another PhD 
student. I encourage my supervisor to continue this research program. 
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Appendix A 
Atomic Force Spectroscopy Protocols 
 
Molecular Weights of Reagents (g/mol) 
aminopropylsilatrane (APS)   232.4 
aminopropyl-triethoxysilane (APTES) 221.4 
triethanolamine    149.2 
NHS-PEG-maleimide    3400 
Cys-Aβ42     4617.3 
HEPES     238.3 
tris(2-carboxyethyl)phosphine (TCEP) 286.7 
SG1 (note-30% of weight is retained H2O) 991.2 
Sodium Chloride (NaCl)   58.4 
 
All reagents can be purchased from Sigma-Aldrich except APS which must be synthesized. 
Peptides are purchased from Anaspec. SG1 is synthesized by the Rauk group and stored in -20C. 
 
Cleaning Surfaces 
Reagents and Supplies: 
Bruker MLCT cantilevers 
Mica (SPI Supplies) 
Ethanol (lab grade) 
MilliQ Water 
1 mL microcentrifuge tubes or similar 
Tweezers (curved, blunt nose work best) 
Scotch Tape 
 
Protocol 
1. Wash MLCT cantilever tips in ethanol and water, dry with dryed argon or nitrogen 
 - Cut off the cap for a 1 mL microcentrifuge tube. These caps will be used for all 
chemical modifications of the cantilever tips.  
 - Fill 1 cap with ethanol and another with MilliQ water. 
 - Using curved blunt nose tweezers, gently remove a cantilever from the case and dip in 
and out of the ethanol bath 3 times. Remove the cantilever and dip in and out of the water 
bath 3 times. 
 - Place a piece of mica in a petri dish. Place the cleaned cantilever on the mica inside the 
petri dish. Place a nitrogen hose under the petri dish cover and apply a low pressure 
stream of nitrogen into the petri dish until all liquid has evaporated from around the 
cantilever. This will take approximately 10 minutes depending on ambient humidity. 
 - Remove the mica sheet with the cantilever on tip and place the mica and cantilever into 
a UV cleaner. The mica serves as a suitable platform for handling the cantilever.  
2. Cleave Mica 
 - Use scotch tape and press to attach to mica. 
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 - Remove the scotch tape from mica. You should see a very thin layer of mica stuck to 
the tape. 
 - Place cleaved mica into a petri dish for dust free storage. 
 
 
Synthesize Aminopropyl Silatrane (APS) 
Reagents and Supplies 
Vacuum evaporation apparatus 
Triethanolamine  
Sodium 
Aminopropyl-triethoxy-silane (APTES) 
Round bottom flask 
Magnetic stirrer and stir bar 
Pistle and Mortar 
Syringe 
 
Protocol 
1. Heat silicon oil bath to 60C. 
2. Remove 4.13g (3.67mL) of triethanolamine with a syringe from the container (note 
triathenaolamine has very low viscosity and will take a while to get drawn into the syringe) and  
place in round bottom flask. 
3. Add 1mg sodium and add to round bottom flask. 
 - Na acts as a catalyst and is removed from the reaction during evaporation. 
 - Na is not included in the reaction, so you can just cut off a “speck”. An exact amount is 
not necessary 
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4. Add 6.12g of APTES to round bottom flask. 
4. Add magnetic stir bar to flask and set up vacuum evaporator to top of flask to apply a vacuum.  
5. Stir mixture until the reaction is complete. This is indicated by the precipitation of the product  
into a solid white crystalline product. This may take upto 1 hour. The product will be hard and  
encase the stir bar. You will need to use a mortar and pestle to make the product into a powder. 
6. Make a 50 mM stock solution of APS in deionized water. The molecular weight of APS is  
232.4. Add 5.81g of APS to 500mL of deionized water. 
7. Take a sample of the product to the NMR lab and obtain a 1D NMR spectra. The spectra  
should look similar to the one shown below. 
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Preparing Stock Solutions 
Reagents and Supplies 
Aminopropylsilatrane (APS) 
N-hydroxyl succinamide-polyethelene glycol-maleimide (NHS-PEG-mal) (also called mal-PEG-
SVA) 
tris(2-carboxyethyl)phosphine (TCEP) 
Dimethylsulfoxide (DMSO) 
HEPES buffer 
Sodium Chloride (NaCl) 
Hydrochloric Acid (HCl) 
Sodium hydroxide (NaOH)  
Pipettes 
Beakers 
Balance 
Bottles  
 
HEPES Buffer 
1. Prepare HEPES buffer with a concentration of 50mM and 150mM of NaCl, pH 7.4. 
2. Fill a 1L bottle with approximately 750mL of MilliQ water. Add 11.9g of HEPES buffer and 
8.76g NaCl. Stir until dissolved completely using magnetic stir bar. 
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3. Add water until level reaches the 1L mark. 
4. Test pH. Adjust pH using HCl or NaOH. 
5. Store in fridge. 
 
Aminopropylsilatrane (APS) - 167μM 
1. To make 167μM solution of APS, add 334μL of 50mM stock solution of APS to 100mL of 
MilliQ water. 
 - It is not absolutely necessary that APS is prepared at this solution but probably should  
be within an order of magnitude to work best. 
2. Store in fridge. 
 
tris(2-carboxyethyl)phosphine (TCEP) – 200nM 
1. To make 200nM solution of TCEP, serial dilutions must be made. 
2. Add 57.3mg TCEP to 1L of water. This will yield a 200μM solution. Mix well. 
3. Add 1mL of the 200μM solution to 1L of water. Mix well. This solution is 200nM. 
4. Store in -20C freezer. 
 
NHS-PEG-mal - 167μM 
1. Add 56.8mg of NHS-PEG-mal to 100mL of DMSO. Mix well. 
2. Store in aliquots for further use in -20C freezer. 
 
Cys-Amyloid-β (1-42) – 20nM 
1. Add 0.5mL of DMSO to 0.5mg bottle of cys-Aβ (Anaspec-Freemont, CA) and shake to 
dissolve. There are 1.08e-7 moles of Aβ in this solution. 
2. Add Aβ to 50mL HEPES in a beaker or centrigufe tube to make a stock solution of 2.2μM. 
Mix well. 
3. Add 1mL of the 2.2μM stock solution to 100mL of HEPES to make a 22nM solution of cys-
Aβ. Store Aβ for 15 minutes at room temperature. 
4. Aliquot the Aβ in 1mL centrifuge tubes by taking 0.5mL of Aβ and 0.5mL of TCEP. 
5. Store Aβ aliquots in -20C freezer. 
6. When ready for use, thaw Aβ and centrifuge at 14000RPM for 15 minutes. Remove the top 
half of the aliquot and place in another centrifuge tube. This will ensure primarily monomeric 
forms of the peptide are used. 
 
Surface Modification of AFM tips and Mica 
Reagents and Supplies 
167μM APS solution 
167μM NHS-PEG-Maleimide solution 
22nM cys-Aβ42 solution 
Mica (freshly cleaved) 
Bruker MLCT cantilevers (cleaned) 
Pipettes 
Petri dishes 
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Protocol - Cantilevers 
1. Remove the caps of a number of centrifuge tubes.  
- These will serve as a bath for the reagents when modifying the surface of the cantilever 
tips. Place these caps in a petri dish to keep dust free. 
2. Using a pipette, fill tube caps with APS solution. Using blunt nose curved tweezers, place 1 
cantilever chip in each tube cap. Soak 30 minutes. 
 - This silanates the surface preparing it for linker attachment. 
4. Fill other tube caps with MilliQ water. After 30 minutes, remove cantilever chips and immerse 
in water 3 times, placing the cantilevers in and out of the water. Place cantilevers on mica and 
place in a petri dish and dry with nitrogen. 
5. Fill different tube caps with NHS-PEG-mal solution. Place cantilevers in NHS-PEG-mal 
solution for 3 hours.  
6. After 3 hours, rinse cantilevers with DMSO by immersing them 3 times in a DMSO filled tube 
cap. Store in HEPES solution. 
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Protocol - Mica 
1. Place freshly cleaved mica in petri dish. Soak mica in APS solution for 30 minutes by 
applying 100μL of APS to the surface of the mica. 
2. After 30 minutes, rinse mica 3 times with 100μL of water from pipette. Dry in petri dish with 
nitrogen. 
3. Apply 100μL of NHS-PEG-mal to each mica surface and allow to soak for 3 hours. 
4. After 3 hours use pipette to rinse mica 3 times with 100μL of DMSO. Store mica in petri dish 
soaked with HEPES buffer. 
 
Protocol – cys-Aβ42 Attachement 
1. Using the above techniques, soaking cantilever tips in tube caps and using 100μL to soak 
mica, prepare to attach the Aβ. 
2. Centrifuge Aβ solution at 14000RPM for 15 minutes as described above.  
3. Using the top of the solution (it doesn’t separate in phases) and the above techniques immerse 
tips and cantilevers in Aβ solution for 30 minutes.  
4. After 30 minutes rinse tips and mica with HEPES buffer. 
5. Immerse mica and tips in beta-mercaptoethanol to quench unreacted maleimide groups. 
- This ensures that there are no binding events between Aβ on the tip and maleimide on 
the surface or vice versa. 
- Maleimide is very toxic and this step must be done under a fume hood. Everything must 
be disposed of (gloves, etc) in a garbage can located outside or cleaned well with DMSO. 
- If you open a bottle of DMSO this will likely result in the lab being uninhabitable for at 
least 2 days. 
6. Wash mica and tip with HEPES buffer 3 times and store in HEPES until ready for use. 
 - Do not store for greater than 24 hours. 
 
Preparation of Inhibitors and Metal Ions 
Reagents and Supplies 
Inhibitor powder (eg SG1) 
Metal ion powder 
Pipettes 
Microcentrifuge tubes 
 
Protocol – Inhibitors 
1. Prepare 7μM stock solution of SG1 (MW 991.2) by adding 1mg of SG1 to 100mL HEPES. 
 - Inhibitors come in different amounts. Use entire amount to make solution. 
 - 30% of the mass of inhibitors is retained water. 
2. Dilute stock solution to desired concentrations – typically 20, 40 and 200nM. 
 
Protocol 
1. Prepare stock solution of metal solutions such as Cu, Zn or Fe. 
2. Dilute stock solutions to desired concentrations – typically 20nM. 
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Atomic Force Spectroscopy – JPK Nanowizard II4 
Calibration of Cantilever5 
 
 
1. Load Bruker MLCT cantilever chip into glass cantilever holder. Secure with retaining spring 
and install in AFM head. 
4 All images from JPK User Manual. © JPK Instruments AG 2009. 
5 Adapted from a protocol written by Youngjik (Vince) Choi 
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2. Open JPK Desktop and select Contact Mode and Force Spectroscopy mode  
3. Adjust the laser and mirror to achieve laser alignment with a good sum signal 
 
4. Select run and collect one force curve. Stop scanning and save this force curve as a calibration 
curve.  
3. SelectVF, click “Relative” tab. 
 - This is in the “spectroscopy control” in the left. 
 - This will open the calibration window. 
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4. Calibrate sensitivity 
 - This converts mV to nm. 
 - Select magnifying glass and szoom in to the deflection part (steep part) of the force  
curve. 
 - Click “manual sensitivity selection”. 
 - Click and drag a line that matchs the deflection of the force curve. 
 - Click “accept value” and “use it” 
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5. Calibrate spring constant 
 - Click on “Spring Constant” tab 
 - Raise the motors 500μm up 
 - Click the infinity symbol at the bottom. You should see a Bell curve appear. 
 - Click the infinity symbol again. 
 - Select “Select Fit Range” drag and select the Bell curve from left to right. 
 - Click “Accept Value” and “Use it” 
 
 
171 
 
 
Atomic Force Spectroscopy Data Collection 
1. Select a grid of 30x30 data points over 100μm (or whatever you want). 
2. Select a z-length of 0.1μm. 
3. Select “Constant Velocity” and select a suitable retraction velocity. 
4. Select a dwell time of 0.5 sec.  
- This will allow adequate time for the peptides to bind. The time for bond formation is 
about 0.1 sec. 
5. Ensure you are saving force curves in a suitable folder. 
6. Click “Run”. Ensure that force curves are being saved and that suitable curves are being 
collected. 
7. Typical force spectroscopy settings are Igain 40, pgain 0.0048, set point 10 nN, relative set 
point 0.9. 
 
Dynamic Force Spectroscopy (DFS) 
1. DFS is done by using different loading rates. Loading rate, r=vkc. where v is the retraction 
velocity and kc is the cantilever spring constant. 
2. Loading rates should be collected across 4 orders of magnitude. Suggested loading rates are 
300, 1000, 3000, 10000, 30000, 100000 pN/s. Assuming a spring constant of 100 mN/m, 
retraction velocities should be set as follows for the corresponding mean loading rate: 
Loading Rate 
(pN/s) 
Retraction 
Velocity (nm/s) 
300 3 
1000 10 
3000 30 
10000 100 
30000 300 
100000 1000 
3. Each set of loading rates should be saved in a different folder with a descriptive name. 
 
Force Spectroscopy Analysis – Selecting Successful Binding Events 
1. Open JPKSPM Data Porcessing Software. 
2. Open the folder where files are located. 
3. Click on each curve file name and look at the curve. If there is a successful binding event go to 
the next curve. If there is no successful binding event, click “delete”. 
 - See images for example 
 - Notice large non-specific interaction in the first image, but a successful WLC event  
after. 
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Force Spectroscopy Analysis – Creating Batch Processing File 
1. Open the JPKSPM Data Processing software 
2. File – Open 
 - Open a selected force curve 
3. Smooth Force Data 
4. Subtract baseline 
 - This makes the approach and retract equal to zero 
 - You may need to select a region with a constant approach height (ie flat section) 
5. Calibrate for sensitivity and spring constant. 
 - Ensure these values are equal to the calibrated values of the cantilever 
6. Correct height for cantilever bending. 
 - Because the cantilever bends, this height must be corrected.  
 - This process will make the steep tip-surface contact section vertical. 
7. Shift origin of force curve. 
 - Ensure that the point at which the retraction passes through the base line is equal to 0 on  
the x-axis. 
8. Apply a worm like chain (WLC) fit. 
 - It is best to do this manually by clicking on the WLC icon and selecting “new”  
 - Manually select the fit by finding the WLC region of the force curve 
9. Save the batch process. 
  
GOOD GOOD 
BAD BAD 
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* Numbers in boxes below correspond to steps in above protocol 
 
 
 
 
 
Force Spectroscopy Analysis – Batch Processing 
1. Click open batch of force curves. 
2. Select folder where curves are located. 
3. Select batch process. 
 - Click browse 
 - Select “Save curve position in file” 
4. Select “Export as .txt?”. Click finish. 
5. Select all batch processes (ie smooth, level curve, etc). 
6. Manually level baseline, shift origin and select WLC region if needed. 
7. Click “keep” or “discard” if the curve is not good. 
8. When all curves have been analyzed, select “save”. 
 
Force Spectroscopy Analysis – Data Analysis 
1. Open the text file containing the results of the data. This file will be called something similar 
to “results-#date-chainfits. Select and copy all text. 
2. Copy data into MS Excel. 
3. Keep columns for rupture force, contour length, loading rate and persistence length. 
4. Put all relevant information into this spreadsheet (date, spring constant, concentrations, etc.). 
This will save you from referencing your lab notbook constantly. 
5. Calculate means and standard errors for all data. 
3 5 4 7 6 8 Open Batch 
Process 
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6. This data can be exported into Origin for presenting histograms and rupture force vs. loading 
rate plots. 
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